Lolcde inhibiting compounds as antibiotics

Novel lolCDE inhibiting compounds address the challenge of antibiotic resistance in Gram-negative bacteria by providing potent and resistant-prone antibiotics with improved efficacy and compliance, effectively targeting ESBL-CRE and multi-drug-resistant infections.

WO2026236569A1PCT designated stage Publication Date: 2026-11-12PRESIDENT & FELLOWS OF HARVARD COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027202
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The rapid emergence of antibiotic-resistant bacteria, particularly Gram-negative Enterobacteriaceae such as carbapenem-resistant K. pneumoniae and extended-spectrum beta-lactamase-producing E. coli, poses a significant threat due to high frequency of resistance and high minimum inhibitory concentrations, hindering the development of effective lolCDE inhibitors.

Method used

Development of novel lolCDE inhibiting compounds with improved potency, lower resistance frequency, and broader therapeutic window, including ciprimelpin, which demonstrates potent activity against ESBL-CRE and effective in vivo models of multi-drug-resistant infections.

Benefits of technology

The compounds exhibit low spontaneous resistance, high efficacy in murine models, and are effective against ESBL-CRE and multi-drug-resistant E. coli and K. pneumoniae infections, offering a promising solution to antibiotic-resistant pathogens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027202_12112026_PF_FP_ABST
    Figure US2026027202_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides compounds of Formula (I'). The provided compounds may be lolCDE inhibitors and useful as antibiotics. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating or preventing infections).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] LOLCDE INHIBITING COMPOUNDS AS ANTIBIOTICS

[0002] RELATED APPLICATIONS

[0003] This application claims priority under 35 U. S. C. § 119(e) to U. S. Provisional Patent Application, U. S. S. N. 63 / 801,757, filed May 7, 2025, which is incorporated herein by reference.

[0004] GOVERNMENT SUPPORT

[0005] This invention was made with government support under AI187556 awarded by National Institutes of Health (NIH). The government has certain rights in this invention.

[0006] BACKGROUND OF THE DISCLOSURE

[0007] The rise in human morbidity due to the evolution and rapid dissemination of bacteria resistant to the “modern” arsenal of antibiotics and the attendant economic consequences of this are now widely recognized1. Antibiotic-resistant pathogens of the Gram-negative family Enterobacteriaceae are currently positioned one (carbapenem-resistant K. pneumoniae') and two (extended- spectrum beta-lactamase-producing E. coli) within the 2024 edition of the Bacterial Priority Pathogens List published by the World Health Organization (WHO). They are frequent causes of multi-drug resistant urinary-tract infections, bloodstream infections, pneumonia, intraabdominal infections, and gastroenteritis. Infections associated with these bacteria are in many cases unbeatable, require longer hospitalizations, and incur higher costs when compared to other types of infections5. A 2017 meta-analysis of Klebsiella pneumoniae infections revealed that 54.3% of patients with bloodstream infections died, mortality in ICU patients was 48.9%, 43.1% of solid organ-transplant patients died, and 13.5% of UTI patients succumbed7. Extended-spectrum beta-lactamase-producing and carbapenem-resistant Enterobacteriaceae (ESBL-CRE) infections (200,000 cases and 10,200 deaths) in the US far outnumbered multidrug -resistant infections caused by other Gram-negative pathogens, such as MDR-Pseudomonas sp. (32,600 cases and 2,700 deaths) and CR-Acinetobacter baumannii (8,500 cases and 700 deaths) in 2019, underscoring the acute need for antibiotics targeting these bacteria6.

[0008] Using a cell-based high-throughput screen, researchers at AstraZeneca discovered that molecules 1 and 2 (FIG. 1) inhibit the growth of Enterobacteriaceae and conducted compelling mechanistic studies to show that this activity arises from the inhibition of the lolCDE component of the localization of lipoproteins (lol) pathway. The lol pathway is responsible for transferring lipoproteins essential for maintaining outer-membrane (OM) integrity and function from the inner-membrane (IM) to the OM of Gram-negative bacteria12,13. It is now well understood that inhibition of lolCDE results in mislocalization of OM lipoproteins and rapid bacterial death14,15,16. While lolCDE has been shown to be, in principle, an attractive antibiotic target,AstraZeneca chose not to further develop screening hits 1 and 2 as therapeutic agents because they suffered from a high frequency of resistance (FoR, ~ IO6): isolated colonies of resistant E. Coli exhibited a 16-fold increase in minimum inhibitory concentration (MIC), arising from a single-amino acid mutation (N265K) in the LolC protein.

[0009] At least three other research groups have reported advances in the development of lolCDE inhibitors since the original reports by AstraZeneca, discovering molecules with improvements in both MICs and FoRs. For example, 3 was discovered by Lorenz et al. and used to study the transcriptional response of P. aeruginosa expressing E. coli lolCDE to lolCDE inhibition, and Munoz et al. employed 4 to investigate the ability of narrow- spectrum antibiotics to preserve gut microbiome diversity while treating ESBL-CRE infections in a murine model21,22. However, high FoR ( IO7with a greater-than 16-fold increase in MIC from lolC-N265K in E. Coli) has remained a formidable roadblock to the advancement of 3 and 4 as therapeutic candidates. Further work has yielded 5, which boasts the most potent reported MICs to-date (<1 pg / mL) and a significant reduction in FoR ( 109) but nevertheless suffers from a 16-fold increase in MIC arising from a single amino acid mutation (lolC-L256R) in E. coli. There is a need for improved lolCDE inhibiting compounds as antibiotics.

[0010] SUMMARY OF THE DISCLOSURE

[0011] In one aspect, the present disclosure provides compounds, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, wherein the compounds are of Formula I':

[0012]

[0013] The provided compounds may be lolCDE inhibitors. The provided compounds may also be useful as antibiotics. In certain embodiments, the provided compounds’ use as antibiotics is at least in part because the provided compounds are lolCDE inhibitors. The provided compounds may be advantageous over known antibiotics at least in part because the provided compounds may be more potent, be more efficacious, be less toxic, have wider therapeutic window, be less resistance-prone, be easier administered, and / or show higher subject compliance. For example,ciprimelpin showed potent activity against extended- spectrum beta-lactamase-producing and carbapenem-resistant Enterobacteriaceae (ESBL-CRE), low frequency of spontaneous resistance (with no observed single-step high-level resistance), and in vivo efficacy in murine multi-drug- resistant E. coli and K. pneumoniae infection models by oral or intravenous administration. The provided compounds may be able to inhibit the growth or reproduction of microorganisms or kill microorganisms in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface, treat diseases, or prevent diseases.

[0014] In another aspect, the present disclosure provides pharmaceutical compositions comprising a provided compound and optionally a pharmaceutically acceptable excipient.

[0015] In another aspect, the present disclosure provides kits comprising a provided compound or pharmaceutical composition, and instructions for using the provided compound or pharmaceutical composition.

[0016] In another aspect, the present disclosure provides methods of treating a disease in a subject in need thereof, the methods comprising administering to the subject an effective amount of a provided compound or pharmaceutical composition.

[0017] In another aspect, the present disclosure provides use of a provided compound or pharmaceutical composition for the manufacture of a medicament for treating a disease in a subject in need thereof.

[0018] In another aspect, the present disclosure provides compounds and pharmaceutical compositions for use in treating a disease in a subject in need thereof.

[0019] In another aspect, the present disclosure provides methods of preventing a disease in a subject, the methods comprising administering to the subject an effective amount of a provided compound or pharmaceutical composition.

[0020] In another aspect, the present disclosure provides use of a provided compound or pharmaceutical composition for the manufacture of a medicament for preventing a disease in a subject.

[0021] In another aspect, the present disclosure provides compounds and pharmaceutical compositions for use in preventing a disease in a subject.

[0022] In certain embodiments, the disease is an infection, e.g., a Gram-negative bacterial infection.

[0023] In another aspect, the present disclosure provides methods of inhibiting the growth or reproduction of a microorganism or killing a microorganism in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface, the methods comprising administering to the subject or contacting the cell, tissue, biological sample, microorganism, or surface with an effective amount of a provided compound or pharmaceutical composition.In another aspect, the present disclosure provides use of a provided compound or pharmaceutical composition for the manufacture of a medicament for inhibiting the growth or reproduction of a microorganism or killing a microorganism in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface.

[0024] In another aspect, the present disclosure provides the provided compounds and pharmaceutical compositions for use in inhibiting the growth or reproduction of a microorganism or killing a microorganism in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface.

[0025] In another aspect, the present disclosure provides in vitro methods of inhibiting the growth or reproduction of a microorganism or killing a microorganism in a cell, tissue, biological sample, or microorganism, or on a surface, the method comprising contacting the cell, tissue, biological sample, microorganism, or surface with an effective amount of a provided compound or pharmaceutical composition.

[0026] The details of one or more embodiments of the present disclosure are set forth herein. Other features, objects, and advantages of the present disclosure will be apparent from the Detailed Description, Examples, Figures, and Claims.

[0027] DEFINITIONS

[0028] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March’ s Advanced Organic Chemistry, 5thEdition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modem Methods of Organic Synthesis, 3rdEdition, Cambridge University Press, Cambridge, 1987.

[0029] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and / or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC), supercritical fluid chromatography (SFC), and the formation andcrystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present disclosure additionally encompasses compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.

[0030] In a formula, the bond -~w is a single bond, the dashed line — is a single bond or absent, and the bond = or is a single or double bond.

[0031] Unless otherwise provided, a formula depicted herein includes compounds that do not include isotopically enriched atoms and also compounds that include isotopically enriched atoms. Compounds that include isotopically enriched atoms may be useful as, for example, analytical tools, and / or probes in biological assays.

[0032] The term “aliphatic” includes both saturated and unsaturated, nonaromatic, straight chain (i.e., unbranched), branched, acyclic, and cyclic (i.e., carbocyclic) hydrocarbons. In some embodiments, an aliphatic group is optionally substituted with one or more functional groups (e.g., halo, such as fluorine). As will be appreciated by one of ordinary skill in the art, “aliphatic” is intended herein to include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties.

[0033] When a range of values (“range”) is listed, it is intended to encompass each value and sub-range within the range. A range is inclusive of the values at the two ends of the range unless otherwise provided. For example, “an integer between 1 and 4” refers to 1, 2, 3, and 4. For example “Ci-6 alkyl” is intended to encompass, Ci, C2, C3, C4, C5, Cs, Ci-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2 4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6 alkyl.

[0034] “Alkyl” refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“Ci-2o alkyl”). In some embodiments, an alkyl group has 1 to 12 carbon atoms (“Ci-12 alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“Ci-10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C1-9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“Ci-8 alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C1-7 alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“Ci-6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C1-5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1-4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C1-3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“Ci alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-6alkyl”). Examples of Ci-6 alkyl groups include methyl (Ci), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (Ce).

[0035] Additional examples of alkyl groups include n-heptyl (C7), n-octyl (Cs) and the like. Unless otherwise specified, each instance of an alkyl group is independently optionally substituted, e.g., unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents. In certain embodiments, the alkyl group is unsubstituted Ci-12 alkyl (e.g., -CH3 (Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, e.g., unsubstituted n-propyl (n-Pr), unsubstituted isopropyl (z-Pr)), unsubstituted butyl (Bu, e.g., unsubstituted n-butyl (zz-Bu), unsubstituted tert-butyl (tert-Bu or t-Bu), unsubstituted \ec-butyl Csec-Bu or s- Bu), unsubstituted isobutyl (z-Bu)). In certain embodiments, the alkyl group is substituted Ci-12 alkyl (such as substituted C1-6 alkyl, e.g., -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2-CH2CF3, or benzyl (Bn)). The attachment point of alkyl may be a single bond (e.g., as in -CH3), double bond (e.g., as in =CH2), or triple bond (e.g., as in =CH). The moieties =CH2 and =CH are also alkyl.

[0036] In some embodiments, an alkyl group is substituted with one or more halogens.

[0037] “Perhaloalkyl” is a substituted alkyl group as defined herein wherein all of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo. In some embodiments, the alkyl moiety has 1 to 8 carbon atoms (“Ci-8 perhaloalkyl”). In some embodiments, the alkyl moiety has 1 to 6 carbon atoms (“Ci-6 perhaloalkyl”). In some embodiments, the alkyl moiety has 1 to 4 carbon atoms (“Ci^i perhaloalkyl”). In some embodiments, the alkyl moiety has 1 to 3 carbon atoms (“C1-3 perhaloalkyl”). In some embodiments, the alkyl moiety has 1 to 2 carbon atoms (“C1-2 perhaloalkyl”). In some embodiments, all of the hydrogen atoms are replaced with fluoro. In some embodiments, all of the hydrogen atoms are replaced with chloro. Examples of perhaloalkyl groups include -CF3, -CF2CF3, -CF2CF2CF3, -CCI3, -CFCI2, -CF2CI, and the like.

[0038] “Alkenyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more (e.g., two, three, or four, as valency permits) carboncarbon double bonds, and no triple bonds (“C2-20 alkenyl”). In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C2-10 alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C2-9 alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C2-8 alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C2-7 alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C2-6 alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C2-5 alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C2-4 alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C2-3 alkenyl”). In some embodiments, an alkenylgroup has 2 carbon atoms (“C2 alkenyl”). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2 4 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (Ce), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (Cs), octatrienyl (Cs), and the like. Unless otherwise specified, each instance of an alkenyl group is independently optionally substituted, e.g., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents. In certain embodiments, the alkenyl group is unsubstituted C2-10 alkenyl. In certain embodiments, the alkenyl group is substituted C2-10 alkenyl. In an alkenyl group, a C=C

[0039] double bond for which the stereochemistry is not specified (e.g., -CH=CHCH3 or

[0040]

[0041] ) may be in the (E)- or (Z)-configuration.

[0042] “Alkynyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more e.g., two, three, or four, as valency permits) carboncarbon triple bonds, and optionally one or more double bonds (“C2-20 alkynyl”). In some embodiments, an alkynyl group has 2 to 10 carbon atoms (“C2-10 alkynyl”). In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C2-9 alkynyl”). In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C2-8 alkynyl”). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C2-7 alkynyl”). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C2-6 alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C2-5 alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C2-4 alkynyl”). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C2-3 alkynyl”). In some embodiments, an alkynyl group has 2 carbon atoms (“C2 alkynyl”). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C2-4 alkynyl groups include ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkynyl groups as well as pentynyl (C5), hexynyl (Ce), and the like.

[0043] Additional examples of alkynyl include heptynyl (C7), octynyl (Cs), and the like. Unless otherwise specified, each instance of an alkynyl group is independently optionally substituted, e.g., unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents. In certain embodiments, the alkynyl group is unsubstituted C2-10 alkynyl. In certain embodiments, the alkynyl group is substituted C2-10 alkynyl.

[0044] “Carbocyclyl” or “carbocyclic” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 13 ring carbon atoms (“C3-13 carbocyclyl”) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 8 ring carbonatoms (“C3-8 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms (“C3-7 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C3-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C5-10 carbocyclyl”). Exemplary C3-6 carbocyclyl groups include cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (Ce), cyclohexenyl (Ce), cyclohexadienyl (Ce), and the like. Exemplary C3-8 carbocyclyl groups include the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (Cs), cyclooctenyl (Cs), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (Cs), and the like.

[0045] Exemplary C3-10 carbocyclyl groups include the aforementioned C3-8 carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro- 177- indenyl (C9), decahydronaphthalenyl (C10), spiro[4.5]decanyl (C10), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or contain a fused, bridged, or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”). Carbocyclyl can be saturated, and saturated carbocyclyl is referred to as “cycloalkyl.” In some embodiments, carbocyclyl is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms (“C3-10 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C3-8 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C3-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C5-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C5-10 cycloalkyl”). Examples of C5-6 cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). Examples of C3-6 cycloalkyl groups include the aforementioned C5-6 cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-8 cycloalkyl groups include the aforementioned C3-6 cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (Cs). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl group is unsubstituted C3-10 cycloalkyl. In certain embodiments, the cycloalkyl group is substituted C3-10 cycloalkyl. Carbocyclyl can be partially unsaturated.

[0046] Carbocyclyl may include zero, one, or more (e.g., two, three, or four, as valency permits) C=C double bonds in all the rings of the carbocyclic ring system that are not aromatic or heteroaromatic. Carbocyclyl including one or more (e.g., two or three, as valency permits) C=C double bonds in the carbocyclic ring is referred to as “cycloalkenyl.” Carbocyclyl including one or more (e.g., two or three, as valency permits) C=C triple bonds in the carbocyclic ring is referred to as “cycloalkynyl.” “Carbocyclyl” also includes ring systems wherein the carbocyclylring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently optionally substituted, e.g., unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents. In certain embodiments, the carbocyclyl group is unsubstituted C3-10 carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C3-10 carbocyclyl. In certain embodiments, the carbocyclyl is substituted or unsubstituted, 3- to 7-membered, and monocyclic. In certain embodiments, the carbocyclyl is substituted or unsubstituted, 5- to 13-membered, and bicyclic.

[0047] In some embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms (“C3-10 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C3-8 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C3-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C5-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C5-10 cycloalkyl”). Examples of C5-6 cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). Examples of C3-6 cycloalkyl groups include the aforementioned C5-6 cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-8 cycloalkyl groups include the aforementioned C3-6 cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (Cs). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl group is unsubstituted C3-10 cycloalkyl. In certain embodiments, the cycloalkyl group is substituted C3-10 cycloalkyl. In certain embodiments, the carbocyclyl includes oxo substituted thereon.

[0048] “Heterocyclyl” or “heterocyclic” refers to a radical of a 3- to 13-membered nonaromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“3-13 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged, or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”). A heterocyclyl group can be saturated or can be partially unsaturated. Heterocyclyl may include zero, one, or more e.g., two, three, or four, as valency permits) double bonds in all the rings of the heterocyclic ring system that are not aromatic or heteroaromatic. Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein theheterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently optionally substituted, e.g., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents. In certain embodiments, the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3-10 membered heterocyclyl. In certain embodiments, the heterocyclyl is substituted or unsubstituted, 3- to 7-membered, and monocyclic. In certain embodiments, the heterocyclyl is substituted or unsubstituted, 5- to 13-membered, and bicyclic. In certain embodiments, the heterocyclyl includes oxo substituted thereon.

[0049] In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.

[0050] Exemplary 3-membered heterocyclyl groups containing one heteroatom include azirdinyl, oxiranyl, or thiiranyl. Exemplary 4-membered heterocyclyl groups containing one heteroatom include azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclyl groups containing one heteroatom include tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2, 5-dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include piperidinyl, tetrahydropyranyl,dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include triazinanyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include azepanyl, oxepanyl and thiepanyl.

[0051] Exemplary 8-membered heterocyclyl groups containing one heteroatom include azocanyl, oxecanyl, and thiocanyl. Exemplary 5-membered heterocyclyl groups fused to a G, aryl ring (also referred to herein as a 5,6-bicyclic heterocyclic ring) include indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocyclic ring) include tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.

[0052] “Aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 147i electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“Ce-14 aryl”). In some embodiments, an aryl group has six ring carbon atoms (“ aryl”; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms (“Cioaryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“Cnaryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of an aryl group is independently optionally substituted, e.g., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents. In certain embodiments, the aryl group is unsubstituted Ce-14 aryl. In certain embodiments, the aryl group is substituted Ce-14 aryl.

[0053] “Heteroaryl” refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 107t electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-10 membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one ormore aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl / heteroaryl) ring system. Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, e.g., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).

[0054] In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently optionally substituted, e.g., unsubstituted (“unsubstituted heteroaryl”) or substituted (“substituted heteroaryl”) with one or more substituents. In certain embodiments, the heteroaryl group is unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is substituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is 5-6 membered, monocyclic. In certain embodiments, the heteroaryl group is 8-14 membered, bicyclic.

[0055] Exemplary 5-membered heteroaryl groups containing one heteroatom include pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include triazinyl and tetrazinyl, respectively. Exemplary 7-memberedheteroaryl groups containing one heteroatom include azepinyl, oxepinyl, and thiepinyl.

[0056] Exemplary 5,6-bicyclic heteroaryl groups include indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0057] “Partially unsaturated” refers to a group that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic groups (e.g., aryl or heteroaryl groups) as herein defined. Likewise, “saturated” refers to a group that does not contain a double or triple bond, i.e., contains all single bonds.

[0058] In some embodiments, aliphatic, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are optionally substituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” carbocyclyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group). In general, the term “substituted”, whether preceded by the term “optionally” or not, means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term “substituted” is contemplated to include substitution with all permissible substituents of organic compounds, any of the substituents described herein that results in the formation of a stable compound. The present disclosure contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this disclosure, heteroatoms such as nitrogen may have hydrogen substituents and / or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.

[0059] Exemplary carbon atom substituents include halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -ORaa, -ON(Rbb)2, -N(Rbb)2, -N(Rbb)3+X“, -N(ORcc)Rbb, -SH, -SRaa, -SSRCC, -C(=O)Raa, -CO2H, -CHO, -C(ORCC)2, -CO2Raa, -OC(=O)Raa, -OCO2Raa, -C(=O)N(Rbb)2, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, -C(=NRbb)Raa,-C(=NRbb)ORaa, -OC(=NRbb)Raa, -OC(=NRbb)ORaa, -C(=NRbb)N(Rbb)2, -OC(=NRbb)N(Rbb)2, -NRbbC(=NRbb)N(Rbb)2, -C(=O)NRbbSO2Raa, -NRbbSO2Raa, -SO2N(Rbb)2, -SO2Raa, -SO2ORaa, -OSO2Raa, -S(=O)Raa, -OS(=O)Raa, -Si(Raa)3, -OSi(Raa)3, -C(=S)N(Rbb)2, -C(=O)SRaa, -C(=S)SRaa, -SC(=S)SRaa, -SC(=O)SRaa, -OC(=O)SRaa, -SC(=O)ORaa, -SC(=O)Raa, -P(=O)(Raa)2, -P(=O)(ORCC)2, -OP(=O)(Raa)2, -OP(=O)(ORCC)2, -P(=O)(N(Rbb)2)2, -OP(=O)(N(Rbb)2)2, -NRbbP(=O)(Raa)2, -NRbbP(=O)(ORcc)2, -NRbbP(=O)(N(Rbb)2)2, -P(RCC)2, -P(ORCC)2, -P(RCC)3+X-, -P(ORCC)3+X- -P(RCC)4, -P(ORCC)4, -OP(RCC)2, -OP(RCC)3+X-, -OP(ORCC)2, -OP(ORCC)3+X-, -OP(RCC)4, -OP(ORCC)4, -B(Raa)2, -B(ORCC)2, -BRaa(ORcc), Ci-io alkyl, Ci-io perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, heteroCi-io alkyl, heteroC2-io alkenyl, heteroC2-io alkynyl, C3-io carbocyclyl, 3-14 membered heterocyclyl, Ce-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups;

[0060] or two geminal hydrogens on a carbon atom are replaced with the group =0, =S, =NN(Rbb)2, =NNRbbC(=O)Raa, =NNRbbC(=O)ORaa, =NNRbbS(=O)2Raa, =NRbb, or =NORCC; each instance of Raais, independently, selected from Ci-io alkyl, Ci-io perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, heteroCi-io alkyl, heteroC2-ioalkenyl, heteroC2-ioalkynyl, C3-io carbocyclyl, 3-14 membered heterocyclyl, Ce-i4 aryl, and 5-14 membered heteroaryl, or two Raagroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups;

[0061] each instance of Rbbis, independently, selected from hydrogen, -OH, -ORaa, -N(RCC)2, -CN, -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO2Raa, -C(=NRcc)ORaa, -C(=NRCC)N(RCC)2, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SORaa, -C(=S)N(RCC)2, -C(=O)SRCC, -C(=S)SRCC, -P(=O)(Raa)2, -P(=O)(ORCC)2, -P(=O)(N(RCC)2)2, CI-IO alkyl, Ci-io perhaloalkyl, C2-10 alkenyl, C2. io alkynyl, heteroCi-ioalkyl, heteroC2-ioalkenyl, heteroC2-ioalkynyl, C3-io carbocyclyl, 3-14 membered heterocyclyl, Ce-14 aryl, and 5-14 membered heteroaryl, or two Rbbgroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups;

[0062] each instance of Rccis, independently, selected from hydrogen, Ci-io alkyl, Ci-io perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, heteroCi-io alkyl, heteroC2-io alkenyl, heteroC2-io alkynyl, C3-io carbocyclyl, 3-14 membered heterocyclyl, Ce-14 aryl, and 5-14 membered heteroaryl, or two Rccgroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups;

[0063] each instance of Rddis, independently, selected from halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -ORee, -ON(Rff)2, -N(Rff)2, -N(Rff)3+X“, -N(ORee)Rff, -SH, -SRee, -SSRee, -C(=O)Ree, -CO2H, -CO2Ree, -OC(=O)Ree, -OCO2Ree, -C(=O)N(Rff)2, -OC(=O)N(Rff)2, -NRffC(=O)Ree, -NRffCO2Ree, -NRffC(=O)N(Rff)2, -C(=NRff)ORee, -OC(=NRff)Ree, -OC(=NRff)ORee, -C(=NRff)N(Rff)2, -OC(=NRff)N(Rff)2, -NRffC(=NRff)N(Rff)2, -NRffSO2Ree, -SO2N(Rff)2, -SO2Ree, -SO2ORee, -OSO2Ree, -S(=O)Ree, -Si(Ree)3, -OSi(Ree)3, -C(=S)N(Rff)2, -C(=O)SRee, -C(=S)SRee, -SC(=S)SRee, -P(=O)(ORee)2, -P(=O)(Ree)2, -OP(=O)(Ree)2, -OP(=O)(ORee)2, C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, C2-6 alkynyl, heteroCi-ealkyl, heteroC2-6alkenyl, heteroC2-6alkynyl, C3-10 carbocyclyl, 3-10 membered heterocyclyl, CMO aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups, or two geminal Rddsubstituents can be joined to form =0 or =S;

[0064] each instance of Reeis, independently, selected from C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, C2-6 alkynyl, heteroCi-6 alkyl, heteroC2-6alkenyl, heteroC2-6 alkynyl, C3-10 carbocyclyl, Ce-io aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups;

[0065] each instance of Rffis, independently, selected from hydrogen, C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, C2-6 alkynyl, heteroCi -ealkyl, heteroC2-6alkenyl, heteroC2-6alkynyl, C3 10 carbocyclyl, 3-10 membered heterocyclyl, Ce-io aryl and 5-10 membered heteroaryl, or two Rffgroups are joined to form a 3-10 membered heterocyclyl or 5-10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups; and

[0066] each instance of Rggis, independently, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC1-6 alkyl, -ON(CI-6alkyl)2, -N(CI-6alkyl)2, -N(CI-6alkyl)3+X-, -NH(CI-6alkyl)2+X-, -NH2(CI-6alkyl)+X~, -NH3+X’, -N(OCI-6alkyl)(Ci-6alkyl), -N(OH)(CI-6alkyl), -NH(OH), -SH, -SC1-6 alkyl, -SS(Ci-6alkyl), -C(=O)(Ci-6alkyl), -CO2H, -CO2(Ci-6alkyl), -OC(=O)(Ci-6 alkyl), -OCO2(Ci-6alkyl), -C(=O)NH2, -C(=O)N(CI-6alkyl)2, -OC(=O)NH(CI-6alkyl), -NHC(=O)( C1-6 alkyl), -N(CI-6alkyl)C(=O)( C1-6 alkyl), -NHCO2(CI-6alkyl), -NHC(=O)N(Ci-6 alkyl)2, -NHC(=O)NH(CI-6alkyl), -NHC(=O)NH2, -C(=NH)O(CI-6alkyl), -OC(=NH)(CI-6alkyl), -OC(=NH)OCI-6alkyl, -C(=NH)N(CI-6alkyl)2, -C(=NH)NH(CI-6alkyl), -C(=NH)NH2, -OC(=NH)N(CI-6alkyl)2, -OC(NH)NH(CI-6alkyl), -OC(NH)NH2, -NHC(NH)N(CI-6alkyl)2,-NHC(=NH)NH2, -NHSO2(CI-6 alkyl), -SO2N(CI-6alkyl)2, -SO2NH(CI-6alkyl), -SO2NH2, -SO2Ci-6alkyl, -SO2OC16 alkyl, -OSO2C16 alkyl, -SOCi-6 alkyl, -Si(Ci-6alkyl)3, -OSi(Ci-6alkyl)3-C(=S)N(CI-6alkyl)2, C(=S)NH(CI-6alkyl), C(=S)NH2, -C(=O)S(Ci-6alkyl), -C(=S)SCi-6 alkyl, -SC(=S)SCi-6alkyl, -P(=O)(OCi-6alkyl)2, -P(=O)(Ci-6alkyl)2, -OP(=O)(Ci-6alkyl)2, -0P(=0)(0Ci-6 alkyl)2, Ci-6 alkyl, Ci-6 perhaloalkyl, C2-6 alkenyl, C2-6 alkynyl, heteroCi-ealkyl, heteroC2-6alkenyl, heteroC2-6alkynyl, C3-10 carbocyclyl, Ce-io aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal Rggsubstituents can be joined to form =0 or =S; and each X“ is a counterion.

[0067] In certain embodiments, the carbon atom substituents are independently halogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, -OR32, -SR351, -N(Rbb)2, -CN, -SCN, -NO2, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, -OC(=O)Raa, -OCO2R33, -OC(=O)N(Rbb)2, -NRbbC(=0)R33, -NRbbCO2Raa, or -NRbbC(=O)N(Rbb)2. In certain embodiments, the carbon atom substituents are independently halogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, -ORaa, -SRaa, -N(Rbb)2, -CN, -SCN, -NO2, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, -OC(=O)Raa, -OCO2Raa, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, or -NRbbC(=O)N(Rbb)2, wherein Raais hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group (e.g., acetamidomethyl, t-Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine-sulfenyl, or triphenylmethyl) when attached to a sulfur atom; and each Rbbis independently hydrogen, substituted e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, or a nitrogen protecting group. In certain embodiments, the carbon atom substituents are independently halogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, -ORaa, -SRaa, -N(Rbb)2, -CN, -SCN, or -NO2. In certain embodiments, the carbon atom substituents are independently halogen, substituted (e.g., substituted with one or more halogen moieties) or unsubstituted C1-6 alkyl, -OR33, -SR33, -N(Rbb)2, -CN, -SCN, or -NO2, wherein Raais hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group (e.g., acetamidomethyl, z-Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine-sulfenyl, or triphenylmethyl) when attached to a sulfur atom; and each Rbbis independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, or a nitrogen protecting group. In certain embodiments, each of the carbon atom substituents is independently halo, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR33, -N(Rbb)2, -SH, -SR33, -SSRCC, -C(=0)R33, -CO2H, -CHO, -CO2R33, -0C(=0)R33, -OCO2R33, -C(=O)N(Rbb)2, -OC(=O)N(Rbb)2, -NRbbC(=0)R33, -NRhhCO2R;i;i, -NRbbC(=O)N(Rbb)2, -C(=O)NRbbSO2R33, -NRbbSO2R33, -SO2N(Rbb)2, -SO2R33, -SO2OR33,-0S02Raa, -S(=O)Raa, -OS(=O)Raa, Ci-io alkyl, Ci-io perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, heteroCi-10 alkyl, heteroC2-io alkenyl, heteroC2-io alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, Ce-14 aryl, 5-14 membered heteroaryl, or =0, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups. In certain embodiments, each of the carbon atom substituents is independently halo, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -0Raa, -N(Rbb)2, -SH, -SRaa, -SSRCC, -C(=O)Raa, -CO2H, -CHO, -CO2Raa, -OC(=O)Raa, -OCO2Raa, -C(=O)N(Rbb)2, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, -C(=O)NRbbSO2Raa, -NRbbSO2Raa, -SO2N(Rbb)2, -SO2Raa, -SO2ORaa, -OSO2Raa, -S(=O)Raa, -OS(=O)Raa, Ci -10 alkyl, Ci-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, or =0, wherein each alkyl, alkenyl, and alkynyl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups. In certain embodiments, each of the carbon atom substituents is independently halo, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -0Raa, -N(Rbb)2, -SH, -SRaa, -SSRCC, -C(=O)Raa, -CO2H, -CHO, -CO2Raa, -OC(=O)Raa, -OCO2Raa, -C(=O)N(Rbb)2, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, -C(=O)NRbbSO2Raa, -NRbbSO2Raa, -SO2N(Rbb)2, -SO2Raa, -SO2ORaa, -OSO2Raa, -S(=O)Raa, -OS(=O)Raa, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, or =0, wherein Raais C1-10 alkyl or C1-10 perhaloalkyl, and each of Rbband Rccis independently hydrogen, C1-10 alkyl, or C1-10 perhaloalkyl.

[0068] A “counterion” or “anionic counterion” is a negatively charged group associated with a positively charged group in order to maintain electronic neutrality. An anionic counterion may be monovalent (i.e., including one formal negative charge). An anionic counterion may also be multivalent (i.e., including more than one formal negative charge), such as divalent or trivalent. Exemplary counterions include halide ions (e.g., F, Cl", Br, I"), NO3", CIO4", OH", H2PO4, HCOs", HSO4", sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene- 1 -sulfonic acid-5-sulfonate, ethan-l-sulfonic acid-2-sulfonate, and the like), carboxylate ions (e.g., acetate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, gluconate, and the like), BFr, PF4", PFe", AsEs", SbFc,, B[3,5-(Cp3)2C6H3]4]", B(C6F5)4“, BPhr, A1(OC(CF3)3)4", and carborane anions (e.g., CB11H12" or (HCBnMesBre) ). Exemplary counterions which may be multivalent include CO?2", HPO ", PO " B4O?2", SO42", S2O32", carboxylate anions (e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like), and carboranes.

[0069] “Halo” or “halogen” refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include hydrogen, -OH, -ORaa, -N(RCC)2, -CN, -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO2Raa, -C(=NRbb)Raa, -C(=NRcc)ORaa, -C(=NRCC)N(RCC)2, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SORaa, -C(=S)N(RCC)2, -C(=O)SRCC, -C(=S)SRCC, -P(=O)(ORCC)2, -P(=O)(Raa)2, -P(=O)(N(RCC)2)2, Ci-io alkyl, Ci-io perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, heteroCi-ioalkyl, heteroC2-ioalkenyl, heteroC2-ioalkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, Ce-14 aryl, and 5-14 membered heteroaryl, or two Rccgroups attached to an N atom are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups, and wherein Raa, Rbb, Rcc, and Rddare as defined above.

[0070] In certain embodiments, the nitrogen atom substituents are independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, -C(=O)Raa, -CCbR 'k -C(=O)N(Rbb)2, or a nitrogen protecting group. In certain embodiments, the nitrogen atom substituents are independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, or a nitrogen protecting group, wherein Raais hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, or an oxygen protecting group when attached to an oxygen atom; and each Rbbis independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl, or a nitrogen protecting group. In certain embodiments, the nitrogen atom substituents are independently substituted (e.g., substituted with one or more halogen) or unsubstituted C1-6 alkyl or a nitrogen protecting group.

[0071] In certain embodiments, the substituent present on a nitrogen atom is a nitrogen protecting group (also referred to as an amino protecting group). Nitrogen protecting groups include -OH, -ORaa, -N(RCC)2, -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO2Raa, -C(=NRcc)Raa, -C(=NRcc)ORaa, -C(=NRCC)N(RCC)2, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SORaa, -C(=S)N(RCC)2, -C(=O)SRCC, -C(=S)SRCC, Ci-10 alkyl (e.g., aralkyl, heteroaralkyl), C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, Ce-14 aryl, and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups, and wherein Raa, Rbb, Rcc, and Rddare as defined herein. Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, incorporated herein by reference.In certain embodiments, each of the nitrogen atom substituents is independently -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO2Raa, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SORaa, Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, Ce-14 aryl, or 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups. In certain embodiments, each of the nitrogen atom substituents is independently -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO2Raa, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SORaa, Ci-io alkyl, C210 alkenyl, or C2-10 alkynyl, wherein each alkyl, alkenyl, and alkynyl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups. In certain embodiments, each of the nitrogen atom substituents is independently -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO^^, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SORaa, Ci-10 alkyl, C2-10 alkenyl, or C2-10 alkynyl, wherein each alkyl, alkenyl, and alkynyl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; Raais C1-10 alkyl or C1-10 perhaloalkyl; each Rccis independently hydrogen, C1-10 alkyl, or C1-10 perhaloalkyl; and each Rddis independently halo, -CN, -OH, -O(Ci-6 alkyl), -NH2, -NH(CI-6 alkyl), -N(CI-6 alkyl)2, C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, or C2-6 alkynyl.

[0072] Amide nitrogen protecting groups (e.g., -C(=O)Raa) include formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, A-benzoylphenylalanyl derivative, benzamide, p-phenylbenzarnide, o-nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (A-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, A-acetylmethionine, o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide.

[0073] Carbamate nitrogen protecting groups (e.g., -C(=O)ORaa) include methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fhioroenyhnethyl carbamate, 2,7-di-t-butyl-[9-(10, 10-dioxo-10, 10, 10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), l-(l-adamantyl)-l -methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, l,l-dimethyl-2,2-dibromoethyl carbamate (DB- / -BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1 -methyl- l-(4-biphenylyl)ethyl carbamate (Bpoc), l-(3,5-di- / -biitylphenyl)- l-methylethyl carbamate (t-Bumeoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N, A-dicyclohexylcarboxamido)ethyl carbamate, / -butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolylcarbamate, iV-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(l,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), l,l-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxy benzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenylf -nitrophenyl)methyl carbamate, / -amyl carbamate,. S'-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, o-(N, A i methy Icarboxam idojbenzy I carbamate, 1, 1 - i methy l-3-( N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p ’-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1 -methylcyclohexyl carbamate, 1 -methyl- 1 -cyclopropylmethyl carbamate, l-methyl-l-(3,5-dimethoxyphenyl)ethyl carbamate, 1 -methyl- l-(p-phenylazophenyl)ethyl carbamate, 1 -methyl- 1 -phenylethyl carbamate, 1 -methyl- 1 -(4-pyridyl)ethyl carbamate, phenyl carbamate, -(phenylazo)benzyl carbamate, 2,4,6-tri- / -butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.

[0074] Sulfonamide nitrogen protecting groups (e.g., -S(=O)2Raa) include -toliienesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), 0-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8 -dimethoxynaphthylmethyl)benzenesulfonamide (DNMB S), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.

[0075] Other nitrogen protecting groups include phenothiazinyl-(10)-acyl derivative, N’-p-toluenesulfonylaminoacyl derivative, iV’-phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, A-acetylmethionine derivative, 4,5-diphenyl-3-oxazolin-2-one, A-phthalimide, A-di th iasuccin imide (Dts), A-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, A, 1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted l,3-dimethyl-l,3,5-triazacyclohexan-2-one, 5-substituted l,3-dibenzyl-l,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, A-methylamine, A-allylamine, A-[2-(trimethylsilyl)ethoxy]methylamine (SEM), A-3-acetoxypropylamine, A-( l-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, A-benzylamine, A-di(4-methoxyphenyl)methylamine, A-5-dibenzosuberylamine, A-triphenylmethylamine (Tr), A-[(4-methoxyphenyl) diphenylmethyl] amine (MMTr), A-9-phenylfluorenylamine (PhF), N-2,2-dichloro-9-fluorenylmethyleneamine, A-ferrocenylmethylamino (Fem), A-2-picolylamino N’-oxide, AM,l-dimethylthiomethyleneamine, A-benzylideneamine, N-p-methoxybenzylideneamine, A-diphenylmethyleneamine, N-[(2-pyridyl)mesityl] methyleneamine, A-(A', A-dimethylaminomethylene)amine, N, N’~ isopropylidenediamine, A-p-nitrobenzylideneamine, A-salicylideneamine, N-5-chlorosalicylideneamine, A-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, A-(5,5-dimethyl-3-oxo- l-cyclohexenyl)amine, A-borane derivative, A-diphenylborinic acid derivative, A-[phenyl(pentaacylchromium- or tungsten) acyl] amine, A-copper chelate, A-zinc chelate, A-nitroamine, A-nitrosoamine, amine A-oxide, diphenylphosphinamide (Dpp), dimethylthiopho sphinamide (Mpt), diphenylthiopho sphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys).

[0076] In certain embodiments, a nitrogen protecting group is Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts.

[0077] In certain embodiments, the oxygen atom substituents are independently substituted (e.g., substituted with one or more halogen) or unsubstituted Ci-6 alkyl, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, or an oxygen protecting group. In certain embodiments, the oxygen atom substituents are independently substituted (e.g., substituted with one or more halogen) or unsubstituted Ci-6 alkyl, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, or an oxygen protecting group, wherein Raais hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted Ci-6 alkyl, or an oxygen protecting group when attached to an oxygen atom; and each Rbbis independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted Ci-6 alkyl, or a nitrogen protecting group. In certain embodiments, the oxygen atom substituentsare independently substituted (e.g., substituted with one or more halogen) or unsubstituted Ci-6 alkyl or an oxygen protecting group.

[0078] In certain embodiments, the substituent present on an oxygen atom is an oxygen protecting group (also referred to herein as an “hydroxyl protecting group”). Oxygen protecting groups include -Raa, -N(Rbb)2, -C(=O)SRaa, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, -C(=NRbb)Raa, -C(=NRbb)ORaa, -C(=NRbb)N(Rbb)2, -S(=O)Raa, -SO2Raa, -Si(Raa)3, -P(RCC)2, -P(RCC)3+X-, -P(ORCC)2, -P(ORCC)3+X- -P(=O)(Raa)2, -P(=O)(ORCC)2, and -P(=O)(N(Rbb) 2)2, wherein X-, Raa, Rbb, and Rccare as defined herein. Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, incorporated herein by reference.

[0079] Exemplary oxygen protecting groups include methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxy benzyl oxy methyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), / -butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S, S-dioxide, l-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), l,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, l-(2-chloroethoxy)ethyl, 1-methyl-l-methoxyethyl, 1-methyl-l-benzyloxyethyl, 1 -methyl- l-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, / -butyl, allyl, p-chloropheny 1, p-methoxypheny 1, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl A-oxido, diphenylmethyl, p,p -dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, a-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4,4',4"-tris(benzoyloxyphenyl)methyl, 3-(imidazol-l-yl)bis(4',4"-dimethoxyphenyl)methyl, 1, l-bis(4-methoxyphenyl)-l'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, l,3-benzodisulfuran-2-yl, benzisothiazolyl S, S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), z butyldi phenyl si lyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-methoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl. S'-benzyl thiocarbonate, 4-ethoxy-l-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-( 1, 1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis( 1, 1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, ( )-2-methyl-2-butenoate,

[0080] methoxyacyl) benzoate, a-naphthoate, nitrate, alkyl N, N, N', N'-tetramethylphosphorodiamidate, alkyl / V-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts).

[0081] In certain embodiments, an oxygen protecting group is silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl.

[0082] In certain embodiments, the sulfur atom substituents are independently substituted (e.g., substituted with one or more halogen) or unsubstituted Ci-6 alkyl, -C(=O)Raa, -CO2Raa, -C(=0)N(Rbb)2, or a sulfur protecting group. In certain embodiments, the sulfur atom substituents are independently substituted (e.g., substituted with one or more halogen) or unsubstituted Ci-6 alkyl, -C(=O)Raa, -CO2Raa, -C(=0)N(Rbb)2, or a sulfur protecting group, wherein Raais hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted Ci-6 alkyl, or an oxygen protecting group when attached to an oxygen atom; and each Rbbis independently hydrogen, substituted (e.g., substituted with one or more halogen) or unsubstituted Ci-6 alkyl, or a nitrogen protecting group. In certain embodiments, the sulfur atom substituents are independently substituted (e.g., substituted with one or more halogen) or unsubstituted Ci-6 alkyl or a sulfur protecting group.In certain embodiments, the substituent present on a sulfur atom is a sulfur protecting group (also referred to as a “thiol protecting group”). Sulfur protecting groups include -Raa, -N(Rbb)2, -C(=O)SRaa, -C(=O)Raa, -CO2Raa, -C(=O)N(Rbb)2, -C(=NRbb)Raa, -C(=NRbb)ORaa, -C(=NRbb)N(Rbb)2, -S(=O)Raa, -SO2Raa, -Si(Raa)3, -P(RCC)2, -P(RCC)3+X“, -P(ORCC)2, -P(ORCC)3+X~, -P(=O)(Raa)2, -P(=O)(ORCC)2, and -P(=O)(N(Rbb)2)2, wherein Raa, Rbb, and Rccare as defined herein. Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, incorporated herein by reference. In certain embodiments, a sulfur protecting group is acetamidomethyl, / -Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine-sulfenyl, or triphenylmethyl.

[0083] The “molecular weight” of -R, wherein -R is any monovalent moiety, is calculated by subtracting the atomic weight of a hydrogen atom from the molecular weight of the molecule R-H. The “molecular weight” of -L-, wherein -L- is any divalent moiety, is calculated by subtracting the combined atomic weight of two hydrogen atoms from the molecular weight of the molecule H-L-H.

[0084] In certain embodiments, the molecular weight of a substituent is lower than 200, lower than 150, lower than 100, lower than 50, or lower than 25 g / mol. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, iodine, oxygen, sulfur, nitrogen, and / or silicon atoms. In certain embodiments, a substituent consists of carbon, hydrogen, fluorine, chlorine, bromine, and / or iodine atoms. In certain embodiments, a substituent consists of carbon, hydrogen, and / or fluorine atoms. In certain embodiments, a substituent does not comprise one or more, two or more, or three or more hydrogen bond donors. In certain embodiments, a substituent does not comprise one or more, two or more, or three or more hydrogen bond acceptors.

[0085] These and other exemplary substituents are described in more detail in the Detailed Description, Examples, Figures, and Claims. The present disclosure is not intended to be limited in any manner by the above exemplary listing of substituents.

[0086] “Pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and other animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically acceptable salts of the compounds describe herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed withinorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, -toliienesiilfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, quaternary salts.

[0087] The term “solvate” refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding.

[0088] Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The provided compounds may be prepared, e.g., in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non- stoichiometric solvates. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid. “Solvate” encompasses both solution-phase and isolable solvates. Representative solvates include hydrates, ethanolates, and methanolates.

[0089] The term “hydrate” refers to a compound that is associated with water. Typically, the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula Rx H2O, wherein R is the compound and wherein x is a number greater than 0. A given compound may form more than one type of hydrates, including, e.g., monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R-0.5 H2O)), and polyhydrates (x is a number greater than 1, e.g., dihydrates (R-2 H2O) and hexahydrates (R-6 H2O)).

[0090] The term “tautomers” refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of n electrons and an atom (usuallyH). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane, that are likewise formed by treatment with acid or base. Another example of tautomerism is heteroaryl (e.g., pyrazole and imidazole) tautomerism. Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.

[0091] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.

[0092] The term “co-crystal” refers to a crystalline structure comprising at least two different components (e.g., a compound and an acid), wherein each of the components is independently an atom, ion, or molecule. In certain embodiments, none of the components is a solvent. In certain embodiments, at least one of the components is a solvent. A co-crystal of a compound and an acid is different from a salt formed from a compound and the acid. In the salt, a compound is complexed with the acid in a way that proton transfer (e.g., a complete proton transfer) from the acid to a compound easily occurs at room temperature. In the co-crystal, however, a compound is complexed with the acid in a way that proton transfer from the acid to a herein does not easily occur at room temperature. In certain embodiments, in the co-crystal, there is substantially no proton transfer from the acid to a compound. In certain embodiments, in the co-crystal, there is partial proton transfer from the acid to a compound. Co-crystals may be useful to improve the properties (e.g., solubility, stability, and ease of formulation) of a compound.

[0093] The term “polymorphs” refers to a crystalline form of a compound (or a salt, hydrate, or solvate thereof) in a particular crystal packing arrangement. All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storagetemperature, and other factors may cause one crystal form to dominate. Various polymorphs of a compound can be prepared by crystallization under different conditions.

[0094] The term “prodrugs” refer to compounds, including derivatives of the provided compounds, which have cleavable groups and become by solvolysis or under physiological conditions the provided compounds which are pharmaceutically active in vivo. Such examples include, but are not limited to, ester derivatives and the like. Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but in the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups pendant on the compounds of this invention are particular prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. Ci to Cs alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C7-C12 substituted aryl, and C7-C12 arylalkyl esters of the provided compounds may be preferred.

[0095] The terms “composition” and “formulation” are used interchangeably.

[0096] A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) and / or other non-human animals, for example, mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and / or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and / or turkeys). In certain embodiments, the subject is a mammal. The subject may be a male or female and at any stage of development. A non-human animal may be a transgenic animal.

[0097] The term “biological sample” refers to any sample including tissue samples (such as tissue sections and needle biopsies of a tissue); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); samples of whole organisms (such as samples of yeasts or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise). Other examples of biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (e.g., obtained by a surgical biopsy or needle biopsy), nipple aspirates, milk, vaginal fluid, saliva,swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.

[0098] The terms “administer,” “administering,” or “administration,” refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound, or a pharmaceutical composition thereof.

[0099] The terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a “pathological condition” (e.g., a disease, disorder, or condition, or one or more signs or symptoms thereof) described herein. In some embodiments, treatment may be administered after one or more signs or symptoms have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease or condition. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.

[0100] The term “prevent,” “preventing,” or “prevention” refers to a prophylactic treatment of a subject who is not and was not with a disease but is at risk of developing the disease or who was with a disease, is not with the disease, but is at risk of regression of the disease. In certain embodiments, the subject is at a higher risk of developing the disease or at a higher risk of regression of the disease than an average healthy member of a population of subjects.

[0101] The terms “condition,” “disease,” and “disorder” are used interchangeably.

[0102] An “effective amount” of a provided compound refers to an amount sufficient to elicit the desired biological response, i.e., treating the condition. As will be appreciated by those of ordinary skill in this art, the effective amount of a provided compound may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. An effective amount encompasses therapeutic and prophylactic treatment. For example, in treating cancer, an effective amount of a compound may reduce the tumor burden or stop the growth or spread of a tumor.

[0103] A “therapeutically effective amount” of a provided compound is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoidssymptoms or causes of the condition, or enhances the therapeutic efficacy of another therapeutic agent.

[0104] A “prophylactically effective amount” of a provided compound is an amount sufficient to prevent a condition, or one or more symptoms associated with the condition or prevent its recurrence. A prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the condition. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.

[0105] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows the evolution of exemplary lolCDE inhibitors. Top panel: evolution of MICs and FoRs of exemplary lolCDE inhibitors. Bottom panel: an exemplary convergent component-based synthesis of ciprimelpin.

[0106] FIG. 2 shows exemplary in vitro cumulative susceptibility of Enterobacteriaceae to ciprimelpin and clinical standard-of-care antibiotics.

[0107] FIGs. 3A to 3D show in vivo efficacy of ciprimelpin. FIG. 3A shows a murine thigh infection model for E. coli with both oral and intravenous administration. FIG. 3B shows a murine thigh infection model for K. pneumoniae with both oral and intravenous administration. FIG. 3C shows a murine bloodstream infection model for E. coli. FIG. 3D shows a murine bloodstream infection model for K. pneumoniae.

[0108] FIGs. 4A to 4E show that ciprimelpin bound to LolCDE and prevented lipoprotein transport. FIG. 4A shows a location of a binding pocket within LolCDE complex. FIG. 4B shows a location of key resistance mutations outlining a putative ciprimelpin binding pocket. FIG. 4C shows a scheme of the one-cycle lipoprotein transfer assay used to measure ciprimelpin inhibition of BamE transport to LolA. FIG. 4D shows relative ATPase activities of LolCDE when treated with ciprimelpin and AMP-PNP. FIG. 4E is a Western blot from a single lipoprotein transport assay showing that ciprimelpin inhibited the transfer of the BamE lipoprotein from LolCDE to Lol A in a concentration-dependent manner.

[0109] FIG. 5 shows an X-ray crystal structure of ciprimelpin where the perspective views showed 50% probability displacement, and the disordered benzene ring was omitted for clarity FIG. 6 shows an X-ray crystal structure of ciprimelpin where the three-dimensional supramolecular architecture was viewed along the a-axis direction.

[0110] DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE DISCLOSURE

[0111] CompoundsIn one aspect, the present disclosure provides compounds, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, wherein:

[0112] the compounds are of Formula I':

[0113]

[0114] each of R1A, R1B, R1C, R1D, R2A, R2B, R3A, R3B, and R3Eis independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2;

[0115] or R1Aand R1Bare joined together with the intervening atoms to form a substituted or unsubstituted phenyl ring;each instance of RAis independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of RAattached to the same intervening atom are joined together with the intervening atom to form a substituted or unsubstituted, monocyclic, heterocyclic or heteroaryl ring;

[0116] R2Cis attached to one of the two ring nitrogen atoms of Ring C2 and is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2N(RA)2, or a nitrogen protecting group;

[0117] R3Cis absent, bond b is attached to the carbon atom to which R3Cis attached, and R3Dis hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA,

[0118] -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2; or R3Dis absent, bond b is attached to the carbon atom to which R3Dis attached, and R3Cis hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA,-S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2;

[0119] nl is 1, 2, or 3;

[0120] each instance of R5is independently hydrogen, halogen, or substituted or unsubstituted alkyl;

[0121] (C4)

[0122] — ' is Ring C4, which is:

[0123] fused bicyclic heteroaryl comprising at least one ring nitrogen atom in the fused bond or at least two adjacent ring nitrogen atoms;

[0124] 5,6-fused bicyclic heteroaryl comprising at least one ring nitrogen atom wherein bond c is attached to the 6-member ring of Ring C; or

[0125] monocyclic heterocyclyl fused with monocyclic heteroaryl or phenyl, wherein at least one ring atom of the monocyclic heterocyclyl is oxygen, and bond c is attached to the monocyclic heterocyclyl, the monocyclic heteroaryl, or the phenyl;

[0126] n2 is an integer between 0 and 8, inclusive;

[0127] when n2 is 0: Ring C4 is unsubstituted; and

[0128] when n2 is an integer between 1 and 8, inclusive: Ring C4 is substituted, each instance of R4at a carbon atom is independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2, and each instance of R4at a nitrogen atom is independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2N(RA)2, or a nitrogen protecting group;

[0129] provided that:Ring C4 is not of the formula:

[0130]

[0131] the compound is not of the formula:

[0132]

[0133]

[0134] In certain embodiments, the compounds are of Formula I:

[0135]

[0136] each of R1A, R1B, R1C, R1D, R2A, R2B, R3A, R3B, and R3Eis independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA,-OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2;

[0137] or R1Aand R1Bare joined together with the intervening atoms to form a substituted or unsubstituted phenyl ring;

[0138] each instance of RAis independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of RAattached to the same intervening atom are joined together with the intervening atom to form a substituted or unsubstituted, monocyclic, heterocyclic or heteroaryl ring;

[0139] R2Cis attached to one of the two ring nitrogen atoms of Ring C2 and is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C(=O)RA, -C(=O)ORA, -C(=0)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2N(RA)2, or a nitrogen protecting group;

[0140] R3Cis absent, bond b is attached to the carbon atom to which R3Cis attached, and R3Dis hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA,

[0141] -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2; or R3Dis absent, bond b is attached to the carbon atom to which R3Dis attached, and R3Cis hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=0)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2;

[0142] nl is 1, 2, or 3;

[0143] each instance of R5is independently hydrogen, halogen, or substituted or unsubstituted alkyl;

[0144]

[0145] is Ring C4, which is fused bicyclic heteroaryl comprising at least one ring nitrogen atom in the fused bond or at least two adjacent ring nitrogen atoms or is 5,6-fused bicyclic heteroaryl comprising at least one ring nitrogen atom wherein bond c is attached to the 6-member ring of Ring C;

[0146] n2 is an integer between 0 and 8, inclusive;

[0147] when n2 is 0: Ring C4 is unsubstituted; and

[0148] when n2 is an integer between 1 and 8, inclusive: Ring C4 is substituted, each instance of R4at a carbon atom is independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2, and each instance of R4at a nitrogen atom is independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2N(RA)2, or a nitrogen protecting group;provided that:

[0149]

[0150] the compound is not of the formula:

[0151]

[0152] , or

[0153]

[0154] The provided compounds may be useful as antibiotics. For example, ciprimelpin (

[0155]

[0156] was 78% orally bioavailable in mice and was both well tolerated and highly efficacious in vivo in murine infection models of Gram-negative bacteria of the family Enterobacteriaceae, either by oral or intravenous administration. The frequency of resistance to ciprimelpin in E. coli was less than one in IO10and required the occurrence of two or more simultaneous amino acid mutations in its bacterial protein target, the lolCDE component of the lipoprotein transport machinery. Even resistant mutants generated through serial passage experiments bearing four concurrent amino acid mutations within the lolCDE target remain highly susceptible to inhibition by ciprimelpin (MICs 1-2 pg mb1) and the spatial proximity of the mutant residues within lolCDE would seem to define a binding pocket. Mechanistically, ciprimelpin prevented lipoprotein transfer from the inner to the outer membrane at least by trapping lipoproteins within the LolCDE protein complex.

[0157] When Formula T, e.g., Formula I, includes two or more instances of a moiety, unless otherwise provided, any two instances of the moiety may be the same or different from each other. In certain embodiments, “at least one instance” is “each instance.”In certain embodiments, the compound of Formula F, e.g., Formula I, is of Formula I-A:

[0158]

[0159] In certain embodiments, the compound of Formula F, e.g., Formula I, is of Formula I-B:

[0160]

[0161] In certain embodiments, the compound of Formula F, e.g., Formula I, is of Formula I-C:

[0162]

[0163] In certain embodiments, the compound of Formula F, e.g., Formula I, is of Formula I-D:

[0164]

[0165] (I’D).

[0166] In certain embodiments, R1Ais hydrogen. In certain embodiments, R1Ais halogen. In certain embodiments, R1Ais -F. In certain embodiments, R1Ais -Cl. In certain embodiments, R1Ais -Br.

[0167] In certain embodiments, R1Ais substituted or unsubstituted alkyl. In certain embodiments, R1Ais unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with halogen. In certain embodiments, R1Ais unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with fluoro or chloro. In certain embodiments, R1Ais unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R1Ais unsubstituted C1-4 alkyl. In certain embodiments, R1Ais Et. In certain embodiments, R1Ais z?-Pr or z-Pr. In certain embodiments, R1Ais zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R1Ais t-Bu. In certain embodiments, R1Ais fluorinated methyl. In certain embodiments, R1Ais -CF3. In certain embodiments, R1Ais fluorinated ethyl. In certain embodiments, R1Ais chlorinated methyl. In certain embodiments, R1Ais chlorinated ethyl. In certain embodiments, R1Ais hydroxylated methyl. In certain embodiments, R1Ais hydroxylated ethyl. In certain embodiments, R1Ais -CH2-OH or -CH(OH)-CH2-OH. In certain embodiments, R1Ais -CH2-(substituted or unsubstituted phenyl). In certain embodiments, R1Ais Bn.

[0168] In certain embodiments, R1Ais substituted or unsubstituted alkenyl. In certain embodiments, R1Ais substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R1Ais unsubstituted C2-6 alkenyl. In certain embodiments, R1Ais unsubstituted vinyl. In certain embodiments, R1Ais unsubstituted allyl or -CH=CHCH3.

[0169] In certain embodiments, R1Ais substituted or unsubstituted alkynyl. In certain embodiments, R1Ais substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R1Ais unsubstituted C2-6 alkynyl. In certain embodiments, R1Ais C=CH. In certain embodiments, R1Ais -OCCH3 or CH2C =CH.In certain embodiments, R1Ais substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R1Ais substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R1Ais unsubstituted cyclopropyl. In certain embodiments, R1Ais saturated carbocyclyl. In certain embodiments, R1Ais partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0170] In certain embodiments, R1Ais substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R1Ais substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R1Ais saturated heterocyclyl. In certain embodiments, R1Ais partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0171] In certain embodiments, R1Ais substituted or unsubstituted aryl. In certain embodiments, R1Ais substituted or unsubstituted phenyl. In certain embodiments, R1Ais unsubstituted phenyl. In certain embodiments, R1Ais 4-mono-substituted phenyl. In certain embodiments, R1Ais 3-mono-substituted phenyl. In certain embodiments, R1Ais 2-mono-substituted phenyl. In certain embodiments, R1Ais di- substituted phenyl. In certain embodiments, R1Ais substituted or unsubstituted naphthyl.

[0172] In certain embodiments, R1Ais substituted or unsubstituted heteroaryl. In certain embodiments, R1Ais substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R1Ais substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R1Ais substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R1Ais substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R1Ais substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0173] In certain embodiments, R1Ais -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA,-OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=0)2RA, -S(=0)20RA, or -S(=O)2N(RA)2. In certain embodiments, R1Ais -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R1Ais -ORA. In certain embodiments, R1Ais -OH. In certain embodiments, R1Ais -O(substituted or unsubstituted alkyl). In certain embodiments, R1Ais -O(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R1Ais -O(unsubstituted C1-6 alkyl). In certain embodiments, R1Ais -OMe. In certain embodiments, R1Ais -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Ais -SRA. In certain embodiments, R1Ais -SH. In certain embodiments, R1Ais -S( substituted or unsubstituted alkyl). In certain embodiments, R1Ais ^(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R1Ais -S(unsubstituted C1-6 alkyl). In certain embodiments, R1Ais -SMe. In certain embodiments, R1Ais -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Ais -NH2. In certain embodiments, R1Ais -NHRA. In certain embodiments, R1Ais -NH(substituted or unsubstituted alkyl). In certain embodiments, R1Ais -NH(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R1Ais -NH(unsubstituted C1-6 alkyl). In certain embodiments, R1Ais -NHMe. In certain embodiments, R1Ais -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Ais -NHBoc. In certain embodiments, R1Ais -N(RA)2. In certain embodiments, R1Ais -N( substituted or unsubstituted alkyl)2. In certain embodiments, R1Ais -N( substituted or unsubstituted, C1-6 alkyl)2. In certain embodiments, R1Ais -N(unsubstituted Ci-6 alkyl)2. In certain embodiments, R1Ais -NMe2. In certain embodiments, R1Ais -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0174] In certain embodiments, R1Ais hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -SRA, or -N(RA)2. In certain embodiments, R1Ais hydrogen, -F, -Cl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted carbocyclyl, -ORA, -SRA, or -N(RA)2. In certain embodiments, R1Ais substituted or unsubstituted, C1-6 alkyl. In certain embodiments, R1Ais substituted or unsubstituted methyl. In certain embodiments, R1Ais -CH3.

[0175] In certain embodiments, at least one instance of RAis hydrogen. In certain embodiments, each instance of RAis hydrogen. In certain embodiments, at least one instance of RAis not hydrogen. In certain embodiments, no instance of RAis hydrogen.In certain embodiments, at least one instance of RAis substituted alkyl (e.g., alkyl substituted with one or more instances of halogen (e.g., F)). In certain embodiments, at least one instance of RAis unsubstituted alkyl. In certain embodiments, at least one instance of RAis unsubstituted Ci-6 alkyl. In certain embodiments, at least one instance of RAis Me. In certain embodiments, at least one instance of RAis Et, Pr, or Bu. In certain embodiments, at least one instance of RAis substituted Ci-6 alkyl. In certain embodiments, at least one instance of RAis substituted methyl (e.g., fluorinated methyl or Bn). In certain embodiments, at least one instance of RAis substituted ethyl, substituted propyl, or substituted butyl.

[0176] In certain embodiments, at least one instance of RAis substituted or unsubstituted alkenyl. In certain embodiments, at least one instance of RAis substituted or unsubstituted, C2-6 alkenyl (e.g., substituted or unsubstituted vinyl or substituted or unsubstituted allyl).

[0177] In certain embodiments, at least one instance of RAis substituted or unsubstituted alkynyl. In certain embodiments, at least one instance of RAis substituted or unsubstituted, C2-6 alkynyl (e.g., substituted or unsubstituted ethynyl).

[0178] In certain embodiments, at least one instance of RAis substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, at least one instance of RAis substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, at least one instance of RAis saturated carbocyclyl. In certain embodiments, at least one instance of RAis partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0179] In certain embodiments, at least one instance of RAis substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, at least one instance of RAis substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, at least one instance of RAis saturated heterocyclyl. In certain embodiments, at least one instance of RAis partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0180] In certain embodiments, at least one instance of RAis substituted or unsubstituted aryl. In certain embodiments, at least one instance of RAis substituted or unsubstituted phenyl. In certain embodiments, at least one instance of RAis unsubstituted phenyl. In certain embodiments, at least one instance of RAis 2-mono-substituted phenyl. In certain embodiments, at least oneinstance of RAis 3-mono-substituted phenyl. In certain embodiments, at least one instance of RAis 4-mono-substituted phenyl. In certain embodiments, RAis di- substituted phenyl. In certain embodiments, at least one instance of RAis substituted or unsubstituted naphthyl.

[0181] In certain embodiments, at least one instance of RAis substituted or unsubstituted heteroaryl. In certain embodiments, at least one instance of RAis substituted or unsubstituted, 5-to 6-membered, monocyclic heteroaryl. In certain embodiments, at least one instance of RAis substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, at least one instance of RAis substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, at least one instance of RAis substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, at least one instance of RAis substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0182] In certain embodiments, at least one instance of RAis a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts) when attached to a nitrogen atom. In certain embodiments, at least one instance of RAis an oxygen protecting group (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl) when attached to an oxygen atom. In certain embodiments, at least one instance of RAis a sulfur protecting group (e.g., acetamidomethyl, z-Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine-sulfenyl, or triphenylmethyl) when attached to a sulfur atom.

[0183] In certain embodiments, two instances of RAattached to the same intervening atom are joined together with the intervening atom to form substituted or unsubstituted, monocyclic heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, two instances of RAattached to the same intervening atom are joined together with the intervening atom to form substituted or unsubstituted, monocyclic heteroaryl (e.g., substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl).

[0184] In certain embodiments, each instance of RAis independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two instances of RAattached to the same intervening atom are joined together with the intervening atom to form a substituted or unsubstituted, monocyclic, heterocyclic or heteroaryl ring.

[0185] In certain embodiments, R1Bis halogen. In certain embodiments, R1Bis -F. In certain embodiments, R1Bis -Cl. In certain embodiments, R1Bis -Br.In certain embodiments, R1Bis substituted or unsubstituted alkyl. In certain embodiments, R1Bis substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, R1Bis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with halogen. In certain embodiments, R1Bis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with fluoro or chloro. In certain embodiments, R1Bis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R1Bis unsubstituted C1-4 alkyl. In certain embodiments, R1Bis Me. In certain embodiments, R1Bis Et. In certain embodiments, R1Bis z?-Pr or z-Pr. In certain embodiments, R1Bis zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R1Bis t-Bu. In certain embodiments, R1Bis fluorinated methyl. In certain embodiments, R1Bis -CF3. In certain embodiments, R1Bis fluorinated ethyl. In certain embodiments, R1Bis chlorinated methyl. In certain embodiments, R1Bis chlorinated ethyl. In certain embodiments, R1Bis -CH2-( substituted or unsubstituted phenyl). In certain embodiments, R1Bis Bn.

[0186] In certain embodiments, R1Bis substituted or unsubstituted alkenyl. In certain embodiments, R1Bis substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R1Bis unsubstituted C2-6 alkenyl. In certain embodiments, R1Bis unsubstituted vinyl. In certain embodiments, R1Bis unsubstituted allyl or -CH=CHCH3.

[0187] In certain embodiments, R1Bis substituted or unsubstituted alkynyl. In certain embodiments, R1Bis substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R1Bis unsubstituted C2-6 alkynyl. In certain embodiments, R1Bis C=CH. In certain embodiments, R1Bis -OCCH3 or CH2C =CH.

[0188] In certain embodiments, R1Bis substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R1Bis substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R1Bis saturated carbocyclyl. In certain embodiments, R1Bis partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0189] In certain embodiments, R1Bis substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R1Bis substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R1Bis saturated heterocyclyl. In certain embodiments, R1Bis partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).In certain embodiments, R1Bis substituted or unsubstituted aryl. In certain embodiments, R1Bis substituted or unsubstituted phenyl. In certain embodiments, R1Bis unsubstituted phenyl. In certain embodiments, R1Bis 4-mono-substituted phenyl. In certain embodiments, R1Bis 3-mono-substituted phenyl. In certain embodiments, R1Bis 2-mono-substituted phenyl. In certain embodiments, R1Bis di- substituted phenyl. In certain embodiments, R1Bis substituted or unsubstituted naphthyl.

[0190] In certain embodiments, R1Bis substituted or unsubstituted heteroaryl. In certain embodiments, R1Bis substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R1Bis substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R1Bis substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R1Bis substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R1Bis substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0191] In certain embodiments, R1Bis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, R1Bis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R1Bis -ORA. In certain embodiments, R1Bis -OH. In certain embodiments, R1Bis -O(substituted or unsubstituted alkyl). In certain embodiments, R1Bis -O(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R1Bis -O(unsubstituted Ci-6 alkyl). In certain embodiments, R1Bis -OMe. In certain embodiments, R1Bis -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Bis -SRA. In certain embodiments, R1Bis -SH. In certain embodiments, R1Bis -S( substituted or unsubstituted alkyl). In certain embodiments, R1Bis -S( substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R1Bis -S(unsubstituted Ci-6 alkyl). In certain embodiments, R1Bis -SMe. In certain embodiments, R1Bis -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Bis -NH2. In certain embodiments, R1Bis-NHRA. In certain embodiments, R1Bis -NH(substituted or unsubstituted alkyl). In certain embodiments, R1Bis -NH(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R1Bis -NH(unsubstituted Ci-6 alkyl). In certain embodiments, R1Bis -NHMe. In certain embodiments, R1Bis -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Bis -N(RA)2. In certain embodiments, R1Bis -N( substituted or unsubstituted alkyl)2. In certain embodiments, R1Bis -N( substituted or unsubstituted, Ci-6 alkyl)2. In certain embodiments, R1Bis -N(unsubstituted Ci-6 alkyl)2. In certain embodiments, R1Bis -NMe2. In certain embodiments, R1Bis -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0192] In certain embodiments, R1Bis hydrogen, halogen, or substituted or unsubstituted alkyl. In certain embodiments, R1Bis hydrogen.

[0193] In certain embodiments, R1Aand R1Bare joined together with the intervening atoms to form a substituted or unsubstituted phenyl ring.

[0194] In certain embodiments, R1Cis halogen. In certain embodiments, R1Cis -F. In certain embodiments, R1Cis -Cl. In certain embodiments, R1Cis -Br.

[0195] In certain embodiments, R1Cis substituted or unsubstituted alkyl. In certain embodiments, R1Cis substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, R1Cis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with halogen. In certain embodiments, R1Cis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with fluoro or chloro. In certain embodiments, R1Cis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R1Cis unsubstituted C1-4 alkyl. In certain embodiments, R1Cis Me. In certain embodiments, R1Cis Et. In certain embodiments, R1Cis z?-Pr or z-Pr. In certain embodiments, R1Cis zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R1Cis t-Bu. In certain embodiments, R1Cis fluorinated methyl. In certain embodiments, R1Cis -CF3. In certain embodiments, R1Cis fluorinated ethyl. In certain embodiments, R1Cis chlorinated methyl. In certain embodiments, R1Cis chlorinated ethyl. In certain embodiments, R1Cis -CH2-( substituted or unsubstituted phenyl). In certain embodiments, R1Cis Bn.

[0196] In certain embodiments, R1Cis substituted or unsubstituted alkenyl. In certain embodiments, R1Cis substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R1Cis unsubstituted C2-6 alkenyl. In certain embodiments, R1Cis unsubstituted vinyl. In certain embodiments, R1Cis unsubstituted allyl or -CH=CHCH3.

[0197] In certain embodiments, R1Cis substituted or unsubstituted alkynyl. In certain embodiments, R1Cis substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R1Cis unsubstituted C2-6 alkynyl. In certain embodiments, R1Cis C=CH. In certain embodiments, R1Cis -OCCH3 or CH2C =CH.In certain embodiments, R1Cis substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R1Cis substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R1Cis saturated carbocyclyl. In certain embodiments, R1Cis partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0198] In certain embodiments, R1Cis substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R1Cis substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R1Cis saturated heterocyclyl. In certain embodiments, R1Cis partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0199] In certain embodiments, R1Cis substituted or unsubstituted aryl. In certain embodiments, R1Cis substituted or unsubstituted phenyl. In certain embodiments, R1Cis unsubstituted phenyl. In certain embodiments, R1Cis 4-mono-substituted phenyl. In certain embodiments, R1Cis 3-mono-substituted phenyl. In certain embodiments, R1Cis 2-mono-substituted phenyl. In certain embodiments, R1Cis di- substituted phenyl. In certain embodiments, R1Cis substituted or unsubstituted naphthyl.

[0200] In certain embodiments, R1Cis substituted or unsubstituted heteroaryl. In certain embodiments, R1Cis substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R1Cis substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R1Cis substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R1Cis substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R1Cis substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0201] In certain embodiments, R1Cis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA,-OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=0)2RA, -S(=0)20RA, or -S(=O)2N(RA)2. In certain embodiments, R1Cis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R1Cis -ORA. In certain embodiments, R1Cis -OH. In certain embodiments, R1Cis -O(substituted or unsubstituted alkyl). In certain embodiments, R1Cis -O(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R1Cis -O(unsubstituted C1-6 alkyl). In certain embodiments, R1Cis -OMe. In certain embodiments, R1Cis -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Cis -SRA. In certain embodiments, R1Cis -SH. In certain embodiments, R1Cis -S( substituted or unsubstituted alkyl). In certain embodiments, R1Cis -S( substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R1Cis -S(unsubstituted C1-6 alkyl). In certain embodiments, R1Cis -SMe. In certain embodiments, R1Cis -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Cis -NH2. In certain embodiments, R1Cis -NHRA. In certain embodiments, R1Cis -NH(substituted or unsubstituted alkyl). In certain embodiments, R1Cis -NH(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R1Cis -NH(unsubstituted C1-6 alkyl). In certain embodiments, R1Cis -NHMe. In certain embodiments, R1Cis -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Cis -N(RA)2. In certain embodiments, R1Cis -N( substituted or unsubstituted alkyl)2. In certain embodiments, R1Cis -N( substituted or unsubstituted, C1-6 alkyl)2. In certain embodiments, R1Cis -N(unsubstituted C1-6 alkyl)2. In certain embodiments, R1Cis -NMe2. In certain embodiments, R1Cis -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0202] In certain embodiments, R1Cis hydrogen or halogen. In certain embodiments, R1Cis hydrogen.

[0203] In certain embodiments, R1Dis halogen. In certain embodiments, R1Dis -F. In certain embodiments, R1Dis -Cl. In certain embodiments, R1Dis -Br.

[0204] In certain embodiments, R1Dis substituted or unsubstituted alkyl. In certain embodiments, R1Dis substituted or unsubstituted, C1-6 alkyl. In certain embodiments, R1Dis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with halogen. In certain embodiments, R1Dis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with fluoro or chloro. In certain embodiments, R1Dis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R1Dis unsubstituted C1-4 alkyl. In certain embodiments, R1Dis Me. In certain embodiments, R1Dis Et. In certain embodiments, R1Dis zz-Pr or z-Pr. In certain embodiments, R1Dis zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R1Dis t-Bu. In certain embodiments, R1Dis fluorinated methyl. In certain embodiments, R1Dis -CF3. In certain embodiments, R1Dis fluorinated ethyl. In certain embodiments, R1Dis chlorinated methyl. In certain embodiments, R1Dis chlorinated ethyl. In certain embodiments, R1Dis -CH2-(substituted or unsubstituted phenyl). In certain embodiments, R1Dis Bn.

[0205] In certain embodiments, R1Dis substituted or unsubstituted alkenyl. In certain embodiments, R1Dis substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R1Dis unsubstituted C2-6 alkenyl. In certain embodiments, R1Dis unsubstituted vinyl. In certain embodiments, R1Dis unsubstituted allyl or -CH=CHCH3.

[0206] In certain embodiments, R1Dis substituted or unsubstituted alkynyl. In certain embodiments, R1Dis substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R1Dis unsubstituted C2-6 alkynyl. In certain embodiments, R1Dis C=CH. In certain embodiments, R1Dis -OCCH3 or CH2C =CH.

[0207] In certain embodiments, R1Dis substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R1Dis substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R1Dis saturated carbocyclyl. In certain embodiments, R1Dis partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0208] In certain embodiments, R1Dis substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R1Dis substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R1Dis saturated heterocyclyl. In certain embodiments, R1Dis partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0209] In certain embodiments, R1Dis substituted or unsubstituted aryl. In certain embodiments, R1Dis substituted or unsubstituted phenyl. In certain embodiments, R1Dis unsubstituted phenyl. In certain embodiments, R1Dis 4-mono-substituted phenyl. In certain embodiments, R1Dis 3-mono-substituted phenyl. In certain embodiments, R1Dis 2-mono-substituted phenyl. In certain embodiments, R1Dis di- substituted phenyl. In certain embodiments, R1Dis substituted or unsubstituted naphthyl.In certain embodiments, R1Dis substituted or unsubstituted heteroaryl. In certain embodiments, R1Dis substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R1Dis substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R1Dis substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R1Dis substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R1Dis substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0210] In certain embodiments, R1Dis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, R1Dis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R1Dis -ORA. In certain embodiments, R1Dis -OH. In certain embodiments, R1Dis -O(substituted or unsubstituted alkyl). In certain embodiments, R1Dis -O(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R1Dis -O(unsubstituted Ci-6 alkyl). In certain embodiments, R1Dis -OMe. In certain embodiments, R1Dis -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Dis -SRA. In certain embodiments, R1Dis -SH. In certain embodiments, R1Dis -S( substituted or unsubstituted alkyl). In certain embodiments, R1Dis ^(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R1Dis -S(unsubstituted Ci-6 alkyl). In certain embodiments, R1Dis -SMe. In certain embodiments, R1Dis -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Dis -NH2. In certain embodiments, R1Dis -NHRA. In certain embodiments, R1Dis -NH(substituted or unsubstituted alkyl). In certain embodiments, R1Dis -NH(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R1Dis -NH(unsubstituted C1-6 alkyl). In certain embodiments, R1Dis -NHMe. In certain embodiments, R1Dis -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R1Dis -N(RA)2. In certain embodiments, R1Dis -N(substituted or unsubstituted alkyl)2. In certain embodiments, R1Dis -N(substituted or unsubstituted, C1-6alkyl)2. In certain embodiments, R1Dis -N(unsubstituted Ci-6 alkyl)2. In certain embodiments, R1Dis -NMe2. In certain embodiments, R1Dis -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0211] In certain embodiments, R1Dis hydrogen, halogen, or substituted or unsubstituted alkyl. In certain embodiments, R1Dis hydrogen, -F, -Cl, or substituted or unsubstituted alkyl. In certain embodiments, R1Dis hydrogen.

[0212] In certain embodiments, R2Ais halogen. In certain embodiments, R2Ais -F. In certain embodiments, R2Ais -Cl. In certain embodiments, R2Ais -Br.

[0213] In certain embodiments, R2Ais substituted or unsubstituted alkyl. In certain embodiments, R2Ais substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, R2Ais unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with halogen. In certain embodiments, R2Ais unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with fluoro or chloro. In certain embodiments, R2Ais unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R2Ais unsubstituted C1-4 alkyl. In certain embodiments, R2Ais Me. In certain embodiments, R2Ais Et. In certain embodiments, R2Ais z?-Pr or z-Pr. In certain embodiments, R2Ais zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R2Ais t-Bu. In certain embodiments, R2Ais fluorinated methyl. In certain embodiments, R2Ais -CF3. In certain embodiments, R2Ais fluorinated ethyl. In certain embodiments, R2Ais chlorinated methyl. In certain embodiments, R2Ais chlorinated ethyl. In certain embodiments, R2Ais -CH2-(substituted or unsubstituted phenyl). In certain embodiments, R2Ais Bn.

[0214] In certain embodiments, R2Ais substituted or unsubstituted alkenyl. In certain embodiments, R2Ais substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R2Ais unsubstituted C2-6 alkenyl. In certain embodiments, R2Ais unsubstituted vinyl. In certain embodiments, R2Ais unsubstituted allyl or -CH=CHCH3.

[0215] In certain embodiments, R2Ais substituted or unsubstituted alkynyl. In certain embodiments, R2Ais substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R2Ais unsubstituted C2-6 alkynyl. In certain embodiments, R2Ais C=CH. In certain embodiments, R2Ais -C =CCH3or CH2C =CH.

[0216] In certain embodiments, R2Ais substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R2Ais substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R2Ais saturated carbocyclyl. In certain embodiments, R2Ais partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).In certain embodiments, R2Ais substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R2Ais substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R2Ais saturated heterocyclyl. In certain embodiments, R2Ais partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0217] In certain embodiments, R2Ais substituted or unsubstituted aryl. In certain embodiments, R2Ais substituted or unsubstituted phenyl. In certain embodiments, R2Ais unsubstituted phenyl. In certain embodiments, R2Ais 4-mono-substituted phenyl. In certain embodiments, R2Ais 3-mono-substituted phenyl. In certain embodiments, R2Ais 2-mono-substituted phenyl. In certain embodiments, R2Ais di- substituted phenyl. In certain embodiments, R2Ais substituted or unsubstituted naphthyl.

[0218] In certain embodiments, R2Ais substituted or unsubstituted heteroaryl. In certain embodiments, R2Ais substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R2Ais substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R2Ais substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R2Ais substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R2Ais substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0219] In certain embodiments, R2Ais -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, R2Ais -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R2Ais -ORA. In certain embodiments, R2Ais -OH. In certain embodiments, R2Ais -O(substituted or unsubstituted alkyl).In certain embodiments, R2Ais -O(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R2Ais -O(unsubstituted Ci-6 alkyl). In certain embodiments, R2Ais -OMe. In certain embodiments, R2Ais -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R2Ais -SRA. In certain embodiments, R2Ais -SH. In certain embodiments, R2Ais -S( substituted or unsubstituted alkyl). In certain embodiments, R2Ais ^(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R2Ais -S(unsubstituted Ci-6 alkyl). In certain embodiments, R2Ais -SMe. In certain embodiments, R2Ais -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R2Ais -NH2. In certain embodiments, R2Ais -NHRA. In certain embodiments, R2Ais -NH(substituted or unsubstituted alkyl). In certain embodiments, R2Ais -NH(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R2Ais -NH(unsubstituted C1-6 alkyl). In certain embodiments, R2Ais -NHMe. In certain embodiments, R2Ais -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R2Ais -N(RA)2. In certain embodiments, R2Ais -N(substituted or unsubstituted alkyl)2. In certain embodiments, R2Ais -N(substituted or unsubstituted, C1-6 alkyl)2. In certain embodiments, R2Ais -N(unsubstituted C1-6 alkyl)2. In certain embodiments, R2Ais -NMe2. In certain embodiments, R2Ais -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0220] In certain embodiments, R2Ais hydrogen.

[0221] In certain embodiments, R2Bis hydrogen. In certain embodiments, R2Bis halogen. In certain embodiments, R2Bis -F. In certain embodiments, R2Bis -Cl. In certain embodiments, R2Bis -Br.

[0222] In certain embodiments, R2Bis substituted or unsubstituted alkyl. In certain embodiments, R2Bis substituted or unsubstituted, C1-6 alkyl. In certain embodiments, R2Bis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with halogen. In certain embodiments, R2Bis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with fluoro or chloro. In certain embodiments, R2Bis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R2Bis unsubstituted C1-4 alkyl. In certain embodiments, R2Bis Me. In certain embodiments, R2Bis Et. In certain embodiments, R2Bis z?-Pr or z-Pr. In certain embodiments, R2Bis zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R2Bis t-Bu. In certain embodiments, R2Bis fluorinated methyl. In certain embodiments, R2Bis -CF3. In certain embodiments, R2Bis fluorinated ethyl. In certain embodiments, R2Bis chlorinated methyl. In certain embodiments, R2Bis chlorinated ethyl. In certain embodiments, R2Bis -CH2-( substituted or unsubstituted phenyl). In certain embodiments, R2Bis Bn. In certain embodiments, R2Bis -CH2-CH2-(substituted or unsubstituted phenyl). In certain embodiments, R2Bis -(CH2)3-6-(substituted or unsubstituted phenyl).In certain embodiments, R2Bis substituted or unsubstituted alkenyl. In certain embodiments, R2Bis substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R2Bis unsubstituted C2-6 alkenyl. In certain embodiments, R2Bis unsubstituted vinyl. In certain embodiments, R2Bis unsubstituted allyl or -CH=CHCH3. In certain embodiments, R2Bis -CH=CHCH2CH3, -CH2CH=CHCH3, -CH2CH2CH=CH2, -CH=C(CH3)2, or -C(CH3)=CHCH3.

[0223] In certain embodiments, R2Bis substituted or unsubstituted alkynyl. In certain embodiments, R2Bis substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R2Bis unsubstituted C2-6 alkynyl. In certain embodiments, R2Bis C=CH. In certain embodiments, R2Bis -C =CCH3or CH2C =CH.

[0224] In certain embodiments, R2Bis substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R2Bis substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R2Bis saturated carbocyclyl. In certain embodiments, R2Bis partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0225] In certain embodiments, R2Bis substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R2Bis substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R2Bis 3-methyl-oxetan-3-yl. In certain embodiments, R2Bis saturated heterocyclyl. In certain embodiments, R2Bis partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0226] In certain embodiments, R2Bis substituted or unsubstituted aryl. In certain embodiments, R2Bis substituted or unsubstituted phenyl. In certain embodiments, R2Bis unsubstituted phenyl. In certain embodiments, R2Bis 4-mono-substituted phenyl. In certain embodiments, R2Bis 3-mono-substituted phenyl. In certain embodiments, R2Bis 2-mono-substituted phenyl. In certain embodiments, R2Bis di- substituted phenyl. In certain embodiments, R2Bis substituted or unsubstituted naphthyl. In certain embodiments, R2Bis substituted or unsubstituted phenyl fused with substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl. In certain

[0227] embodiments,

[0228]

[0229] In certain embodiments, R2Bis substituted or unsubstituted heteroaryl. In certain embodiments, R2Bis substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R2Bis substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, In certain embodiments, R2Bis substituted or unsubstituted 2-furanyl or substituted or unsubstituted 3-furanyl. In certain embodiments, R2Bis substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R2Bis substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R2Bis substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl. In certain embodiments, R2Bis substituted or unsubstituted quinolinyl. In certain embodiments, R2Bis substituted or unsubstituted 3-quinolinyl.

[0230] In certain embodiments, R2Bis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, R2Bis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R2Bis -ORA. In certain embodiments, R2Bis -OH. In certain embodiments, R2Bis -O(substituted or unsubstituted alkyl). In certain embodiments, R2Bis -O(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R2Bis -O(unsubstituted Ci-6 alkyl). In certain embodiments, R2Bis -OMe. In certain embodiments, R2Bis -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R2Bis -SRA. In certain embodiments, R2Bis -SH. In certain embodiments, R2Bis -S( substituted or unsubstituted alkyl). In certain embodiments, R2Bis -S( substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R2Bis -S(unsubstituted Ci-6 alkyl). In certain embodiments, R2Bis -SMe. In certain embodiments, R2Bis -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R2Bis -NH2. In certain embodiments, R2Bis -NHRA. In certain embodiments, R2Bis -NH(substituted or unsubstituted alkyl). In certain embodiments, R2Bis -NH(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R2Bis -NH(unsubstituted C1-6 alkyl). In certain embodiments, R2Bis -NHMe. In certainembodiments, R2Bis -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R2Bis -N(RA)2. In certain embodiments, R2Bis -N( substituted or unsubstituted alkyl)2. In certain embodiments, R2Bis -N( substituted or unsubstituted, Ci-6 alkyl)2. In certain embodiments, R2Bis -N(unsubstituted Ci-6 alkyl)2. In certain embodiments, R2Bis -NMe2. In certain embodiments, R2Bis -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0231] In certain embodiments, R2Bis substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In certain embodiments, R2Bis substituted or unsubstituted, monocyclic, 3- to 7-membered, saturated carbocyclyl. In certain embodiments, R2Bis substituted or unsubstituted cyclopropyl. In certain embodiments, R2Bis unsubstituted cyclopropyl. In certain embodiments, R2Bis substituted or unsubstituted, monocyclic, 5- or 6-membered heteroaryl. In certain embodiments, R2Bis substituted or unsubstituted furanyl. In certain embodiments, R2Bis unsubstituted 3-furanyl.

[0232] In certain embodiments, R2Cis substituted or unsubstituted alkyl. In certain embodiments, R2Cis substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, R2Cis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with halogen. In certain embodiments, R2Cis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with fluoro or chloro. In certain embodiments, R2Cis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R2Cis unsubstituted Ci-4 alkyl. In certain embodiments, R2Cis Me. In certain embodiments, R2Cis Et. In certain embodiments, R2Cis z?-Pr or z-Pr. In certain embodiments, R2Cis zz-Bu, z-Bu, or ec-Bu. In certain embodiments, R2Cis t-Bu. In certain embodiments, R2Cis fluorinated methyl. In certain embodiments, R2Cis -CF3. In certain embodiments, R2Cis fluorinated ethyl. In certain embodiments, R2Cis chlorinated methyl. In certain embodiments, R2Cis chlorinated ethyl. In certain embodiments, R2Cis -CH2-( substituted or unsubstituted phenyl). In certain embodiments, R2Cis Bn.

[0233] In certain embodiments, R2Cis substituted or unsubstituted alkenyl. In certain embodiments, R2Cis substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R2Cis unsubstituted C2-6 alkenyl. In certain embodiments, R2Cis unsubstituted vinyl. In certain embodiments, R2Cis unsubstituted allyl or -CH=CHCH3.

[0234] In certain embodiments, R2Cis substituted or unsubstituted alkynyl. In certain embodiments, R2Cis substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R2Cis unsubstituted C2-6 alkynyl. In certain embodiments, R2Cis C=CH. In certain embodiments, R2Cis -OCCH3 or CH2C =CH.In certain embodiments, R2Cis substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R2Cis substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R2Cis saturated carbocyclyl. In certain embodiments, R2Cis partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0235] In certain embodiments, R2Cis substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R2Cis substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R2Cis saturated heterocyclyl. In certain embodiments, R2Cis partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0236] In certain embodiments, R2Cis substituted or unsubstituted aryl. In certain embodiments, R2Cis substituted or unsubstituted phenyl. In certain embodiments, R2Cis unsubstituted phenyl. In certain embodiments, R2Cis 4-mono-substituted phenyl. In certain embodiments, R2Cis 3-mono-substituted phenyl. In certain embodiments, R2Cis 2-mono-substituted phenyl. In certain embodiments, R2Cis di- substituted phenyl. In certain embodiments, R2Cis substituted or unsubstituted naphthyl.

[0237] In certain embodiments, R2Cis substituted or unsubstituted heteroaryl. In certain embodiments, R2Cis substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R2Cis substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R2Cis substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R2Cis substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R2Cis substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0238] In certain embodiments, R2Cis -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, R2Cis -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2, wherein each instance of RAisindependently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R2Cis -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2, wherein each instance of RAis independently substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, R2Cis a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts). In certain embodiments, R2Cis Boc.

[0239] In certain embodiments, R2Cis hydrogen, substituted or unsubstituted alkyl, or a nitrogen protecting group. In certain embodiments, R2Cis hydrogen or substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, R2Cis hydrogen.

[0240] In certain embodiments, R3Ais halogen. In certain embodiments, R3Ais -F. In certain embodiments, R3Ais -Cl. In certain embodiments, R3Ais -Br.

[0241] In certain embodiments, R3Ais substituted or unsubstituted alkyl. In certain embodiments, R3Ais substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, R3Ais unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with halogen. In certain embodiments, R3Ais unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with fluoro or chloro. In certain embodiments, R3Ais unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R3Ais unsubstituted C1-4 alkyl. In certain embodiments, R3Ais Me. In certain embodiments, R3Ais Et. In certain embodiments, R3Ais z?-Pr or z-Pr. In certain embodiments, R3Ais zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R3Ais t-Bu. In certain embodiments, R3Ais fluorinated methyl. In certain embodiments, R3Ais -CF3. In certain embodiments, R3Ais fluorinated ethyl. In certain embodiments, R3Ais chlorinated methyl. In certain embodiments, R3Ais chlorinated ethyl. In certain embodiments, R3Ais -CH2-(substituted or unsubstituted phenyl). In certain embodiments, R3Ais Bn.

[0242] In certain embodiments, R3Ais substituted or unsubstituted alkenyl. In certain embodiments, R3Ais substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R3Ais unsubstituted C2-6 alkenyl. In certain embodiments, R3Ais unsubstituted vinyl. In certain embodiments, R3Ais unsubstituted allyl or -CH=CHCH3.

[0243] In certain embodiments, R3Ais substituted or unsubstituted alkynyl. In certain embodiments, R3Ais substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R3Ais unsubstituted C2-6 alkynyl. In certain embodiments, R3Ais C=CH. In certain embodiments, R3Ais -OCCH3 or CH2C =CH.

[0244] In certain embodiments, R3Ais substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R3Ais substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstitutedcycloheptyl. In certain embodiments, R3Ais saturated carbocyclyl. In certain embodiments, R3Ais partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0245] In certain embodiments, R3Ais substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R3Ais substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R3Ais saturated heterocyclyl. In certain embodiments, R3Ais partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0246] In certain embodiments, R3Ais substituted or unsubstituted aryl. In certain embodiments, R3Ais substituted or unsubstituted phenyl. In certain embodiments, R3Ais unsubstituted phenyl. In certain embodiments, R3Ais 4-mono-substituted phenyl. In certain embodiments, R3Ais 3-mono-substituted phenyl. In certain embodiments, R3Ais 2-mono-substituted phenyl. In certain embodiments, R3Ais di- substituted phenyl. In certain embodiments, R3Ais substituted or unsubstituted naphthyl.

[0247] In certain embodiments, R3Ais substituted or unsubstituted heteroaryl. In certain embodiments, R3Ais substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R3Ais substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R3Ais substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R3Ais substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R3Ais substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0248] In certain embodiments, R3Ais -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, R3Ais -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA,-C(=0)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R3Ais -ORA. In certain embodiments, R3Ais -OH. In certain embodiments, R3Ais -O(substituted or unsubstituted alkyl). In certain embodiments, R3Ais -O(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R3Ais -O(unsubstituted C1-6 alkyl). In certain embodiments, R3Ais -OMe. In certain embodiments, R3Ais -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Ais -SRA. In certain embodiments, R3Ais -SH. In certain embodiments, R3Ais -S( substituted or unsubstituted alkyl). In certain embodiments, R3Ais ^(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R3Ais -S(unsubstituted C1-6 alkyl). In certain embodiments, R3Ais -SMe. In certain embodiments, R3Ais -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Ais -NH2. In certain embodiments, R3Ais -NHRA. In certain embodiments, R3Ais -NH(substituted or unsubstituted alkyl). In certain embodiments, R3Ais -NH(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R3Ais -NH(unsubstituted C1-6 alkyl). In certain embodiments, R3Ais -NHMe. In certain embodiments, R3Ais -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Ais -N(RA)2. In certain embodiments, R3Ais -N(substituted or unsubstituted alkyl)2. In certain embodiments, R3Ais -N(substituted or unsubstituted, C1-6 alkyl)2. In certain embodiments, R3Ais -N(unsubstituted C1-6 alkyl)2. In certain embodiments, R3Ais -NMe2. In certain embodiments, R3Ais -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0249] In certain embodiments, R3Ais hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R3Ais hydrogen.

[0250] In certain embodiments, R3Bis halogen. In certain embodiments, R3Bis -F. In certain embodiments, R3Bis -Cl. In certain embodiments, R3Bis -Br.

[0251] In certain embodiments, R3Bis substituted or unsubstituted alkyl. In certain embodiments, R3Bis substituted or unsubstituted, C1-6 alkyl. In certain embodiments, R3Bis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with halogen. In certain embodiments, R3Bis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with fluoro or chloro. In certain embodiments, R3Bis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R3Bis unsubstituted C1-4 alkyl. In certain embodiments, R3Bis Me. In certain embodiments, R3Bis Et. In certain embodiments, R3Bis z?-Pr or z-Pr. In certain embodiments, R3Bis zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R3Bis t-Bu. In certain embodiments, R3Bis fluorinated methyl. In certain embodiments, R3Bis -CF3. In certain embodiments, R3Bis fluorinated ethyl. In certain embodiments, R3Bis chlorinated methyl. In certain embodiments, R3Bis chlorinated ethyl. In certain embodiments, R3Bis -CH2-( substituted or unsubstituted phenyl). In certain embodiments, R3Bis Bn.

[0252] In certain embodiments, R3Bis substituted or unsubstituted alkenyl. In certain embodiments, R3Bis substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R3Bis unsubstituted C2-6 alkenyl. In certain embodiments, R3Bis unsubstituted vinyl. In certain embodiments, R3Bis unsubstituted allyl or -CH=CHCHs.

[0253] In certain embodiments, R3Bis substituted or unsubstituted alkynyl. In certain embodiments, R3Bis substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R3Bis unsubstituted C2-6 alkynyl. In certain embodiments, R3Bis C=CH. In certain embodiments, R3Bis -OCCH3 or CH2C =CH.

[0254] In certain embodiments, R3Bis substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R3Bis substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R3Bis saturated carbocyclyl. In certain embodiments, R3Bis partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0255] In certain embodiments, R3Bis substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R3Bis substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R3Bis saturated heterocyclyl. In certain embodiments, R3Bis partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0256] In certain embodiments, R3Bis substituted or unsubstituted aryl. In certain embodiments, R3Bis substituted or unsubstituted phenyl. In certain embodiments, R3Bis unsubstituted phenyl. In certain embodiments, R3Bis 4-mono-substituted phenyl. In certain embodiments, R3Bis 3-mono-substituted phenyl. In certain embodiments, R3Bis 2-mono-substituted phenyl. In certain embodiments, R3Bis di- substituted phenyl. In certain embodiments, R3Bis substituted or unsubstituted naphthyl.

[0257] In certain embodiments, R3Bis substituted or unsubstituted heteroaryl. In certain embodiments, R3Bis substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R3Bis substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substitutedor unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R3Bis substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R3Bis substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R3Bis substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0258] In certain embodiments, R3Bis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, R3Bis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R3Bis -ORA. In certain embodiments, R3Bis -OH. In certain embodiments, R3Bis -O(substituted or unsubstituted alkyl). In certain embodiments, R3Bis -O(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R3Bis -O(unsubstituted Ci-6 alkyl). In certain embodiments, R3Bis -OMe. In certain embodiments, R3Bis -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Bis -SRA. In certain embodiments, R3Bis -SH. In certain embodiments, R3Bis -S( substituted or unsubstituted alkyl). In certain embodiments, R3Bis -S( substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R3Bis -S(unsubstituted Ci-6 alkyl). In certain embodiments, R3Bis -SMe. In certain embodiments, R3Bis -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Bis -NH2. In certain embodiments, R3Bis -NHRA. In certain embodiments, R3Bis -NH(substituted or unsubstituted alkyl). In certain embodiments, R3Bis -NH(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R3Bis -NH(unsubstituted C1-6 alkyl). In certain embodiments, R3Bis -NHMe. In certain embodiments, R3Bis -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Bis -N(RA)2. In certain embodiments, R3Bis -N( substituted or unsubstituted alkyl)2. In certain embodiments, R3Bis -N( substituted or unsubstituted, C1-6 alkyl)2. In certain embodiments, R3Bis -N(unsubstituted C1-6 alkyl)2. In certain embodiments, R3Bis -NMe2. In certain embodiments, R3Bis -N(CI-6 alkyl substituted with one or more instances of halogen)2.In certain embodiments, R3Bis hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R3Bis hydrogen.

[0259] In certain embodiments, R3Cis halogen. In certain embodiments, R3Cis -F. In certain embodiments, R3Cis -Cl. In certain embodiments, R3Cis -Br.

[0260] In certain embodiments, R3Cis substituted or unsubstituted alkyl. In certain embodiments, R3Cis substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, R3Cis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with halogen. In certain embodiments, R3Cis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with fluoro or chloro. In certain embodiments, R3Cis unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R3Cis unsubstituted C1-4 alkyl. In certain embodiments, R3Cis Me. In certain embodiments, R3Cis Et. In certain embodiments, R3Cis z?-Pr or z-Pr. In certain embodiments, R3Cis zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R3Cis t-Bu. In certain embodiments, R3Cis fluorinated methyl. In certain embodiments, R3Cis -CF3. In certain embodiments, R3Cis fluorinated ethyl. In certain embodiments, R3Cis chlorinated methyl. In certain embodiments, R3Cis chlorinated ethyl. In certain embodiments, R3Cis -CH2-( substituted or unsubstituted phenyl). In certain embodiments, R3Cis Bn.

[0261] In certain embodiments, R3Cis substituted or unsubstituted alkenyl. In certain embodiments, R3Cis substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R3Cis unsubstituted C2-6 alkenyl. In certain embodiments, R3Cis unsubstituted vinyl. In certain embodiments, R3Cis unsubstituted allyl or -CH=CHCH3.

[0262] In certain embodiments, R3Cis substituted or unsubstituted alkynyl. In certain embodiments, R3Cis substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R3Cis unsubstituted C2-6 alkynyl. In certain embodiments, R3Cis C=CH. In certain embodiments, R3Cis -OCCH3 or CH2C =CH.

[0263] In certain embodiments, R3Cis substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R3Cis substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R3Cis saturated carbocyclyl. In certain embodiments, R3Cis partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0264] In certain embodiments, R3Cis substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R3Cis substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted orunsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R3Cis saturated heterocyclyl. In certain embodiments, R3Cis partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0265] In certain embodiments, R3Cis substituted or unsubstituted aryl. In certain embodiments, R3Cis substituted or unsubstituted phenyl. In certain embodiments, R3Cis unsubstituted phenyl. In certain embodiments, R3Cis 4-mono-substituted phenyl. In certain embodiments, R3Cis 3-mono-substituted phenyl. In certain embodiments, R3Cis 2-mono-substituted phenyl. In certain embodiments, R3Cis di- substituted phenyl. In certain embodiments, R3Cis substituted or unsubstituted naphthyl.

[0266] In certain embodiments, R3Cis substituted or unsubstituted heteroaryl. In certain embodiments, R3Cis substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R3Cis substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R3Cis substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R3Cis substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R3Cis substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0267] In certain embodiments, R3Cis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, R3Cis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R3Cis -ORA. In certain embodiments, R3Cis -OH. In certain embodiments, R3Cis -O(substituted or unsubstituted alkyl). In certain embodiments, R3Cis -O(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R3Cis -O(unsubstituted Ci-6 alkyl). In certain embodiments, R3Cis -OMe. In certain embodiments, R3Cis -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Cis -SRA. In certain embodiments, R3Cis -SH. In certain embodiments,R3Cis -S( substituted or unsubstituted alkyl). In certain embodiments, R3Cis -S( substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R3Cis -S(unsubstituted Ci-6 alkyl). In certain embodiments, R3Cis -SMe. In certain embodiments, R3Cis -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Cis -NH2. In certain embodiments, R3Cis -NHRA. In certain embodiments, R3Cis -NH(substituted or unsubstituted alkyl). In certain embodiments, R3Cis -NH(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R3Cis -NH(unsubstituted C1-6 alkyl). In certain embodiments, R3Cis -NHMe. In certain embodiments, R3Cis -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Cis -N(RA)2. In certain embodiments, R3Cis -N( substituted or unsubstituted alkyl)2. In certain embodiments, R3Cis -N( substituted or unsubstituted, C1-6 alkyl)2. In certain embodiments, R3Cis -N(unsubstituted C1-6 alkyl)2. In certain embodiments, R3Cis -NMe2. In certain embodiments, R3Cis -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0268] In certain embodiments, R3Cis hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R3Cis hydrogen.

[0269] In certain embodiments, R3Dis halogen. In certain embodiments, R3Dis -F. In certain embodiments, R3Dis -Cl. In certain embodiments, R3Dis -Br.

[0270] In certain embodiments, R3Dis substituted or unsubstituted alkyl. In certain embodiments, R3Dis substituted or unsubstituted, C1-6 alkyl. In certain embodiments, R3Dis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with halogen. In certain embodiments, R3Dis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with fluoro or chloro. In certain embodiments, R3Dis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, R3Dis unsubstituted C1-4 alkyl. In certain embodiments, R3Dis Me. In certain embodiments, R3Dis Et. In certain embodiments, R3Dis z?-Pr or z-Pr. In certain embodiments, R3Dis zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R3Dis t-Bu. In certain embodiments, R3Dis fluorinated methyl. In certain embodiments, R3Dis -CF3. In certain embodiments, R3Dis fluorinated ethyl. In certain embodiments, R3Dis chlorinated methyl. In certain embodiments, R3Dis chlorinated ethyl. In certain embodiments, R3Dis -CH2-(substituted or unsubstituted phenyl). In certain embodiments, R3Dis Bn.

[0271] In certain embodiments, R3Dis substituted or unsubstituted alkenyl. In certain embodiments, R3Dis substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R3Dis unsubstituted C2-6 alkenyl. In certain embodiments, R3Dis unsubstituted vinyl. In certain embodiments, R3Dis unsubstituted allyl or -CH=CHCH3.

[0272] In certain embodiments, R3Dis substituted or unsubstituted alkynyl. In certain embodiments, R3Dis substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R3Disunsubstituted C2-6 alkynyl. In certain embodiments, R3Dis C=CH. In certain embodiments, R3Dis -OCCH3 or CH2C =CH.

[0273] In certain embodiments, R3Dis substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R3Dis substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R3Dis saturated carbocyclyl. In certain embodiments, R3Dis partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0274] In certain embodiments, R3Dis substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R3Dis substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R3Dis saturated heterocyclyl. In certain embodiments, R3Dis partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0275] In certain embodiments, R3Dis substituted or unsubstituted aryl. In certain embodiments, R3Dis substituted or unsubstituted phenyl. In certain embodiments, R3Dis unsubstituted phenyl. In certain embodiments, R3Dis 4-mono-substituted phenyl. In certain embodiments, R3Dis 3-mono-substituted phenyl. In certain embodiments, R3Dis 2-mono-substituted phenyl. In certain embodiments, R3Dis di- substituted phenyl. In certain embodiments, R3Dis substituted or unsubstituted naphthyl.

[0276] In certain embodiments, R3Dis substituted or unsubstituted heteroaryl. In certain embodiments, R3Dis substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R3Dis substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R3Dis substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R3Dis substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R3Dis substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0277] In certain embodiments, R3Dis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3,-NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=0)2RA, -S(=0)20RA, or -S(=O)2N(RA)2. In certain embodiments, R3Dis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R3Dis -ORA. In certain embodiments, R3Dis -OH. In certain embodiments, R3Dis -O(substituted or unsubstituted alkyl). In certain embodiments, R3Dis -O(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R3Dis -O(unsubstituted C1-6 alkyl). In certain embodiments, R3Dis -OMe. In certain embodiments, R3Dis -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Dis -SRA. In certain embodiments, R3Dis -SH. In certain embodiments, R3Dis -S( substituted or unsubstituted alkyl). In certain embodiments, R3Dis ^(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R3Dis -S(unsubstituted C1-6 alkyl). In certain embodiments, R3Dis -SMe. In certain embodiments, R3Dis -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Dis -NH2. In certain embodiments, R3Dis -NHRA. In certain embodiments, R3Dis -NH(substituted or unsubstituted alkyl). In certain embodiments, R3Dis -NH(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, R3Dis -NH(unsubstituted C1-6 alkyl). In certain embodiments, R3Dis -NHMe. In certain embodiments, R3Dis -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Dis -N(RA)2. In certain embodiments, R3Dis -N(substituted or unsubstituted alkyl)2. In certain embodiments, R3Dis -N(substituted or unsubstituted, C1-6 alkyl)2. In certain embodiments, R3Dis -N(unsubstituted C1-6 alkyl)2. In certain embodiments, R3Dis -NMe2. In certain embodiments, R3Dis -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0278] In certain embodiments, R3Dis hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R3Dis hydrogen.

[0279] In certain embodiments, R3Eis halogen. In certain embodiments, R3Eis -F. In certain embodiments, R3Eis -Cl. In certain embodiments, R3Eis -Br.

[0280] In certain embodiments, R3Eis substituted or unsubstituted alkyl. In certain embodiments, R3Eis substituted or unsubstituted, C1-6 alkyl. In certain embodiments, R3Eis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with halogen. In certain embodiments, R3Eis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with fluoro or chloro. In certain embodiments, R3Eis unsubstituted C1-6 alkyl or C1-6 alkyl substituted with substituted or unsubstituted phenyl. In certainembodiments, R3Eis unsubstituted C1-4 alkyl. In certain embodiments, R3Eis Me. In certain embodiments, R3Eis Et. In certain embodiments, R3Eis z?-Pr or z-Pr. In certain embodiments, R3Eis zz-Bu, Z-BU, or ec-Bu. In certain embodiments, R3Eis t-Bu. In certain embodiments, R3Eis fluorinated methyl. In certain embodiments, R3Eis -CF3. In certain embodiments, R3Eis fluorinated ethyl. In certain embodiments, R3Eis chlorinated methyl. In certain embodiments, R3Eis chlorinated ethyl. In certain embodiments, R3Eis -CH2-( substituted or unsubstituted phenyl). In certain embodiments, R3Eis Bn.

[0281] In certain embodiments, R3Eis substituted or unsubstituted alkenyl. In certain embodiments, R3Eis substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, R3Eis unsubstituted C2-6 alkenyl. In certain embodiments, R3Eis unsubstituted vinyl. In certain embodiments, R3Eis unsubstituted allyl or -CH=CHCH3.

[0282] In certain embodiments, R3Eis substituted or unsubstituted alkynyl. In certain embodiments, R3Eis substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, R3Eis unsubstituted C2-6 alkynyl. In certain embodiments, R3Eis C=CH. In certain embodiments, R3Eis -OCCH3 or CH2C =CH.

[0283] In certain embodiments, R3Eis substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, R3Eis substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cycloheptyl. In certain embodiments, R3Eis saturated carbocyclyl. In certain embodiments, R3Eis partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0284] In certain embodiments, R3Eis substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, R3Eis substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, R3Eis saturated heterocyclyl. In certain embodiments, R3Eis partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0285] In certain embodiments, R3Eis substituted or unsubstituted aryl. In certain embodiments, R3Eis substituted or unsubstituted phenyl. In certain embodiments, R3Eis unsubstituted phenyl. In certain embodiments, R3Eis 4-mono-substituted phenyl. In certain embodiments, R3Eis 3-mono-substituted phenyl. In certain embodiments, R3Eis 2-mono-substituted phenyl. In certainembodiments, R3Eis di- substituted phenyl. In certain embodiments, R3Eis substituted or unsubstituted naphthyl.

[0286] In certain embodiments, R3Eis substituted or unsubstituted heteroaryl. In certain embodiments, R3Eis substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, R3Eis substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, R3Eis substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, R3Eis substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstituted pyridazinyl. In certain embodiments, R3Eis substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0287] In certain embodiments, R3Eis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, R3Eis -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, R3Eis -ORA. In certain embodiments, R3Eis -OH. In certain embodiments, R3Eis -O(substituted or unsubstituted alkyl). In certain embodiments, R3Eis -O(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R3Eis -O(unsubstituted Ci-6 alkyl). In certain embodiments, R3Eis -OMe. In certain embodiments, R3Eis -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Eis -SRA. In certain embodiments, R3Eis -SH. In certain embodiments, R3Eis ^(substituted or unsubstituted alkyl). In certain embodiments, R3Eis -S( substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R3Eis -S(unsubstituted Ci-6 alkyl). In certain embodiments, R3Eis -SMe. In certain embodiments, R3Eis -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, R3Eis -NH2. In certain embodiments, R3Eis -NHRA. In certain embodiments, R3Eis -NH(substituted or unsubstituted alkyl). In certain embodiments, R3Eis -NH(substituted or unsubstituted, Ci-6 alkyl). In certain embodiments, R3Eis -NH(unsubstituted Ci-6 alkyl). In certain embodiments, R3Eis -NHMe. In certain embodiments, R3Eis -NH(CI-6 alkyl substituted with one or more instances of halogen). Incertain embodiments, R3Eis -N(RA)2. In certain embodiments, R3Eis -N(substituted or unsubstituted alkyl)2. In certain embodiments, R3Eis -N(substituted or unsubstituted, Ci-6 alkyl)2. In certain embodiments, R3Eis -N(unsubstituted Ci-6 alkyl)2. In certain embodiments, R3Eis -NMe2. In certain embodiments, R3Eis -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0288] In certain embodiments, R3Eis hydrogen or substituted or unsubstituted alkyl. In certain embodiments, R3Eis hydrogen.

[0289] In certain embodiments, nl is 1. In certain embodiments, nl is 2. In certain embodiments, nl is 3.

[0290] In certain embodiments, each instance of R5is hydrogen. In certain embodiments, at least one instance of R5is halogen. In certain embodiments, at least one instance of R5is -F. In certain embodiments, at least one instance of R5is -Cl. In certain embodiments, each instance of R5is -F. In certain embodiments, at least one instance of R5is substituted or unsubstituted alkyl. In certain embodiments, at least one instance of R5is substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, at least one instance of R5is unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with at least one instance of halogen. In certain embodiments, at least one instance of R5is unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with at least one instance of fluoro or chloro. In certain embodiments, at least one instance of R5is unsubstituted C1-4 alkyl. In certain embodiments, at least one instance of R5is Me. In certain embodiments, at least one instance of R5is Et.

[0291] Ring C2 is heteroaromatic.

[0292] In certain embodiments, Ring C4 is fused bicyclic heteroaryl comprising at least one ring nitrogen atom in the fused bond or at least two adjacent ring nitrogen atoms. In certain embodiments, Ring C4 is fused bicyclic heteroaryl comprising only one ring nitrogen atom in the fused bond. In certain embodiments, Ring C4 is fused bicyclic heteroaryl comprising two ring nitrogen atoms in the fused bond. In certain embodiments, Ring C4 is fused bicyclic heteroaryl comprising at least two adjacent ring nitrogen atoms. In certain embodiments, Ring C4 is 5,6-fused bicyclic heteroaryl comprising at least one ring nitrogen atom in the fused bond. In certain embodiments, Ring C4 is 6,6-fused bicyclic heteroaryl comprising at least one ring nitrogen atom in the fused bond. In certain embodiments, Ring C4 is 5,6-fused bicyclic heteroaryl comprising at least two adjacent ring nitrogen atoms. In certain embodiments, Ring C4 is 6,6-fused bicyclic heteroaryl comprising at least two adjacent ring nitrogen atoms. In certain embodiments, Ring C4 is 5,6-fused bicyclic heteroaryl comprising at least one ring nitrogen atom wherein bond c is attached to the 6-member ring of Ring C. In certain embodiments, Ring C4 is 5,6-fused bicyclic heteroaryl comprising only one ring nitrogen atom wherein bond c is attached to the 6-memberring of Ring C. In certain embodiments, Ring C4 is 5,6-fused bicyclic heteroaryl comprising only two ring nitrogen atoms wherein bond c is attached to the 6-member ring of Ring C. In certain embodiments, Ring C4 is 5,6-fused bicyclic heteroaryl comprising only three ring nitrogen atoms wherein bond c is attached to the 6-member ring of Ring C. In certain embodiments, Ring C4 comprises no ring heteroatoms other than nitrogen. In certain embodiments, Ring C4 comprises only one ring heteroatom other than nitrogen.

[0293] In certain embodiments, Ring C4 is of the formula:

[0294]

[0295] In certain embodiments, Ring C4 is of the formula:

[0296]

[0297] In certain embodiments, Ring C4 is of the formula:

[0298]

[0299] In certain embodiments,

[0300]

[0301] of the formula:

[0302]

[0303]

[0304] In certain embodiments, Ring C4 is monocyclic heterocyclyl fused with monocyclic heteroaryl or phenyl, wherein at least one ring atom of the monocyclic heterocyclyl is oxygen, and bond c is attached to the monocyclic heterocyclyl, the monocyclic heteroaryl, or the phenyl. In certain embodiments, Ring C4 is monocyclic heterocyclyl fused with monocyclic heteroaryl, wherein at least one ring atom of the monocyclic heterocyclyl is oxygen, and bond c is attached to the monocyclic heterocyclyl or the monocyclic heteroaryl. In certain embodiments, Ring C4 is 6-membered monocyclic heterocyclyl fused with 5-membered monocyclic heteroaryl, wherein at least one ring atom of the 6-membered monocyclic heterocyclyl is oxygen, and bond c is attached to the 6-membered monocyclic heterocyclyl or 5-membered monocyclic heteroaryl. In certain embodiments, Ring C4 is 6-membered monocyclic heterocyclyl fused with 5-membered monocyclic heteroaryl, wherein at least one ring atom of the 6-membered monocyclic heterocyclyl is oxygen, and bond c is attached to the 6-membered monocyclic heterocyclyl.

[0305] lC4b) In certain embodiments, Ring C4 is of the formula:

[0306]

[0307] , wherein - is Ring C4b, which is monocyclic heteroaryl. In certain embodiments, Ring C4 is of the formula:

[0308]

[0309] certain embodiments, Ring C4b is 5-membered monocyclic heteroaryl. In

[0310] certain embodiments, Ring C4 is of the formula:

[0311]

[0312] certain embodiments,

[0313]

[0314] In certain embodiments, n2 is 0. In certain embodiments, n2 is 1. In certain embodiments, n2 is 2. In certain embodiments, n2 is 3.

[0315] In certain embodiments, at least one instance of R4at a carbon atom is -F. In certain embodiments, at least one instance of R4at a carbon atom is -Br.

[0316] In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted alkyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with halogen. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom isunsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with fluoro or chloro. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is unsubstituted Ci-6 alkyl or Ci-6 alkyl substituted with substituted or unsubstituted phenyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is unsubstituted C1-4 alkyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is Me. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is Et. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is z?-Pr or z-Pr. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is zz-Bu, z-Bu, or ec-Bu. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is / -Bu. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is fluorinated methyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is -CF3. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is fluorinated ethyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is chlorinated methyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is chlorinated ethyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is -CH2-(substituted or unsubstituted phenyl). In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is Bn.

[0317] In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted alkenyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted, C2-6 alkenyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is unsubstituted C2-6 alkenyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is unsubstituted vinyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is unsubstituted allyl or-CH=CHCH3.

[0318] In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted alkynyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted, C2-6 alkynyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is unsubstituted C2-6 alkynyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is C=CH. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is -C=CCH3or CH2C=CH.

[0319] In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted carbocyclyl (e.g., substituted or unsubstituted, monocyclic, 3- to 7-membered carbocyclyl). In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, or substituted orunsubstituted cycloheptyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is saturated carbocyclyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is partially unsaturated carbocyclyl (e.g., comprising only one C=C bond in the carbocyclic ring system).

[0320] In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl). In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, or substituted or unsubstituted piperazinyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is saturated heterocyclyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is partially unsaturated heterocyclyl (e.g., comprising only one C=C bond in the heterocyclic ring system).

[0321] In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted aryl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted phenyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is unsubstituted phenyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is 4-mono-substituted phenyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is 3- mono-substituted phenyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is 2-mono-substituted phenyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is di-substituted phenyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted naphthyl.

[0322] In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted heteroaryl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, or substituted or unsubstituted isothiazolyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted pyridinyl (e.g., 2-, 3-, or 4-pyridinyl). In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl, or substituted or unsubstitutedpyridazinyl. In certain embodiments, at least one instance of R4at a carbon or nitrogen atom is substituted or unsubstituted, 9- to 10-membered, bicyclic heteroaryl.

[0323] In certain embodiments, at least one instance of R4at a carbon atom is -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, at least one instance of R4at a carbon atom is -ORA, halogen, substituted or unsubstituted alkyl, -N(RA)2, -SRA, -CN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -OC(=O)RA, -OC(=O)ORA, or -OC(=O)N(RA)2. In certain embodiments, at least one instance of R4at a carbon atom is -ORA. In certain embodiments, at least one instance of R4at a carbon atom is -OH. In certain embodiments, at least one instance of R4at a carbon atom is -O(substituted or unsubstituted alkyl). In certain embodiments, at least one instance of R4at a carbon atom is -O(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, at least one instance of R4at a carbon atom is -O(unsubstituted C1-6 alkyl). In certain embodiments, at least one instance of R4at a carbon atom is -OMe. In certain embodiments, at least one instance of R4at a carbon atom is -O(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, at least one instance of R4at a carbon atom is -SRA. In certain embodiments, at least one instance of R4at a carbon atom is -SH. In certain embodiments, at least one instance of R4at a carbon atom is -S( substituted or unsubstituted alkyl). In certain embodiments, at least one instance of R4at a carbon atom is ^(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, at least one instance of R4at a carbon atom is -S(unsubstituted C1-6 alkyl). In certain embodiments, at least one instance of R4at a carbon atom is -SMe. In certain embodiments, at least one instance of R4at a carbon atom is -S(Ci-6 alkyl substituted with one or more instances of halogen). In certain embodiments, at least one instance of R4at a carbon atom is -NH2. In certain embodiments, at least one instance of R4at a carbon atom is -NHRA. In certain embodiments, at least one instance of R4at a carbon atom is -NH(substituted or unsubstituted alkyl). In certain embodiments, at least one instance of R4at a carbon atom is -NH(substituted or unsubstituted, C1-6 alkyl). In certain embodiments, at least one instance of R4at a carbon atom is -NH(unsubstituted C1-6 alkyl). In certain embodiments, at least one instance of R4at a carbon atom is -NHMe. In certain embodiments, at least one instance of R4at a carbon atom is -NH(CI-6 alkyl substituted with one or more instances of halogen). In certain embodiments, at least one instance of R4at a carbon atom is -N(RA)2. Incertain embodiments, at least one instance of R4at a carbon atom is -N(substituted or unsubstituted alkyl)2. In certain embodiments, at least one instance of R4at a carbon atom is -N( substituted or unsubstituted, Ci-6 alkyl)2. In certain embodiments, at least one instance of R4at a carbon atom is -N(unsubstituted Ci-6 alkyl)2. In certain embodiments, at least one instance of R4at a carbon atom is -NMe2. In certain embodiments, at least one instance of R4at a carbon atom is -N(CI-6 alkyl substituted with one or more instances of halogen)2.

[0324] In certain embodiments, at least one instance of R4at a nitrogen atom is -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2. In certain embodiments, at least one instance of R4at a nitrogen atom is -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2, wherein each instance of RAis independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, at least one instance of R4at a nitrogen atom is -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2, wherein each instance of RAis independently substituted or unsubstituted, Ci-6 alkyl. In certain embodiments, at least one instance of R4at a nitrogen atom is a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts).

[0325] In certain embodiments, at least one instance of R4at a carbon atom is halogen, -CN, or substituted or unsubstituted alkyl. In certain embodiments, at least one instance of R4at a carbon atom is halogen, -CN, -C(=O)OH, unsubstituted Ci-6 alkyl, or Ci-6 alkyl substituted with one or more halogen. In certain embodiments, at least one instance of R4at a carbon atom is halogen. In certain embodiments, at least one instance of R4at a carbon atom is -Cl. In certain embodiments, at least one instance of R4at a carbon atom is -F, -Cl, -Br, -CN, -C(=O)OH, -CH3, or -CF3.

[0326] In certain embodiments, each of the carbon atom substituents is independently halo, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -ORaa, -N(Rbb)2, -SH, -SRaa, -SSRCC, -C(=O)Raa, -CO2H, -CHO, -CO2Raa, -OC(=O)Raa, -OCO2Raa, -C(=O)N(Rbb)2, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, -C(=O)NRbbSO2Raa, -NRbbSO2Raa, -SO2N(Rbb)2, -SO2Raa, -SO2ORaa, -OSO2Raa, -S(=O)Raa, -OS(=O)Raa, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, or =0, wherein Raais C1-10 alkyl or C1-10 perhaloalkyl, and each of Rbband Rccis independently hydrogen, C1-10 alkyl, or C1-10 perhaloalkyl; and

[0327] each of the nitrogen atom substituents is independently -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO2Raa, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SORaa, CHO alkyl, C2-10 alkenyl, or C2-10 alkynyl, wherein each alkyl, alkenyl, and alkynyl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; Raais C1-10 alkyl or C1-10 perhaloalkyl; each Rccis independently hydrogen, C1-10 alkyl, or C1-10 perhaloalkyl; and each Rddis independently halo, -CN, -OH, -0(Ci-6 alkyl),-NH2, -NH(CI-6 alkyl), -N(CI-6 alkyl)2, Ci-6 alkyl, Ci-6 perhaloalkyl, C2-6 alkenyl, or C2-6 alkynyl.

[0328] In certain embodiments, each of the carbon atom substituents is independently halo, -CN, -NO2, -OH, -ORaa, -N(Rbb)2, -C(=O)Raa, -CO2H, -CHO, -CO2Raa, -OC(=O)Raa, -OCO2Raa, -C(=O)N(Rbb)2, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, Ci-io alkyl, C1-10 perhaloalkyl, or =0, wherein Raais C1-10 alkyl or C1-10 perhaloalkyl, and each of Rbbis independently hydrogen, C1-10 alkyl, or C1-10 perhaloalkyl; and

[0329] each of the nitrogen atom substituents is independently -C(=O)Raa, -C(=O)N(RCC)2, -C02Raa, or Ci-10 alkyl, wherein the alkyl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; Raais CMO alkyl or Cuo perhaloalkyl; each Rccis independently hydrogen, C O alkyl, or CMO perhaloalkyl; and each Rddis independently halo, -CN, -OH, -O(Ci-6 alkyl), -NH2, -NH(CI-6 alkyl), -N(CI-6 alkyl)2, C1-6 alkyl, or C1-6 perhaloalkyl.

[0330] In certain embodiments, heteroatoms other than nitrogen are unsubstituted.

[0331] In certain embodiments, the compound is of the formula:

[0332]

[0333]

[0334]

[0335]

[0336]

[0337]

[0338]

[0339]

[0340]

[0341]

[0342]

[0343]

[0344]

[0345]

[0346]

[0347] In certain embodiments, the compound is of the formula:

[0348]

[0349] (ciprimelpin). In certain embodiments, the compound is of the formula:

[0350]

[0351] (I-C-008).

[0352] In certain embodiments, the compound is of the formula:

[0353]

[0354]

[0355] In certain embodiments, the compound is of the formula:

[0356]

[0357] (Il-l) or (II-2).

[0358] In certain embodiments, the compound is not any one of Formulae I-A-014, 1-A-016, 1-B- 001, I-B-002, I-B-004, 1-B-006, 1-B-007, 1-B-008, 1-D-003, 1-D-018, 1-D-027, 1-D-029, 1-D-032, I-D-033, 1-D-034, 1-D-035, 1-D-037, 1-D-038, and I-D-039.

[0359] In certain embodiments, a provided compound (a compound provided herein or a compound of the present disclosure) is a compound of Formula F, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof. In certain embodiments, a provided compound is acompound of Formula F, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, or isotopically labeled compound thereof. In certain embodiments, a provided compound is a compound of Formula F, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. In certain embodiments, a provided compound is a compound of Formula F, or a pharmaceutically acceptable salt or tautomer thereof. In certain embodiments, a provided compound is a compound of Formula F, or a pharmaceutically acceptable salt thereof.

[0360] In certain embodiments, a provided compound (a compound provided herein or a compound of the present disclosure) is a compound of Formula I, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof. In certain embodiments, a provided compound is a compound of Formula I, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, or isotopically labeled compound thereof. In certain embodiments, a provided compound is a compound of Formula I, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. In certain embodiments, a provided compound is a compound of Formula I, or a pharmaceutically acceptable salt or tautomer thereof. In certain embodiments, a provided compound is a compound of Formula I, or a pharmaceutically acceptable salt thereof.

[0361] In certain embodiments, the molecular weight of a compound of Formula F, e.g., Formula I, is lower than 400, between 400 and 500, between 500 and 600, between 600 and 800, between 800 and 1000, between 1000 and 1200, or between 1200 and 1500, inclusive, g / mol.

[0362] Pharmaceutical Compositions and Administration

[0363] In another aspect, the present disclosure provides pharmaceutical compositions comprising a provided compound and a pharmaceutically acceptable excipient.

[0364] In certain embodiments, the pharmaceutical composition comprises an effective amount of the provided compound. In certain embodiments, the effective amount is a therapeutically effective amount. In certain embodiments, an effective amount is an amount effective for treating a disease in a subject in need thereof. In certain embodiments, the effective amount is a prophylactically effective amount. In certain embodiments, an effective amount is an amount effective for preventing a disease in a subject. In certain embodiments, an effective amount is an amount effective for inhibiting the growth or reproduction of a microorganism or killing a microorganism in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface. In certain embodiments, an effective amount is an amount effective for inhibitingthe growth or reproduction of a microorganism or killing a microorganism in a cell, tissue, biological sample, or microorganism, or on a surface.

[0365] In certain embodiments, the subject is an animal. The animal may be of either sex and may be at any stage of development. In certain embodiments, the subject is a human (e.g., an adult, juvenile, or child). In certain embodiments, the subject is a non-human animal. In certain embodiments, the subject is a mammal. In certain embodiments, the subject is a non-human mammal. In certain embodiments, the subject is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep, or goat. In certain embodiments, the subject is a companion animal, such as a dog or cat. In certain embodiments, the subject is a livestock animal, such as a cow, pig, horse, sheep, or goat. In certain embodiments, the subject is a zoo animal. In another embodiment, the subject is a research animal, such as a rodent (e.g., mouse, rat), dog, pig, or non-human primate. In certain embodiments, the subject is a genetically engineered animal. In certain embodiments, the subject is a transgenic animal (e.g., transgenic mice, transgenic pigs). In certain embodiments, the subject is a fish or reptile.

[0366] In certain embodiments, the cell, tissue, biological sample, or microorganism (e.g., the biological sample, tissue, or cell being contacted with a provided compound or pharmaceutical composition) is in vitro. In certain embodiments, the cell, tissue, biological sample, or microorganism is in vivo. In certain embodiments, the cell, tissue, biological sample, or microorganism is ex vivo.

[0367] In certain embodiments, the surface is the surface of a tissue or organ. In certain embodiments, the surface is the surface of the skin.

[0368] In certain embodiments, the surface is the surface of a medical device. In certain embodiments, the surface is the surface of a household item. In certain embodiments, the surface is a high-touch surface. In certain embodiments, the surface is the surface of a handle, pull, button, valve, or switch. In certain embodiments, the surface is the surface of an electronic device. In certain embodiments, the surface is a kitchen surface or bathroom surface. In certain embodiments, the surface is the surface of a toy, trash lid, pet habitat, or shopping cart.

[0369] Pharmaceutical compositions can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include bringing the provided compound (“active ingredient”) into association with a carrier or excipient, and / or one or more other accessory ingredients, and then, if necessary and / or desirable, shaping, and / or packaging the product into a desired single- or multi-dose unit.

[0370] Pharmaceutical compositions can be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single unit doses. A “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. Theamount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and / or a convenient fraction of such a dosage, such as one-half or one-third of such a dosage.

[0371] Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and / or any additional ingredients in a pharmaceutical composition will vary, depending upon the identity, size, and / or condition of the subject treated and further depending upon the route by which the pharmaceutical composition is to be administered. The pharmaceutical composition may comprise between 0.1% and 100% (w / w) active ingredient.

[0372] Pharmaceutically acceptable excipients used in the manufacture of provided pharmaceutical compositions include inert diluents, dispersing and / or granulating agents, surface active agents and / or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and / or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the pharmaceutical composition.

[0373] Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.

[0374] Exemplary granulating and / or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.

[0375] Exemplary surface active agents and / or emulsifiers include natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g.,carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate (Tween® 20), polyoxyethylene sorbitan (Tween® 60), polyoxyethylene sorbitan monooleate (Tween® 80), sorbitan monopalmitate (Span® 40), sorbitan monostearate (Span® 60), sorbitan tristearate (Span® 65), glyceryl monooleate, sorbitan monooleate (Span® 80), polyoxyethylene esters (e.g., polyoxyethylene monostearate (Myrj® 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol®), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., Cremophor®), polyoxyethylene ethers, (e.g., polyoxyethylene lauryl ether (Brij® 30)), poly (vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic® F-68, poloxamer P-188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and / or mixtures thereof.

[0376] Exemplary binding agents include starch (e.g., cornstarch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly (vinyl-pyrrolidone), magnesium aluminum silicate (Veegum®), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and / or mixtures thereof.

[0377] Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoan preservatives, alcohol preservatives, acidic preservatives, and other preservatives. In certain embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent.

[0378] Exemplary antioxidants include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.

[0379] Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydratesthereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.

[0380] Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.

[0381] Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.

[0382] Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.

[0383] Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant® Plus, Phenonip®, methylparaben, Germall® 115, Germaben® II, NeoIone®, Kathon®, and Euxyl®.

[0384] Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer’s solution, ethyl alcohol, and mixtures thereof.

[0385] Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.

[0386] Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, com, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed,geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof.

[0387] Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredients, the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral pharmaceutical compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. In certain embodiments for parenteral administration, the conjugates are mixed with solubilizing agents such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.

[0388] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer’s solution, U. S. P., and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[0389] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid pharmaceutical compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form may be accomplished by dissolving or suspending the drug in an oil vehicle.

[0390] Pharmaceutical compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the conjugates with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.

[0391] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may include a buffering agent.

[0392] Solid pharmaceutical compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the art of pharmacology. They may optionally comprise opacifying agents and can be of a pharmaceutical composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.

[0393] Examples of encapsulating pharmaceutical compositions which can be used include polymeric substances and waxes. Solid pharmaceutical compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.The active ingredient can be in a micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings, and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active ingredient can be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may comprise buffering agents. They may optionally comprise opacifying agents and can be of a pharmaceutical composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of encapsulating agents which can be used include polymeric substances and waxes.

[0394] Dosage forms for topical and / or transdermal administration of a provided compound may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and / or patches. Generally, the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier or excipient and / or any needed preservatives and / or buffers as can be required. Additionally, the present disclosure contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of an active ingredient to the body. Such dosage forms can be prepared, for example, by dissolving and / or dispensing the active ingredient in the proper medium. Alternatively or additionally, the rate can be controlled by either providing a rate controlling membrane and / or by dispersing the active ingredient in a polymer matrix and / or gel.

[0395] Suitable devices for use in delivering intradermal pharmaceutical compositions include short needle devices. Intradermal pharmaceutical compositions can be administered by devices which limit the effective penetration length of a needle into the skin. Alternatively or additionally, conventional syringes can be used in the classical mantoux method of intradermal administration. Jet injection devices which deliver liquid formulations to the dermis via a liquid jet injector and / or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable. Ballistic powder / particle delivery devices which use compressed gas to accelerate the provided compound in powder form through the outer layers of the skin to the dermis are suitable.

[0396] Formulations suitable for topical administration include, but are not limited to, liquid and / or semi-liquid preparations such as liniments, lotions, oil-in-water and / or water-in-oil emulsions such as creams, ointments, and / or pastes, and / or solutions and / or suspensions.

[0397] Topically administrable formulations may, for example, comprise from about 1% to about 10%(w / w) active ingredient, although the concentration of the active ingredient can be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients.

[0398] A pharmaceutical composition can be prepared, packaged, and / or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, or from about 1 to about 6 nanometers. Such pharmaceutical compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant can be directed to disperse the powder and / or using a self-propelling solvent / powder dispensing container such as a device comprising the active ingredient dissolved and / or suspended in a low-boiling propellant in a sealed container. Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder pharmaceutical compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.

[0399] Low boiling propellants generally include liquid propellants having a boiling point of below 65 °F at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% (w / w) of the pharmaceutical composition, and the active ingredient may constitute 0.1 to 20% (w / w) of the pharmaceutical composition. The propellant may further comprise additional ingredients such as a liquid non-ionic and / or solid anionic surfactant and / or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).

[0400] Pharmaceutical compositions formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and / or suspension. Such formulations can be prepared, packaged, and / or sold as aqueous and / or dilute alcoholic solutions and / or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and / or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and / or a preservative such as methylhydroxybenzoate. The droplets provided by this route of administration may have an average diameter in the range from about 0.1 to about 200 nanometers.

[0401] Formulations as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to500 micrometers. Such a formulation is administered by rapid inhalation through the nasal passage from a container of the powder held close to the nares.

[0402] Formulations for nasal administration may, for example, comprise from about as little as 0.1% (w / w) to as much as 100% (w / w) of the active ingredient, and may comprise one or more of the additional ingredients. A pharmaceutical composition can be prepared, packaged, and / or sold in a formulation for buccal administration. Such formulations may, for example, be in the form of tablets and / or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w / w) active ingredient, the balance comprising an orally dissolvable and / or degradable pharmaceutical composition and, optionally, one or more of the additional ingredients.

[0403] Alternately, formulations for buccal administration may comprise a powder and / or an aerosolized and / or atomized solution and / or suspension comprising the active ingredient. Such powdered, aerosolized, and / or aerosolized formulations, when dispersed, may have an average particle and / or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients.

[0404] A pharmaceutical composition can be prepared, packaged, and / or sold in a formulation for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1- 1.0% (w / w) solution and / or suspension of the active ingredient in an aqueous or oily liquid carrier or excipient. Such drops may further comprise buffering agents, salts, and / or one or more other of the additional ingredients. Other opthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and / or in a liposomal preparation. Ear drops and / or eye drops are also contemplated as being within the scope of this disclosure.

[0405] Although the descriptions of the pharmaceutical compositions are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such pharmaceutical compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the pharmaceutical compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and / or perform such modification with ordinary experimentation.

[0406] The provided compounds are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the pharmaceutical compositions will be decided by a physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specificpharmaceutical composition employed; the age, body weight, general health, sex, and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.

[0407] The provided compounds and pharmaceutical compositions can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and / or drops), mucosal, nasal, bucal, sublingual; by intratracheal instillation, bronchial instillation, and / or inhalation; and / or as an oral spray, nasal spray, and / or aerosol. Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), regional administration via blood and / or lymph supply, and / or direct administration to an affected site. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), and / or the condition of the subject (e.g., whether the subject is able to tolerate oral administration). In certain embodiments, the provided compound or pharmaceutical composition is suitable for topical administration to the eye of a subject.

[0408] The exact amount of a provided compound required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound, mode of administration, and the like. An effective amount may be included in a single dose (e.g., single oral dose) or multiple doses (e.g., multiple oral doses). In certain embodiments, when multiple doses are administered to a subject or applied to a cell, tissue, biological sample, or microorganism, any two doses of the multiple doses include different or substantially the same amounts of a provided compound. In certain embodiments, when multiple doses are administered to a subject or applied to a cell, tissue, biological sample, or microorganism, the frequency of administering the multiple doses to the subject or applying the multiple doses to the cell, tissue, biological sample, or microorganism is three doses a day, two doses a day, one dose a day, one dose every other day, one dose every third day, one dose every week, one dose every two weeks, one dose every three weeks, or one dose every four weeks. In certain embodiments, the frequency of administering the multiple doses to the subject or applying the multiple doses to the cell, tissue, biological sample, or microorganism is one dose per day. In certain embodiments, the frequency of administering the multiple doses to the subject or applying the multiple doses to the cell, tissue, biological sample, or microorganism is two doses per day. In certain embodiments,the frequency of administering the multiple doses to the subject or applying the multiple doses to the cell, tissue, biological sample, or microorganism is three doses per day. In certain embodiments, when multiple doses are administered to a subject or applied to a cell, tissue, biological sample, or microorganism, the duration between the first dose and last dose of the multiple doses is one day, two days, four days, one week, two weeks, three weeks, one month, two months, three months, four months, six months, nine months, one year, two years, three years, four years, five years, seven years, ten years, fifteen years, twenty years, or the lifetime of the subject or cell. In certain embodiments, the duration between the first dose and last dose of the multiple doses is three months, six months, or one year. In certain embodiments, the duration between the first dose and last dose of the multiple doses is the lifetime of the subject or cell. In certain embodiments, a dose (e.g., a single dose, or any dose of multiple doses) includes independently between 0.1 pg and 1 pg, between 0.001 mg and 0.01 mg, between 0.01 mg and 0.1 mg, between 0.1 mg and 1 mg, between 1 mg and 3 mg, between 3 mg and 10 mg, between 10 mg and 30 mg, between 30 mg and 100 mg, between 100 mg and 300 mg, between 300 mg and 1,000 mg, or between 1 g and 10 g, inclusive, of a provided compound. In certain embodiments, a dose includes independently between 1 mg and 3 mg, inclusive, of a provided compound. In certain embodiments, a dose includes independently between 3 mg and 10 mg, inclusive, of a provided compound. In certain embodiments, a dose includes independently between 10 mg and 30 mg, inclusive, of a provided compound. In certain embodiments, a dose includes independently between 30 mg and 100 mg, inclusive, of a provided compound.

[0409] Dose ranges as provide guidance for the administration of provided pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.

[0410] In certain embodiments, the pharmaceutical composition further comprises an additional pharmaceutical agent. The additional pharmaceutical agent is different from the provided compound. In certain embodiments, the additional pharmaceutical agent is an additional therapeutically active agent. In certain embodiments, the additional pharmaceutical agent is an additional prophylactically active agent. A provided compound or pharmaceutical composition can be administered in combination with one or more additional pharmaceutical agents. The provided compounds or pharmaceutical compositions can be administered in combination with additional pharmaceutical agents that improve their activity (e.g., activity (e.g., potency and / or efficacy) in treating a disease in a subject in need thereof, in preventing a disease in a subject in need thereof, improve bioavailability, improve safety, reduce drug resistance, reduce and / or modify metabolism, inhibit excretion, and / or modify distribution in a subject, biological sample,tissue, or cell. It will also be appreciated that the therapy employed may achieve a desired effect for the same disorder, and / or it may achieve different effects. In certain embodiments, a pharmaceutical composition including a provided compound and an additional pharmaceutical agent shows a synergistic effect that is absent in a pharmaceutical composition including one of the provided compound and the additional pharmaceutical agent, but not both.

[0411] The provided compound or pharmaceutical composition can be administered concurrently with, prior to, or subsequent to one or more additional pharmaceutical agents, which may be useful as, e.g., combination therapies. Pharmaceutical agents include small organic molecules such as drug compounds e.g., compounds approved for human or veterinary use by the U. S. Food and Drug Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells. In certain embodiments, the additional pharmaceutical agent is a pharmaceutical agent useful for treating and / or preventing a disease or premalignant condition. Each additional pharmaceutical agent may be administered at a dose and / or on a time schedule determined for that pharmaceutical agent. The additional pharmaceutical agents may also be administered together with each other and / or with a provided compound or pharmaceutical composition in a single dose or administered separately in different doses. The particular combination to employ in a regimen will take into account compatibility of the provided compound with the additional pharmaceutical agent(s) and / or the desired therapeutic and / or prophylactic effect to be achieved. In general, it is expected that the additional pharmaceutical agent(s) in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.

[0412] The additional pharmaceutical agents include, but are not limited to, cytotoxic chemotherapeutic agents, epigenetic modifiers, glucocorticoids, immunotherapeutic agents, antiproliferative agents, anti-cancer agents, anti-angiogenesis agents, anti-inflammatory agents, immunosuppressants, anti-microbial agents, cardiovascular agents, cholesterol-lowering agents, anti-diabetic agents, anti-allergic agents, contraceptive agents, pain-relieving agents, and a combination thereof. In certain embodiments, at least one additional pharmaceutical agent is a microbicidal agent. In certain embodiments, at least one additional pharmaceutical agent is an anti-bacterial agent. In certain embodiments, at least one additional pharmaceutical agent is an anti-viral agent. In certain embodiments, at least one additional pharmaceutical agent is an anti-parasitic agent. In certain embodiments, at least one additional pharmaceutical agent is aparasitocidal agent. In certain embodiments, at least one additional pharmaceutical agent is a rapid malaria-parasite killing agent. In certain embodiments, at least one additional pharmaceutical agent is a parasitostatic agent. In certain embodiments, at least one additional pharmaceutical agent is an antiplasmodial agent. In some embodiments, the additional pharmaceutical agent is a topoisomerase inhibitor, a MCL1 inhibitor, a BCL-2 inhibitor, a BCL-xL inhibitor, a BRD4 inhibitor, a BRCA1 inhibitor, BRCA2 inhibitor, HER1 inhibitor, HER2 inhibitor, a CDK9 inhibitor, a Jumonji histone demethylase inhibitor, or a DNA damage inducer. In certain embodiments, the additional pharmaceutical agent is a binder or inhibitor of a kinase (e.g., tyrosine kinase). In certain embodiments, the additional pharmaceutical agent is an antibody or a fragment thereof (e.g., monoclonal antibody). In certain embodiments, the additional therapy is an immunotherapy (e.g., an immunotherapeutic monoclonal antibody). In certain embodiments, the additional pharmaceutical agent is an immunosuppressor. In certain embodiments, the additional pharmaceutical agent is an immunoactivator. In certain embodiments, the additional pharmaceutical agent is an immune checkpoint inhibitor. In certain embodiments, the additional pharmaceutical agent is a programmed cell death 1 protein (PD-1) inhibitor. In certain embodiments, the additional pharmaceutical agent is a programmed cell death 1 protein ligand 1 (PD-L1) inhibitor. In certain embodiments, the additional pharmaceutical agent is a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor. In certain embodiments, the additional pharmaceutical agent is a T-cell immunoglobulin domain and mucin domain 3 (TIM3) inhibitor, lymphocyte activation gene-3 (LAG3) inhibitor, V-set domaincontaining T-cell activation inhibitor 1 (VTCN1 or B7-H4) inhibitor, cluster of differentiation 276 (CD276 or B7-H3) inhibitor, B and T lymphocyte attenuator (BTLA) inhibitor, galectin-9 (GAL9) inhibitor, checkpoint kinase 1 (Chkl) inhibitor, adenosine A2A receptor (A2AR) inhibitor, indoleamine 2,3-dioxygenase (IDO) inhibitor, killer-cell immunoglobulin-like receptor (KIR) inhibitor, or V-domain Ig suppressor of T cell activation (VISTA) inhibitor. In certain embodiments, the additional pharmaceutical agent is metformin. In certain embodiments, the additional pharmaceutical agent is approved for human and / or veterinarian administration by a regulatory agency, such as the U. S. Food and Drug Administration (FDA) or the European Agency for the Evaluation of Medicinal Products (EMA). In certain embodiments, the provided compounds or pharmaceutical compositions can be administered in combination with surgery, radiation therapy, and / or transplantation (e.g., stem cell transplantation, bone marrow

[0413] transplantation).Kits

[0414] In another aspect, the present disclosure provides kits comprising a provided compound or pharmaceutical composition, and instructions for using the provided compound or pharmaceutical composition. In certain embodiments, the kit comprises a first container, wherein the first container comprises the provided compound or pharmaceutical composition. In some embodiments, the kit further comprises a second container. In certain embodiments, the second container includes an excipient (e.g., an excipient for dilution or suspension of the provided compound or pharmaceutical composition). In certain embodiments, the second container includes an additional pharmaceutical agent. In some embodiments, the kit further comprises a third container. In certain embodiments, the third container includes an additional pharmaceutical agent. In some embodiments, the provided compound or pharmaceutical composition included in the first container and the excipient or additional pharmaceutical agent included in the second container are combined to form one unit dosage form. In some embodiments, the provided compound or pharmaceutical composition included in the first container, the excipient included in the second container, and the additional pharmaceutical agent included in the third container are combined to form one unit dosage form. In certain embodiments, each of the first, second, and third containers is independently a vial, ampule, bottle, syringe, dispenser package, tube, or inhaler.

[0415] In certain embodiments, the first container, second container, and third container do not comprise the instructions. In certain embodiments, the instructions are for administering the provided compound or pharmaceutical composition to a subject (e.g., a subject in need of treatment or prevention of a disease). In certain embodiments, the instructions are for contacting a cell, tissue, biological sample, microorganism, or surface with the provided compound or pharmaceutical composition. In certain embodiments, the instructions comprise information required by a regulatory agency, such as the FDA or EMA. In certain embodiments, the instructions comprise prescribing information.

[0416] Methods of Use and Uses

[0417] The present disclosure also provides methods of using the provided compounds and pharmaceutical compositions.

[0418] In another aspect, the present disclosure provides methods of treating a disease in a subject in need thereof, the methods comprising administering to the subject an effective amount of a provided compound or pharmaceutical composition.In another aspect, the present disclosure provides use of a provided compound or pharmaceutical composition for the manufacture of a medicament for treating a disease in a subject in need thereof.

[0419] In another aspect, the present disclosure provides compounds and pharmaceutical compositions for use in treating a disease in a subject in need thereof.

[0420] In another aspect, the present disclosure provides methods of preventing a disease in a subject, the methods comprising administering to the subject an effective amount of a provided compound or pharmaceutical composition.

[0421] In another aspect, the present disclosure provides use of a provided compound or pharmaceutical composition for the manufacture of a medicament for preventing a disease in a subject.

[0422] In another aspect, the present disclosure provides compounds and pharmaceutical compositions for use in preventing a disease in a subject.

[0423] In certain embodiments, the disease is an infection. In certain embodiments, the disease is a bacterial infection, biofilm infection, mycosis, prion disease, sepsis, parasitic infection, or viral infection. In certain embodiments, the disease is a bacterial infection. In certain embodiments, the disease is a Gram-negative bacterial infection. In certain embodiments, the disease is a multidrug-resistant bacterial infection. In certain embodiments, the disease is an Enterobacteriaceae infection. In certain embodiments, the disease is a Biostraticola infection, Buttiauxella infection, Cedecea infection, Citrobacter infection, Cronobacter infection, Enterobacillus infection, Enterobacter infection, Escherichia infection, Franconibacter infection, Gibbsiella infection, Izhakiella infection, Klebsiella infection, Kluyvera infection, Kosakonia infection, Leclercia infection, Lelliottia infection, Limnobaculum infection, Mangrovibacter infection, Metakosakonia infection, Phytobacter infection, Pluralibacter infection, Proteus infection, Pseudescherichia infection, Pseudocitrobacter infection, Raoultella infection, Rosenbergiella infection, Saccharobacter infection, Salmonella infection, Scandinavium infection, Shigella infection, Shimwellia infection, Siccibacter infection, Trabulsiella infection, or Yokenella infection. In certain embodiments, the disease is an Escherichia infection, Klebsiella infection, Kluyvera infection, Citrobacter infection, Salmonella infection, Enterobacter infection, Yersinia infection, or Serratia infection. In certain embodiments, the disease is an Escherichia coli infection, Klebsiella pneumoniae infection, Salmonella typhimurium infection, Yersinia pestis infection, or Serratia marcescens infection. In certain embodiments, the disease is a Shigella infection. In certain embodiments, the infection is an abdominal infection, adrenal gland infection, asymptomatic infection, biofilm infection, blood-borne infection, digestive system infection, ear infection, iatrogenic infection, importedcommunicable disease, infectious endocarditis, limb infection, mammary gland infection, mediastinal infection, mucosal infection, musculoskeletal infection, nervous system infection, nosocomial infection, prosthesis-associated infection, reinfection, respiratory infection, secondary infection, sepsis, sexually transmitted disease, skin infection, spleen infection, thymus gland infection, urogenital system infection, vector-borne infection, wound infection, or zoonosis.

[0424] In certain embodiments, the provided method further comprises administering to the subject in need thereof an additional therapy. In certain embodiments, the additional therapy is one or more additional pharmaceutical agents. In certain embodiments, the additional pharmaceutical agents are as described in the present disclosure. In certain embodiments, a provided method that further comprises administering to the subject in need thereof the additional therapy is synergistic as compared to a provided method that does not comprise administering to the subject in need thereof the additional therapy and as compared to a method comprises administering to the subject in need thereof the additional therapy as the only active therapy. In certain embodiments, the subject is a subject that has been administered the additional therapy. In certain embodiments, the subject is resistant to the additional therapy. In certain embodiments, the effective amount of a provided compound or pharmaceutical composition is effective in decreasing the resistance to the additional therapy. The additional therapy may be administered to the subject concurrently with, prior to, or subsequent to the administration of the provided compound or pharmaceutical composition.

[0425] In another aspect, the present disclosure provides methods of inhibiting the growth or reproduction of a microorganism or killing a microorganism in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface, the methods comprising administering to the subject or contacting the cell, tissue, biological sample, microorganism, or surface with an effective amount of a provided compound or pharmaceutical composition.

[0426] In another aspect, the present disclosure provides use of a provided compound or pharmaceutical composition for the manufacture of a medicament for inhibiting the growth or reproduction of a microorganism or killing a microorganism in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface.

[0427] In another aspect, the present disclosure provides the provided compounds and pharmaceutical compositions for use in inhibiting the growth or reproduction of a microorganism or killing a microorganism in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface.

[0428] In another aspect, the present disclosure provides in vitro methods of inhibiting the growth or reproduction of a microorganism or killing a microorganism in a cell, tissue, biologicalsample, or microorganism, or on a surface, the method comprising contacting the cell, tissue, biological sample, microorganism, or surface with an effective amount of a provided compound or pharmaceutical composition.

[0429] In certain embodiments, the microorganism is a bacterium, fungus, prion, parasite, or virus. In certain embodiments, the microorganism is a bacterium. In certain embodiments, the microorganism is a Gram-negative bacterium. In certain embodiments, the microorganism is a multi-drug resistant bacterium. In certain embodiments, the microorganism is an Enterobacteriaceae genus. In certain embodiments, the microorganism is a Biostraticola species, Buttiauxella species, Cedecea species, Citrobacter species, Cronobacter species, Enterobacillus species, Enterobacter species, Escherichia species, Franconibacter species, Gibbsiella species, Izhakiella species, Klebsiella species, Kluyvera species, Kosakonia species, Leclercia species, Lelliottia species, Limnobaculum species, Mangrovibacter species, Metakosakonia species, Phytobacter species, Pluralibacter species, Proteus species, Pseudescherichia species, Pseudocitrobacter species, Raoultella species, Rosenbergiella species, Saccharobacter species, Salmonella species, Scandinavium species, Shigella species, Shimwellia species, Siccibacter species, Trabulsiella species, or Yokenella species. In certain embodiments, the microorganism is an Escherichia species, Klebsiella species, Kluyvera species, Citrobacter species, Salmonella species, Enterobacter species, Yersinia species, or Serratia species. In certain embodiments, the microorganism is an Escherichia coli strain, Klebsiella pneumoniae strain, Salmonella typhimurium strain, Yersinia pestis strain, or Serratia marcescens strain. In certain embodiments, the microorganism is Shigella species.

[0430] EXAMPLES

[0431] In order that the present disclosure may be more fully understood, the following examples are set forth. The examples described in this application are offered to illustrate the compounds, pharmaceutical compositions, kits, uses, and methods provided herein and are not to be construed in any way as limiting their scope.

[0432] Example 1. Preparation of provided compounds

[0433] An exemplary preparation of ciprimelpin is shown in FIG. 1. Using 2 and 3 as starting points in our efforts to develop lolCDE inhibitors, we devised a convergent, component-based synthesis that allowed for the modular substitution of each aryl and heteroaryl group within both scaffolds. Using this platform, we were able to synthesize over 100 compounds, including ciprimelpin. We presented here a gram-scale, component-based synthesis of ciprimelpin, which proceeded in five total steps from inexpensive commercially available starting materials. The sequence hinged on the rapid convergent assembly of the molecule’s backbone through theexecution of two Sonogashira couplings and a Williamson Ether Synthesis in a single operation. In one flask, a first Sonogashira coupling was conducted between 4-bromo-2-methylpyridine and trimethylsilylacetylene, and the resulting trimethylsilyl alkyne intermediate was desilylated in situ with the subsequent addition of potassium hydroxide to reveal terminal alkyne 7. Meanwhile, 4-iodophenol was separately treated with cesium carbonate in the presence of 8 (synthesized from commercially available imidazo[l,2-a]pyridin-6-ylmethanol by successive chlorination with N-chlorosuccinimide (85% yield) and thionyl chloride), and the resulting crude reaction mixture containing aryl iodide 9 was directly transferred to the reaction vessel containing 7, where a second Sonogashira coupling took place to afford alkyne 10 (64% overall yield). 10 was then oxidized to its corresponding diketone by the action of potassium permanganate and directly subjected to Debus-Radziszewski imidazole synthesis with cyclopropanecarboxaldehyde to afford 6 (50% yield).

[0434] General Experimental Procedures

[0435] All reactions were performed in flame-dried round-bottom flasks fitted with rubber septa under positive nitrogen pressure, unless otherwise noted. Air- and moisture- sensitive liquids were transferred via syringe or stainless-steel cannula. Organic solutions were concentrated by rotary evaporation (house vacuum, ca. 25-40 Torr) at ambient temperature, unless otherwise noted. Analytical thin-layer chromatography (TLC) was performed using glass plates precoated with silica gel (0.25 mm, 60 A pore-size, 230-400 mesh, Merck KGA) impregnated with a fluorescent indicator (254 nm). TLC plates were visualized by exposure to ultraviolet light, then were stained with either an aqueous sulfuric acid solution of ceric ammonium molybdate (CAM), an ethanol-aqueous sulfuric acid solution of 2, 4- dinitrophenylhydrazine (DNP), or an aqueous sodium hydroxide-potassium carbonate solution of potassium permanganate (KMnO4) then briefly heated using a heat gun. Flash-column chromatography was performed as described by Still et al., employing silica gel (60 A, 15-40 pM, EMD Millipore Corp.)

[0436] Materials

[0437] Commercial solvents and reagents were used as received.

[0438] Instrumentation

[0439] Proton magnetic resonance (1H NMR) spectra were recorded on Bruker 400 (400 MHz) NMR spectrometers at 23 °C. Proton chemical shifts were expressed in parts per million (ppm, 6 scale) and were referenced to residual protium in the NMR solvent (CHCh, 57.26). Data were represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q =quartet, m = multiplet and / or multiple resonances, br = broad, app = apparent), integration, and coupling constant (J) in Hertz. Carbon nuclear magnetic resonance spectra (13C NMR) were recorded on Bruker 400 (100 MHz) NMR spectrometers at 23 °C. Carbon chemical shifts were expressed in parts per million (ppm, 6 scale) and were referenced to the carbon resonances of the NMR solvent (CDCh, 677.0). Infrared (IR) spectra were obtained using a Bruker ALPHA FT-IR spectrometer. Data were represented as follows: frequency of absorption (cm1), intensity of absorption (s = strong, m = medium, w = weak, br = broad). High resolution mass spectra were obtained at the Harvard University Mass Spectrometry Facility. High performance liquid chromatography purifications were performed using an Agilent Technologies 1200 series preparative HPLC system.

[0440] Synthesis of Ciprimelpin and Other Analogs

[0441] methyl 3-(imidazo[l,2-a]pyridin-6-ylmethoxy)benzoate

[0442]

[0443] BOX

[0444] To a solution of imidazo[l,2-a]pyridin-6-ylmethanol 3.6 (2.44 g, 15.77 mmol, 1 equiv) in CH2CI2 (80 mL, 0.2 M) was added SOCI2 (4.64 g, 39.43 mmol, 2.5 equiv). The reaction mixture was stirred for 1 hour at 24 °C and the solvent was thereafter removed in vacuo. The residue was taken up in toluene and concentrated in vacuo three times, and the resulting residue was further dried under high-vacuum to afford 6-(chloromethyl)imidazo[l,2-a]pyridine (3.20 g, quantitative yield) as a hydrochloride salt. The 6-(chloromethyl)imidazo[l,2-a]pyridine hydrochloride (3.20 g, 15.77 mmol, 1 equiv) was taken up in acetone (150 mL, 0.1 M), then methyl-3-hydroxybenzoate (3.60 g, 23.66 mmol, 1.5 equiv) and cesium carbonate (15.42g, 47.31 mmol, 3 equiv) were added. The resulting suspension was heated to 60 °C for 12 hours, before being cooled to 24 °C and filtered through a pad of celite, eluting with EtOAc. The solution was concentrated in vacuo and flash column chromatography (0% — 2% MeOH in DCM) afforded ester 3.7 (3.55 g, 12.59 mmol, 80% yield) as a white solid.

[0445] 1H NMR (400 MHz, DMSO), 8: 8.70 (s, 1H), 7.97 (s, 1H), 7.66 - 7.52 (m, 4H), 7.47 (t, J = 8.1 Hz, 1H), 7.33 (ddd, J = 11.1, 8.8, 2.2 Hz, 2H), 5.19 (s, 2H), 3.85 (s, 2H).13C NMR (100 MHz, DMSO), 6: 165.99, 158.20, 144.07, 133.51, 131.04, 130.08, 125.88, 125.13, 121.83, 121.08, 120.15, 116.87, 114.92, 113.52, 67.12, 52.28.

[0446] FTIR (neat), cm-1: 2967, 1703, 1607, 1513, 1484, 1463, 1434, 1378, 1316, 1286, 1249, 1190, 1162, 1117, 992, 881, 846, 798.

[0447] HRMS (ESI) Calc’d for (Ci6Hi4N2O3+H)+: 283.1077, Found: 283.1085.

[0448] l-(3-(imidazo[l,2-a]pyridin-6-ylmethoxy)phenyl)-2-(pyridin-4-yl)ethan- 1-one

[0449]

[0450] A THF (100 mL) solution of ester 3.7 (3.0 g, 10.63 mmol, 1 equiv) and 4-picoline (1.1 mL, 11.69 mmol, 1.1 equiv) in a 500-mL round bottom flask was cooled to 0 °C, and a THF solution of LiHMDS (1 M, 23.4 mL, 23.4 mmol, 2.2 equiv) was added dropwise over 30 min via a syringe pump at the same temperature. After the addition was complete, the reaction slurry was warmed gradually to 23 °C and further stirred for 15 h. The reaction mixture was then quenched with sat. aq. NH4C1 (200 mL) and the whole mixture was subsequently transferred into a separatory funnel and extracted with EtOAc (4 x 200 mL). The organic layers were combined, washed with brine (1 x 800 mL) and water (1 x 800 mL), dried over MgSO4, filtered, and concentrated in vacuo. Flash column chromatography (0% — 5% MeOH in DCM) afforded ketone 3.8 as a yellow solid (3.32 g, 9.67 mmol, 91% yield).

[0451] ’H NMR (400 MHz, CDCI3), 68.61 - 8.51 (m, 2H), 8.24 (dd, J = 1.9, 1.0 Hz, 1H), 7.69 -7.57 (m, 5H), 7.43 (t, J = 7.9 Hz, 1H), 7.26 - 7.16 (m, 4H), 5.10 (d, J = 1.0 Hz, 2H), 4.27 (s, 2H).

[0452] 13C NMR (100 MHz, CDCI3), 6 195.52, 158.62, 149.97, 144.86, 143.25, 137.67, 133.82, 130.05, 124.82, 124.68, 124.48, 121.85, 121.48, 120.85, 117.99, 113.53, 112.81, 67.58, 44.67.

[0453] FTIR (neat), cm-1: 2907, 1672, 1594, 1507, 1416, 1388, 1337, 1303, 1257, 1248, 1217, 1166, 1133, 984, 884, 870, 818, 736, 570.

[0454] HRMS (ESI): Calc’d for (C2iHi7N3O2+H)+: 344.1394, Found: 344.1385.

[0455] l-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethane-l, 2-dione

[0456]

[0457] Ketone 3.8 (27 mg, 1 Eq, 0.079 mmol) was dissolved in DMSO (0.79 mL, 0.1 M), HBr (40 mg, 27 [iL, 48 % Wt, 3 Eq, 0.240 mmol) was added, and the solution was heated to 100 °C for 1.5 hours in a sealed reaction vessel. At the end of the reaction period, the reaction mixture was cooled to 24 °C, quenched by the careful dropwise addition of saturated aqueous sodium bicarbonate, and extracted with 20% methanol in CH2CI2 (3 x 5rnL). The combined organic extracts were washed with water (4 x 5 mL) and then brine (1 x 5 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo to afford diketone 4.3 as a yellow-brow solid, which was used in the subsequent Debus-Radziszewski imidazole syntheses without further purification.

[0458] 1H NMR (400 MHz, CDCh) 68.91 - 8.86 (m, 2H), 8.25 (s, 1H), 7.79 - 7.75 (m, 2H), 7.70 - 7.64 (m, 3H), 7.57 - 7.54 (m, 1H), 7.48 (d, J = 7.7 Hz, 1H), 7.35 - 7.30 (m, 2H), 5.19 (s, 2H).

[0459] HRMS (ESI): Calc’d for (C2iHi4BrN3O3+CH3OH+H)+: 468.0553, found: 468.0560.

[0460] 3-bromo-6-((3-(2-phenyl-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[l,2-a] pyridine:

[0461]

[0462] l-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethane-l,2-dione (0.0050 g, 1 Eq, 11 pmol) was dissolved in Acetic Acid (0.23 mL, 0.05 M) and ammonium acetate (8.8 mg, 10 Eq, 0.11 mmol) and benzaldehyde (1.8 mg, 1.7 pL, 1.5 Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with EtOAc (3 x 5mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 3-bromo-6-((3-(2-phenyl-4- (pyridin-4-yl)- 1 H-imidazol-5-yl)phenoxy)methyl)imidazo [ 1,2-a] pyridine 4.4 (0.00072 g, 1.4 pmol, 12 %).

[0463] !H NMR (400 MHz, CDCI3) 88.52 (s, 2H), 8.21 (s, 1H), 7.94 (d, J = 7.4 Hz, 2H), 7.68 -7.63 (m, 2H), 7.54 - 7.42 (m, 4H), 7.17 (s, 2H), 7.09 (s, 2H), 5.10 (s, 2H).

[0464] HRMS (ESI): Calc’d for (C28H2oBrN50+H)+: 522.0924, found 522.0926.

[0465] 3-bromo-6-((3-(2-(pyridin-3-yl)-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[ 1,2-a]pyridine

[0466]

[0467] l-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethane-l,2-dione (0.0050 g, 1 Eq, 11 pmol) was dissolved in acetic acid (0.23 mL, 0.05 M) and ammonium acetate (8.8 mg, 10 Eq, 0.11 mmol) and nicotinaldehyde (1.8 mg, 1.7 pL, 1.5 Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2CI2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 3-bromo-6-((3-(2-(pyridin-3-yl)-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[l,2-a]pyridine 4.5 (0.002 g, 3.8 pmol, 33 %).

[0468] !H NMR (400 MHz, CDCI3) 69.27 (s, 1H), 8.59 - 8.47 (m, 3H), 8.18 (d, J= 7.8 Hz, 3H), 7.76 - 7.64 (m, 3H), 7.61 (d, J = 6.9 Hz, 2H), 7.52 - 7.32 (m, 4H), 7.14 (d, J = 5.8 Hz, 2H), 7.07 (s, 1H), 5.06 (s, 2H).

[0469] HRMS (ESI): Calc’d for (C27Hi9BrN6O+H)+: 523.0876, found 523.0880.

[0470] 3-bromo-6-((3-(2-cyclopropyl-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[l,2-a] pyridine

[0471]

[0472] l-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethane-l,2-dione (0.0070 g, 1 Eq, 16 pmol) was dissolved in acetic acid (0.32 mL, 0.05 M) and ammonium acetate (12 mg, 10 Eq, 0.16 mmol) and cyclopropanecarboxaldehyde (1.7 mg, 1.7 pL, 1.5 Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2Q2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 3-bromo-6-((3-(2-cyclopropyl-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[l,2-a]pyridine 4.6 (0.0007 g, 1.6 pmol, 9 %).

[0473] iH NMR (400 MHz, CDCI3) 89.32 (s, 1H), 8.48 (d, J= 5.2 Hz, 2H), 8.19 (s, 1H), 8.15 (s, 1H), 7.67 - 7.62 (m, 2H), 7.53 - 7.45 (m, 2H), 7.35 (t, 7= 8.1 Hz, 2H), 7.07 (d, J = 6.5 Hz, 2H), 7.01 (d, J= 10.8 Hz, 1H), 5.07 (s, 2H), 2.08 - 2.03 (m, 4H), 1.07 (dd, J = 10.8, 6.3 Hz, 4H).

[0474] HRMS (ESI): Calc’d for (C25H2oBrN50+H)+: 486.0924, found 486.0923.

[0475] 3-bromo-6-((3-(2-cyclohexyl-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[l,2-a] pyridine

[0476] D

[0477]

[0478] l-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethane-l,2-dione (0.0055 g, 1 Eq, 13 pmol) was dissolved in Acetic Acid (0.25 mL, 0.05 M) and ammonium acetate (9.7 mg, 10 Eq, 0.13 mmol) and cyclohexanecarboxaldehyde (2.1 mg, 1.5 Eq, 19 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10%CH3OH in CH2Q2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 3-bromo-6-((3-(2-cyclohexyl-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[l,2-a]pyridine 4.7 (0.0027 g, 5.1 pmol, 41 %).

[0479] ’H NMR (400 MHz, CDCh) 88.50 - 8.43 (m, 2H), 8.20 (dd, J= 1.8, 0.9 Hz, 1H), 8.16 (s, 2H), 7.72 - 7.63 (m, 2H), 7.60 - 7.54 (m, 2H), 7.37 (t, 7= 8.1 Hz, 1H), 7.30 (dd, J = 9.3, 1.7 Hz, 1H), 7.09 -7.01 (m, 3H), 5.08 (d, J = 1.0 Hz, 2H), 2.14 (d, J = 12.4 Hz, 2H), 1.97 - 1.83 (m, 2H), 1.79 (s, 1H), 1.55 (td, J = 12.3, 3.1 Hz, 2H), 1.50 - 1.37 (m, 2H), 1.37 - 1.22 (m, 2H).

[0480] HRMS (ESI): Calc’d for (C28H26BrN5O+H)+: 528.1394, found 528.1378.

[0481] 6-((3-(2-(benzo[d][l,3]dioxol-5-yl)-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)-3-bromoimidazo [ 1,2-a] pyridine

[0482]

[0483] l-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethane-l,2-dione (0.0055 g, 1 Eq, 13 pmol) was dissolved in Acetic Acid (0.25 mL, 0.05 M) and ammonium acetate (9.7 mg, 10 Eq, 0.13 mmol) and benzo[d][l,3]dioxole-5-carbaldehyde (2.8 mg, 1.5 Eq, 19 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2Q2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 6-((3-(2-(benzo[d][l,3]dioxol-5-yl)-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)-3-bromoimidazo[l,2-a]pyridine 4.8 (0.00081 g, 1.4 pmol, 11 %).

[0484] !H NMR (400 MHz, CDCh) 68.52 - 8.48 (m, 2H), 8.20 (dd, 7= 1.7, 0.9 Hz, 1H), 8.12 (s, 1H), 7.67 -7.60 (m, 4H), 7.47 (d, 7= 1.7 Hz, 1H), 7.38 (dd, 7= 8.1, 1.7 Hz, 2H), 7.30 (d, 7 = 1.7 Hz, 1H), 7.14 (dd, 7= 6.7, 1.3 Hz, 2H), 7.08 - 7.04 (m, 1H), 6.90 (d, 7= 8.1 Hz, 1H), 5.08 (d, 7= 1.0 Hz, 2H).

[0485] HRMS (ESI): Calc’d for (C29H2oBrN503+H)+: 566.0828, found 566.0824.3-bromo-6-((3-(2-phenethyl-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[l,2-a] pyridine

[0486]

[0487] l-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethane-l,2-dione (0.0055g, 1 Eq, 13 pmol) was dissolved in Acetic Acid (0.25 mL, 0.05 M) and ammonium acetate (9.7 mg, 10 Eq, 0.13 mmol) and 3-phenylpropanal (2.5 mg, 1.5 Eq, 19 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2Q2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 3-bromo-6-((3-(2-phenethyl-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[l,2-a]pyridine: 4.9 (0.00096 g, 1.7 pmol, 14 %).

[0488] ’H NMR (400 MHz, CDCI3) 88.54 - 8.45 (m, 3H), 8.23 - 8.18 (m, 1H), 8.14 (s, 1H), 7.66 (d, J= 1.1 Hz, 1H), 7.65 - 7.63 (m, 2H), 7.48 (d, J= 5.6 Hz, 2H), 7.37 - 7.31 (m, 4H), 7.28 (t, J= 1.4 Hz, 1H), 7.23 (s, 1H), 7.04 - 6.96 (m, 3H), 5.06 (s, 2H), 3.14 (d, J = 3.0 Hz, 4H).

[0489] HRMS (ESI): Calc’d for (C3oH24BrN50+H)+: 550.1237, found 550.1228.

[0490] 3-(5-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-4-(pyridin-4-yl)-lH-imidazol-2-yl)quinoline

[0491] G

[0492]

[0493] ,

[0494] l-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethane-l,2-dione (0.0055 g, 1 Eq, 13 pmol) was dissolved in Acetic Acid (0.25 mL, 0.05 M) and ammonium acetate (9.7 mg, 10 Eq, 0.13 mmol) and quinoline-3-carbaldehyde (3.0 mg, 1.5 Eq, 19 pmol)were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2Q2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 3-(5-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-4-(pyridin-4-yl)-lH-imidazol-2-yl)quinoline 4.10 (0.001 g, 1.87 pmol, 15 %).

[0495] !H NMR (400 MHz, CDCI3) 89.54 (d, J= 2.2 Hz, 1H), 9.38 (d, J= 2.1 Hz, 4H), 8.80 (d, J= 2.3 Hz, 1H), 8.65 (dd, J= 2.1, 0.9 Hz, 4H), 8.61 - 8.48 (m, 2H), 8.26 - 8.17 (m, 5H), 8.17 - 8.11 (m, 2H), 8.01 (dd, J = 8.2, 1.5 Hz, 4H), 7.90 (ddd, J = 8.5, 6.9, 1.4 Hz, 5H), 5.06 (s, 2H).

[0496] HRMS (ESI): Calc’d for (C3iH2iBrN6O+H)+: 573.1033, found 573.1031.

[0497] 3-bromo-6-((3-(2-(2,5-dimethoxyphenyl)-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[ 1,2-a]pyridine

[0498]

[0499] l-(3-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethane-l,2-dione (0.0055 g, 1 Eq, 13 pmol) was dissolved in acetic acid (0.25 mL, 0.05 M) and ammonium acetate (9.7 mg, 10 Eq, 0.13 mmol) and 2,5-dimethoxybenzaldehyde (3.1 mg, 1.5 Eq, 19 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2Q2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 3-bromo-6-((3-(2-(2,5-dimethoxyphenyl)-4-(pyridin-4-yl)-lH-imidazol-5-yl)phenoxy)methyl)imidazo[l,2-a]pyridine 4.11 (0.0027 g, 4.7 pmol, 37 %).

[0500] ’H NMR (400 MHz, CDCI3) 68.56 - 8.49 (m, 2H), 8.24 (s, 3H), 7.98 (d, J = 2.9 Hz, 1H), 7.77 (d, J= 9.3 Hz, 1H), 7.70 (d, J= 10.2 Hz, 3H), 7.44 (t, J= 8.0 Hz, 1H), 7.36 (dd, 7= 9.4, 1.7 Hz, 1H), 7.16 (d, J= 7.3 Hz, 2H), 7.14 - 7.07 (m, 1H), 7.03 - 6.94 (m, 2H), 5.13 (s, 2H), 3.99 (s, 3H), 3.90 (s, 3H).

[0501] HRMS (ESI): Calc’d for (C3oH24BrN503+H)+: 582.1136, found 582.1160.methyl 4-(imidazo[l,2-a]pyridin-6-ylmethoxy)benzoate

[0502]

[0503] To a solution of imidazo[l,2-a]pyridin-6-ylmethanol 3.6 (1.20 g, 9.303 mmol, 1 equiv) in CH2CI2 (40 mL, 0.2 M) was added SOCI2 (2.30 g, 18.05 mmol, 2.5 equiv). The reaction mixture was stirred for 1 hour at 24 °C and the solvent was thereafter removed in vacuo. The residue was taken up in toluene and concentrated in vacuo three times, and the resulting residue was further dried under high-vacuum to afford 6-(chloromethyl)imidazo[l,2-a]pyridine (1.55 g, quantitative yield) as a hydrochloride salt. The 6-(chloromethyl)imidazo[l,2-a]pyridine hydrochloride (1.55 g, 9.303 mmol, 1 equiv) was taken up in acetone (125 mL, 0.08 M), then methyl-3- hydroxybenzoate (1.42 g, 9.303 mmol, 1 equiv) and cesium carbonate (9.09, 27.91 mmol, 3 equiv) were added. The resulting suspension was heated to 60 °C for 12 hours, before being cooled to 24 °C and filtered through a pad of celite, eluting with EtOAc. The solution was concentrated in vacuo and flash column chromatography (0% — 2% MeOH in DCM) afforded methyl 4-(imidazo[l,2-a]pyridin-6-ylmethoxy)benzoate (1.70 g, 6.02 mmol, 65% yield) as a white solid.

[0504] 1H NMR (400 MHz, CDCh) 88.26 - 8.21 (m, 1H), 8.04 - 7.98 (m, 2H), 7.69 - 7.64 (m, 2H), 7.59 (t, J = 1.0 Hz, 1H), 7.22 (dd, J = 9.3, 1.7 Hz, 1H), 6.99 (d, J= 8.9 Hz, 2H), 5.09 (d, J= 1.0 Hz, 2H), 3.88 (s, 3H).

[0505] 13C NMR (101 MHz, CDCh) 6 166.65, 161.84, 144.85, 133.84, 131.72, 124.63, 124.46, 123.38, 121.37, 117.98, 114.33, 112.82, 67.42, 51.95.

[0506] HRMS (ESI): Calc’d for (Ci6Hi4N2O3+H)+: 283.1077, Found 283.1085.

[0507] l-(4-(imidazo[l,2-a]pyridin-6-ylmethoxy)phenyl)-2-(2-methylpyridin-4-yl)ethan- 1-one

[0508]

[0509] In a flame-dried flask, methyl 4-(imidazo[l,2-a]pyridin-6-ylmethoxy)benzoate (920 mg, 1 Eq, 3.26 mmol) was taken up in THF (21.7 mL), and 2,4-dimethylpyridine (698 mg, 753 pL, 2 Eq, 6.52 mmol) was added. Reaction was TLC’d for reference (5% MeOH in DCM, 2x development), cooled to 0 °C then lithium bis(trimethylsilyl)amide (1.91 g, 11.4 mL, 1 molar in THF, 3.5 Eq, 11.4 mmol) was added dropwise over 5 minutes (color change from pale yellow to brown) and the reaction was stirred at 24 °C for 30 min, then sonicated for 60 min. Quenched with sat. aq. ammonium chloride, extracted EtOAc (3 x 20 mL), collected organic layers and washed sequentially with sat. aq. sodium bicarbonate and brine, dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Residue was purified by flash column chromatography eluting with 0 -> 5 -> 10% CH3OH in CH2C12to afford l-(4-(imidazo[l,2-a]pyridin-6-ylmethoxy)phenyl)-2-(2-methylpyridin-4-yl)ethan-l-one 4.1 (710 mg, 1.99 mmol, 61% yield) as a pale yellow solid.

[0510] ’H NMR (400 MHz, CDCh) 88.42 (d, J = 5.2 Hz, 1H), 8.23 (dd, J = 1.7, 1.0 Hz, 1H), 8.03 -7.95 (m, 2H), 7.66 (d, J= 4.3 Hz, 1H), 7.64 (d, J= 3.7 Hz, 1H), 7.59 (t, J= 0.9 Hz, 1H), 7.20 (dd, 7 = 9.3, 1.7 Hz, 1H), 7.05 (d, J = 1.7 Hz, 1H), 7.05 -7.00 (m, 2H), 6.99 (dd, J = 5.1, 1.7 Hz, 1H), 5.11 (d, J = 1.0 Hz, 2H), 4.18 (s, 2H), 2.52 (s, 3H).

[0511] 13C NMR (101 MHz, CDCh) 6 194.56, 162.34, 158.57, 149.19, 144.95, 143.92, 134.12, 130.93, 129.88, 124.49, 124.36, 124.25, 121.83, 121.00, 118.09, 114.68, 112.79, 67.57, 44.34, 24.31.

[0512] HRMS (ESI): Calc’d for (C22HI9N3O2+H)+: 358.1550, Found: 358.1554.

[0513] l-(4-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(2-methylpyridin-4-yl)ethane-l,2- dione

[0514]

[0515] 4.1 €<

[0516] Ketone 4.1 (500 mg, 1 Eq. 1.40 mmol) was dissolved in DMSO (7.0 mL, 0.2 M), HBr (707 mg, 475 pL, 48 % Wt, 3 Eq, 4.20 mmol) was added, and the solution was heated to 100°C for 1.5 hours in a sealed reaction vessel. At the end of the reaction period, the reaction mixture was cooled to 24 °C, quenched by the careful dropwise addition of saturated aqueous sodium bicarbonate, and extracted with 20 % methanol in CH2CI2 (3 x 15rnL). The combined organic extracts were washed with water (4 x 15 mL) and then brine (1 x 15 mL), dried over anhydroussodium sulfate, and concentrated in vacuo to afford diketone 4.2 as a yellow-brown solid, which was used in the subsequent Debus-Radziszewski imidazole syntheses without further purification.

[0517] ’H NMR (400 MHz, CDCh) 68.73 (dd, J = 5.1, 1.0 Hz, 1H), 8.22 - 8.18 (m, 1H), 7.99 (d, J= 9.0 Hz, 2H), 7.66 (dd, 7 = 9.3, 1.0 Hz, 1H), 7.62 -7.55 (m, 3H), 7.29 (dd, J = 9.3, 1.8 Hz, 1H), 7.11 (d, J = 9.0 Hz, 2H), 5.20 (d, J = 1.0 Hz, 2H), 2.65 (s, 3H).

[0518] HRMS (ESI): Calc’d for (C22Hi6BrN3O3+H)+: 406.0953, found 406.0953.

[0519] 3-bromo-6-((4-(4-(2-methylpyridin-4-yl)-2-phenyl-lH-imidazol-5-yl)phenoxy)methyl)imidazo[L2-a]pyridine

[0520]

[0521] Diketone 4.2 (0.0050 g, 1 Eq, 11 pmol) was dissolved in acetic acid (0.23 mL, 0.05 M) and ammonium acetate (8.8 mg, 10 Eq, 0.11 mmol) and benzaldehyde (1.8 mg, 1.7 pL, 1.5 Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2CI2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 3-bromo-6-((4-(4-(2-methylpyridin-4-yl)-2-phenyl-lH-imidazol-5- yl)phenoxy)methyl)inudazo[ 1,2-a]pyridine 4.12 (0.00070 g, 1.3 pmol, 12 %).

[0522] !H NMR (400 MHz, CDCh) 68.37 - 8.29 (m, 1H), 8.30 - 8.24 (m, 2H), 8.03 - 7.94 (m, 2H), 7.73 - 7.68 (m, 1H), 7.66 (s, 1H), 7.62 (dd, J = 9.3, 1.0 Hz, 1H), 7.52 - 7.38 (m, 5H), 7.32 (dd, 7= 9.3, 1.7 Hz, 1H), 7.05 (d, 7= 8.7 Hz, 2H), 5.16 (d, 7= 0.9 Hz, 2H), 2.57 (s, 3H).

[0523] HRMS (ESI): Calc’d for (C29H22BrN5O+H)+: 536.1081, found 536.1077.

[0524] l-(4-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(2-methylpyridin-4-yl)ethane-l,2 dione

[0525]

[0526] Diketone 4.2 (0.0050 g, 1 Eq, 11 pmol) was dissolved in acetic acid (0.23 mL, 0.05 M) and ammonium acetate (8.8 mg, 10 Eq, 0.11 mmol) and nicotinaldehyde (1.8 mg, 1.7 pL, 1.5 Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2CI2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford l-(4-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)”2-(2-methylpyridin" 4- yl)ethane- 1,2-dione 4.13 (0.00072 g, 1.3 pmol, 12 %).

[0527] !H NMR (400 MHz, CDCI3) 89.18 (s, 1H), 8.65 (dd, J= 4.8, 1.7 Hz, 1H), 8.36 (d, J = 7.1 Hz, 1H), 8.26 (s, 1H), 8.09 (s, 1H), 7.67 (s, 1H), 7.62 (d, J = 9.3 Hz, 1H), 7.45 (dd, J = 7.9, 4.9 Hz, 2H), 7.35 - 7.31 (m, 1H), 7.08 (d, J= 8.6 Hz, 2H), 5.17 (s, 2H), 2.63 (s, 3H).

[0528] HRMS (ESI): Calc’d for (C28H2iBrN6O+H)+: 537.1033, found 537.1034.

[0529] 3-bromo-6-((4-(2-cyclopropyl-4-(2-methyIpyridin-4-yl)-lH-imidazoI-5- yl)phenoxy)methyl)imidazo[l,2-a]pyridine

[0530]

[0531] Diketone 4.2 (0.0050 g, 1 Eq, 11 pmol) was dissolved in acetic acid (0.23 mL, 0.05 M) and ammonium acetate (8.8 mg, 10 Eq, 0.11 mmol) and cyclopropanecarboxaldehyde (1.2 mg, 1.7 pL, 1.5 Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2CI2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 ->90% CH3CN in H2O) to afford 3-bromo-6-((4-(2-cyclopropyl-4~(2-methylpyridin-4~yl)~lH- imidazol-5-yl)phenoxy)methyl)imidazo[l,2-a] yridine 4.14 (0.0011 g, 2.2 pmol, 20 %).

[0532] ’H NMR (400 MHz, CDCh) 68.32 (d, J= 5.7 Hz, 1H), 8.26 (s, 1H), 7.67 (d, J= 7.9 Hz, 2H), 7.53 (s, 1H), 7.43 - 7.35 (m, 2H), 7.35 - 7.28 (m, 1H), 7.03 (d, J= 8.5 Hz, 2H), 5.15 (s, 2H), 2.54 (s, 3H), 2.07 - 2.00 (m, 1H), 1.07 (ddt, J = 10.6, 8.3, 2.3 Hz, 4H).

[0533] HRMS (ESI): Calc’d for (C26H22BrN5O+H)+: 500.1081, found 500.1084.

[0534] 3-bromo-6--((4-(2-cyclohexyl-4-(2-methylpyridin-4-yl)-lH-i

[0535]

[0536] .zol-5-yl )phenoxy )methyl )imidazo [ 1, 2- ] pyridi ne

[0537]

[0538] Diketone 4.2 (0.0050 g, 1 Eq, 11 pmol) was dissolved in acetic acid (0.23 mL, 0.05 M) and ammonium acetate (8.8 mg, 10 Eq, 0.11 mmol) and cyclohexancarboxaldehyde (1.9 mg, 1.5 Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2CI2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 3-bromO”6-((4-(2-cyclohexyl-4-(2-methyIpyridin-4-yl)-lH-imidazoI-5- yl)phenoxy)niethyl)imidazo[l,2-a]pyridine 4.15 (0.0025 g, 4.6 pmol, 42 %).

[0539] ’H NMR (400 MHz, CDCh) 68.34 (d, J = 5.7 Hz, 1H), 8.26 (dd, J = 1.8, 0.9 Hz, 1H), 8.20 (s, 1H), 7.70 -7.66 (m, 2H), 7.62 (s, 1H), 7.38 (d, J= 8.7 Hz, 2H), 7.35 (dd, J= 9.3, 1.7 Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H), 5.17 (d, J = 0.9 Hz, 2H), 2.59 (s, 3H), 2.14 (d, J = 12.6 Hz, 2H), 1.97 - 1.84 (m, 2H), 1.77 (d, J = 12.8 Hz, 1H), 1.57 (dd, 7= 12.3, 3.2 Hz, 2H), 1.48 - 1.38 (m, 2H), 1.29 (d, J = 12.4 Hz, 2H).

[0540] HRMS (ESI): Calc’d for (C29H28BrN5O+H)+: 542.1550, found 542.1542.

[0541] 6-((4-(2-(benzo[d][l,3]dioxol-5-yI)-4-(2-methyIpyridin-4-yl)-lH-imidazoI-5- yl)phenoxy)methyl)-3-bromoimidazo[l,2-a]pyridine

[0542]

[0543] Diketone 4.2 (0.0050 g, 1 Eq, 11 pmol) was dissolved in acetic acid (0.23 mL, 0.05 M) and ammonium acetate (8.8 mg, 10 Eq, 0.11 mmol) and benzo[d][l,3]dioxole-5-carbaldehyde (2.5 mg, 1.5 Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2CI2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 6-((4-(2-(benzo[d][l,3]dioxol-5-yl)-4-(2-methylpyridin-4-yl)-lH- imidazol-5-yl)phenoxy)methyl)-3-bromoimidazo[l,2-a]pyridine 4.16 (0.0010 g, 1.7 pmol, 16 %).

[0544] !H NMR (400 MHz, CDCI3) 88.31 (d, J = 5.8 Hz, 1H), 8.26 (s, 2H), 7.68 (d, J = 1.6 Hz, 1H), 7.67 - 7.60 (m, 2H), 7.50 (d, J = 1.7 Hz, 1H), 7.49 - 7.38 (m, 3H), 7.32 (dd, J = 9.3, 1.7 Hz, 1H), 7.04 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.1 Hz, 1H), 6.03 (s, 2H), 5.15 (d, J = 1.0 Hz, 2H), 2.55 (s, 3H).

[0545] HRMS (ESI): Calc’d for (C3oH22BrN503+H)+: 580.0979, found 580.0989.

[0546] l-(4-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(2-methylpyridin-4-yl)ethane-l,2-di one

[0547]

[0548] Diketone 4.2 (0.0050 g, 1 Eq, 11 pmol) was dissolved in acetic acid (0.23 mL, 0.05 M) and ammonium acetate (8.8 mg, 10 Eq, 0.11 mmol) and 3-phenylpropanal (2.5 mg, 1.7 pL, 1.5Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2CI2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford l-(4-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(2-methylpyridin-4-yl)ethane- 1,2-dione 4.17 (0.0005 g, 0.9 pmol, 8 %).

[0549] !H NMR (400 MHz, CDCI3) 88.34 (d, J= 5.7 Hz, 1H), 8.26 (d, J = 7.7 Hz, 1H), 8.19 (s, 2H), 7.95 (d, J = 7.5 Hz, 1H), 7.73 - 7.65 (m, 2H), 7.56 (s, 1H), 7.51 - 7.42 (m, 2H), 7.33 (dd, J = 13.7, 6.8 Hz, 4H), 7.03 (d, J = 8.4 Hz, 2H), 5.15 (s, 2H), 3.13 (s, 4H), 2.58 (s, 3H).

[0550] HRMS (ESI): Calc’d for (C3iH26BrN5O+H)+: 564.1394, found 564.1435.

[0551] l-(4-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(2-methylpyridin-4-yl)ethane-l,2-di one

[0552]

[0553] Diketone 4.2 (0.0050 g, 1 Eq, 11 pmol) was dissolved in acetic acid (0.23 mL, 0.05 M) and ammonium acetate (8.8 mg, 10 Eq, 0.11 mmol) and quinoline-3-carbaldehyde (2.6 mg, 1.5 Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate. Extracted with 10% CH3OH in CH2CI2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford l-(4-((3-bromoimidazo[l,2-a]pyridin-6-yl)methoxy)phenyl)-2-(2-methylpyridin-4-yl)ethane- 1,2-dione 4.17 (0.0025 g, 4.3 pmol, 38 %).

[0554] !H NMR (400 MHz, CDCI3) 69.57 (d, J= 2.2 Hz, 1H), 8.83 - 8.77 (m, 1H), 8.36 (d, J = 5.5 Hz, 1H), 8.28 - 8.23 (m, 2H), 8.13 (d, J = 8.5 Hz, 1H), 7.94 - 7.87 (m, 1H), 7.80 - 7.64 (m, 3H), 7.60 -7.55 (m, 1H), 7.47 (d, J= 8.6 Hz, 2H), 7.37 (d, J= 5.3 Hz, 1H), 7.31 (d, J= 1.7 Hz, 1H), 7.03 (d,. / = 8.7 Hz, 2H), 5.14 (s, 2H), 2.55 (s, 3H).

[0555] HRMS (ESI): Calc’d for (C32H23BrN6O+H)+: 587.1190, found 587.1179.3-bromo-6-((4-(2-(2,5-dimethoxyphenyl)-4-(2-methylpyridin-4-yl)-lH-imidazol-5- yl)phenoxy)methyl)imidazo[ 1,2-a]pyridine

[0556]

[0557] Diketone 4.2 (0.0050 g, 1 Eq, 11 pmol) was dissolved in acetic acid (0.23 mL, 0.05 M) and ammonium acetate (8.8 mg, 10 Eq, 0.11 mmol) and 2,5-dimethoxybenzaldehyde (2.8 mg, 1.5 Eq, 17 pmol) were added. The resulting solution was heated to 100 °C for 5 hours, cooled to 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate.

[0558] Extracted with 10% CH3OH in CH2CI2 (3 x 5 mL), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford l-(4-((3-bromoimidazo[l,2-a]pyridin-6-yI)methoxy)phenyl)-2-(2- methylpyridin-4-yl)ethane- 1,2-dione 4.19 (0.0042 g, 1.3 pmol, 63 %).

[0559] !H NMR (400 MHz, CDCI3) 68.43 (d, J= 5.7 Hz, 1H), 8.29 (s, 2H), 7.98 (d, J= 2.9 Hz, 1H), 7.77 (d, J= 8.1 Hz, 1H), 7.70 (s, 1H), 7.46 (t, J= 8.1 Hz, 3H), 7.44 -7.36 (m, 1H), 7.12 (d, 7= 8.5 Hz, 2H), 7.01 - 6.90 (m, 2H), 5.21 (s, 2H), 4.00 (s, 3H), 3.90 (s, 3H), 2.64 (s, 3H).

[0560] HRMS (ESI): Calc’d for (C3iH26BrN5O+H)+: 596.1292, found 596.1297.

[0561] 3-bromo-6-((4-(2-cyclobutyl-5-(2-methylpyridin-4-yl)-U7-imidazol-4-yl)phenoxy)methyl)imidazo[ 1,2-a]pyridine

[0562]

[0563] Diketone 4.2 (0.0060 g, 1 Eq, 13 pmol) was dissolved in acetic acid (0.28 mL, 0.05 M) and ammonium acetate (10.0 mg, 10 Eq, 0.13 mmol) and cyclobutylcarboxaldehyde (1.5 mg, 1.7 uL, 1.5 Eq, 20 umol) were added. The resulting solution was heated to 100 °C for 5 hours, cooledto 24 °C, then quenched with the careful dropwise addition of sat. aq. sodium bicarbonate.

[0564] Extracted with 10% CH3OH in CH2CI2 (3 x 5 ml..), collected and dried organic layers over anhydrous sodium sulfate, and concentrated in vacuo. Purified residue by HPLC (15 min, 10 -> 90% CH3CN in H2O) to afford 3-bromo-6-((4-(2-cyclobutyl-5-(2-methylpyridin-4-yl)-lZ7-imidazol-4-yl)phenoxy)methyl)imidazo[l,2-a]pyridine 4.20 (0.00061 g, 1.2 pmol, 8 %).

[0565] !H NMR (400 MHz, CDCI3) 88.37 (d, J = 5.1 Hz, 1H), 8.27 (s, 1H), 7.72 - 7.65 (m, 2H), 7.63 - 7.56 (m, 2H), 7.36 (dd, J = 9.2, 1.7 Hz, 1H), 7.28 (s, 1H), 7.05 (d, J= 8.7 Hz, 2H), 6.95 -6.92 (m, 1H), 5.17 (s, 2H), 3.72 (dd, 7 = 9.3, 8.3 Hz, 1H), 2.44 (q, J = 9.2 Hz, 4H), 2.10 (d, J = 5.1 Hz, 2H).

[0566] HRMS (ESI): Calc’d for (C27H24BrN5O+H)+: Calc’d 514.1237, Found 514.1238.

[0567] 3-bromo-6-((4-(2-cyclopentyl-5-(2-methylpyridin-4-yl)-lH-imidazol-4-yl)plienoxy)methyl)imidazo[l,2-a]pyridine

[0568]

[0569] Diketone 4.2 (0.0060 g, 1 Eq, 13 pmol) was dissolved in acetic acid (0.28 mL, 0.05 M) and ammonium acetate (10.0 mg, 10 ...

Claims

CLAIMSWhat is claimed is:

1. A compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein:the compound is of the Formula I':each of R1A, R1B, R1C, R1D, R2A, R2B, R3A, R3B, and R3Eis independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA,-NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2;or R1Aand R1Bare joined together with the intervening atoms to form a substituted or unsubstituted phenyl ring;each instance of RAis independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of RAattached to the same intervening atom are joined together with the intervening atom to form a substituted or unsubstituted, monocyclic, heterocyclic or heteroaryl ring;R2Cis attached to one of the two ring nitrogen atoms of Ring C2 and is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2N(RA)2, or a nitrogen protecting group;R3Cis absent, bond b is attached to the carbon atom to which R3Cis attached, and R3Dis hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA,-C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2; or R3Dis absent, bond b is attached to the carbon atom to which R3Dis attached, and R3Cis hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2,-NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2;nl is 1, 2, or 3;each instance of R5is independently hydrogen, halogen, or substituted or unsubstituted alkyl;(C4)— '' is Ring C4, which is:fused bicyclic heteroaryl comprising at least one ring nitrogen atom in the fused bond or at least two adjacent ring nitrogen atoms;5,6-fused bicyclic heteroaryl comprising at least one ring nitrogen atom wherein bond c is attached to the 6-member ring of Ring C; ormonocyclic heterocyclyl fused with monocyclic heteroaryl or phenyl, wherein at least one ring atom of the monocyclic heterocyclyl is oxygen, and bond c is attached to the monocyclic heterocyclyl, the monocyclic heteroaryl, or the phenyl;n2 is an integer between 0 and 8, inclusive;when n2 is 0: Ring C4 is unsubstituted; andwhen n2 is an integer between 1 and 8, inclusive: Ring C4 is substituted, each instance of R4at a carbon atom is independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -N(RA)2, -SRA, -CN, -SCN, -C(=O)RA, -C(=O)N(RA)2, -C(=NRA)RA, -C(=NRA)ORA, -C(=NRA)N(RA)2, -NO2, -N3, -NRAC(=O)RA, -NRAC(=O)ORA, -NRAC(=O)N(RA)2, -NRAC(=NRA)RA, -NRAC(=NRA)ORA, -NRAC(=NRA)N(RA)2, -OC(=O)RA, -OC(=O)ORA, -OC(=O)N(RA)2, -OC(=NRA)RA, -OC(=NRA)ORA, -OC(=NRA)N(RA)2, -NRAS(=O)RA, -NRAS(=O)ORA, -NRAS(=O)N(RA)2, -OS(=O)RA, -OS(=O)ORA, -OS(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -NRAS(=O)2RA, -NRAS(=O)2ORA, -NRAS(=O)2N(RA)2, -OS(=O)2RA, -OS(=O)2ORA, -OS(=O)2N(RA)2, -S(=O)2RA, -S(=O)2ORA, or -S(=O)2N(RA)2, and each instance of R4at a nitrogen atom is independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, -C(=O)RA, -C(=O)ORA, -C(=O)N(RA)2, -S(=O)RA, -S(=O)ORA, -S(=O)N(RA)2, -S(=O)2RA, -S(=O)2ORA, -S(=O)2N(RA)2, or a nitrogen protecting group;provided that:Ring C4 is not of the formula:the compound is not of the formula:, or2. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is of the Formula I:wherein Ring C4 is fused bicyclic heteroaryl comprising at least one ring nitrogen atom in the fused bond or at least two adjacent ring nitrogen atoms or is 5,6-fused bicyclic heteroaryl comprising at least one ring nitrogen atom wherein bond c is attached to the 6-member ring of Ring C.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is of Formula I-A:(I-A).

4. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is of Formula I-B:

5. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is of Formula I-C:

6. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is of Formula I-D:

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Ais hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -ORA, -SRA, or -N(RA)2.

8. The compound of claim 7, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Ais hydrogen, -F, -Cl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted carbocyclyl, -ORA, -SRA, or -N(RA)2.

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each instance of RAis independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two instances of RAattached to the same intervening atom are joined together with the intervening atom to form a substituted or unsubstituted, monocyclic, heterocyclic or heteroaryl ring.

10. The compound of claim 7, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Ais substituted or unsubstituted, Ci-6 alkyl.

11. The compound of claim 7, or a pharmaceutically acceptable salt, solvate, hydrate,polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Ais substituted or unsubstituted methyl.

12. The compound of claim 7, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Ais -CH3.

13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Bis hydrogen, halogen, or substituted or unsubstituted alkyl.

14. The compound of claim 13, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Bis hydrogen.

15. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Aand R1Bare joined together with the intervening atoms to form a substituted or unsubstituted phenyl ring.

16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Cis hydrogen or halogen.

17. The compound of claim 16, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Cis hydrogen.

18. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Dis hydrogen, halogen, or substituted or unsubstituted alkyl.

19. The compound of claim 18, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Dis hydrogen, -F, -Cl, or substituted or unsubstituted alkyl.

20. The compound of claim 18, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R1Dis hydrogen.

21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Ais hydrogen.

22. The compound of any one of claims 1-4 and 7-21, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Bis substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

23. The compound of claim 22, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Bis substituted or unsubstituted, monocyclic, 3- to 7-membered, saturated carbocyclyl.

24. The compound of claim 22, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Bis substituted or unsubstituted cyclopropyl.

25. The compound of claim 22, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Bis unsubstituted cyclopropyl.

26. The compound of claim 22, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Bis substituted or unsubstituted, monocyclic, 5- or 6-membered heteroaryl.

27. The compound of claim 22, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Bis substituted or unsubstituted furanyl.

28. The compound of claim 22, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Bis unsubstituted 3-furanyl.

29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Cis hydrogen, substituted or unsubstituted alkyl, or a nitrogen protecting group.

30. The compound of claim 29, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Cis hydrogen or substituted or unsubstituted, Ci-6 alkyl.

31. The compound of claim 29, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R2Cis hydrogen.

32. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R3Ais hydrogen or substituted or unsubstituted alkyl.

33. The compound of claim 32, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R3Ais hydrogen.

34. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R3Bis hydrogen or substituted or unsubstituted alkyl.

35. The compound of claim 34, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R3Bis hydrogen.

36. The compound of any one of claims 1, 2, 4, and 6-35, or a pharmaceutically acceptablesalt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R3Cis hydrogen or substituted or unsubstituted alkyl.

37. The compound of claim 36, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R3Cis hydrogen.

38. The compound of any one of claims 1, 2, 3, 5, and 7-35, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R3Dis hydrogen or substituted or unsubstituted alkyl.

39. The compound of claim 38, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R3Dis hydrogen.

40. The compound of any one of claims 1-39, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R3Eis hydrogen or substituted or unsubstituted alkyl.

41. The compound of claim 40, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein R3Eis hydrogen.

42. The compound of any one of claims 1-41, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein nl is 1.

43. The compound of any one of claims 1-42, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein each instance of R5is hydrogen.

44. The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein Ring C4 is fused bicyclic heteroaryl comprising at least one ring nitrogen atom in the fused bond or at least two adjacent ring nitrogen atoms.

45. The compound of claim 44, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein Ring C4 is of the formula:

46. The compound of claim 44, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein Ring C4 is of the formula:

47. The compound of claim 44, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein Ring C4 is of the formula:

48. The compound of claim 44, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrugthereof,49. The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein Ring C4 is monocyclic heterocyclyl fused with monocyclic heteroaryl or phenyl, wherein at least one ring atom of the monocyclic heterocyclyl is oxygen, and bond c is attached to the monocyclic heterocyclyl, the monocyclic heteroaryl, or the phenyl.

50. The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein Ring C4 is 6-membered monocyclic heterocyclyl fused with 5-membered monocyclic heteroaryl, wherein at least one ring atom of the 6-membered monocyclic heterocyclyl is oxygen, and bond c is attached to the 6-membered monocyclic heterocyclyl.

51. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein Ring C4 is of the formula:

52. The compound of any one of claims 1-51, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein n2 is 1.

53. The compound of any one of claims 1-52, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein at least one instance of R4at a carbon atom is halogen, -CN, or substituted or unsubstituted alkyl.

54. The compound of claim 53, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein at least one instance of R4at a carbon atom is halogen.

55. The compound of claim 53, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrugthereof, wherein at least one instance of R4at a carbon atom is -Cl.

56. The compound of any one of claims 1-52, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein at least one instance of R4at a carbon atom is halogen, -CN, -C(=O)OH, unsubstituted Ci-6 alkyl, or Ci-6 alkyl substituted with one or more halogen.

57. The compound of any one of claims 1-51, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein n2 is 0.

58. The compound of any one of claims 1-57, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein:each of the carbon atom substituents is independently halo, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -ORaa, -N(Rbb)2, -SH, -SRaa, -SSRCC, -C(=O)Raa, -CO2H, -CHO, -CO2Raa, -OC(=O)Raa, -OCO2Raa, -C(=O)N(Rbb)2, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, -C(=O)NRbbSO2Raa, -NRbbSO2Raa, -SO2N(Rbb)2, -SO2Raa, -SO2ORaa, -OSO2Raa, -S(=O)Raa, -OS(=O)Raa, C O alkyl, C O perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, or =0, wherein Raais CMO alkyl or C O perhaloalkyl, and each of Rbband Rccis independently hydrogen, C O alkyl, or C O perhaloalkyl; andeach of the nitrogen atom substituents is independently -C(=O)Raa, -C(=O)N(RCC)2, -CO2Raa, -SO2Raa, -SO2N(RCC)2, -SO2RCC, -SO2ORCC, -SORaa, CHO alkyl, C2-10 alkenyl, or C2-10 alkynyl, wherein each alkyl, alkenyl, and alkynyl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; Raais C O alkyl or CMO perhaloalkyl; each Rccis independently hydrogen, C O alkyl, or C O perhaloalkyl; and each Rddis independently halo, -CN, -OH, -O(Ci-6 alkyl), -NH2, -NH(CI-6 alkyl), -N(CI-6 alkyl)2, C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, or C2-6 alkynyl.

59. The compound of claim 58, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein:each of the carbon atom substituents is independently halo, -CN, -NO2, -OH, -ORaa, -N(Rbb)2, -C(=O)Raa, -CO2H, -CHO, -CO2Raa, -OC(=O)Raa, -OCO2Raa, -C(=O)N(Rbb)2, -OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, CMO alkyl, C Operhaloalkyl, or =0, wherein Raais Ci-io alkyl or Ci-io perhaloalkyl, and each of Rbbis independently hydrogen, Ci-io alkyl, or Ci-io perhaloalkyl; andeach of the nitrogen atom substituents is independently -C(=O)Raa, -C(=O)N(RCC)2, -C02Raa, or Ci-io alkyl, wherein the alkyl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; Raais Ci-io alkyl or Ci-io perhaloalkyl; each Rccis independently hydrogen, Ci-io alkyl, or Ci-io perhaloalkyl; and each Rddis independently halo, -CN, -OH, -0(Ci-6 alkyl), -NH2, -NH(CI-6 alkyl), -N(CI-6 alkyl)2, C1-6 alkyl, or C1-6 perhaloalkyl.

60. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is of the formula:CompoundFormula Number61. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is of the formula:

62. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is of the formula:

63. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is of the formula:

64. The compound of any one of claims 1-59, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is not any one of Formulae LA-014, LA-016, LB-001, 1-B-002, LB-004, LB-006, LB-007, LB-008, LD-003, LD-018, LD-027, LD-029, LD-032, LD-033, LD-034, LD-035, LD-037, LD-038, and LD-039.

65. A compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, wherein the compound is of the formula:(II- 1) or (II-2).

66. The compound of any one of claims 1-65, or a pharmaceutically acceptable salt or tautomer thereof.

67. A pharmaceutical composition comprising a compound of any one of claims 1-65, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, and a pharmaceutically acceptable excipient.

68. A kit comprising:a compound of any one of claims 1-65, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof; or a pharmaceutical composition of claim 67; andinstructions for using the compound, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, or pharmaceutical composition.

69. A method of inhibiting the growth or reproduction of a microorganism or killing a microorganism in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface, the method comprising administering to the subject in need thereof or contracting the cell, tissue, biological sample, microorganism, or surface with an effective amount of:a compound of any one of claims 1-65, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof; ora pharmaceutical composition of claim 67.

70. An in vitro method of inhibiting the growth or reproduction of a microorganism or killing a microorganism in a cell, tissue, biological sample, or microorganism, or on a surface comprising contracting the cell, tissue, biological sample, microorganism, or surface with an effective amount of:a compound of any one of claims 1-65, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof; ora pharmaceutical composition of claim 67.

71. The method of any one of claims 69-70, wherein the microorganism is a bacterium.

72. The method of claim 71, wherein the microorganism is a Gram-negative bacterium.

73. The method of any one of claims 71-72, wherein the microorganism is a multi-drugresistant bacterium.

74. The method of any one of claims 71-73, wherein the microorganism is of the Enterobacteriaceae genus.

75. The method of claim 74, wherein the microorganism is an Escherichia species, Klebsiella species, Kluyvera species, Citrobacter species, Salmonella species, Enterobacter species, Yersinia species, or Serratia species.

76. The method of claim 74, wherein the microorganism is an Escherichia coli strain, Klebsiella pneumoniae strain, Salmonella typhimurium strain, Yersinia pestis strain, or Serratia marcescens strain.

77. The method of claim 74, wherein the microorganism is Shigella species.

78. A method of treating a disease in a subject in need thereof comprising administering to the subject in need thereof an effective amount of:a compound of any one of claims 1-65, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof; ora pharmaceutical composition of claim 67.

79. A method of preventing a disease in a subject in need thereof comprising administering to the subject in need thereof an effective amount of:a compound of any one of claims 1-65, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof; ora pharmaceutical composition of claim 67.

80. The method of any one of claims 78-79, wherein the disease is an infection.

81. The method of claim 80, wherein the infection is an abdominal infection, adrenal gland infection, asymptomatic infection, biofilm infection, blood-borne infection, digestive system infection, ear infection, iatrogenic infection, imported communicable disease, infectious endocarditis, limb infection, mammary gland infection, mediastinal infection, mucosal infection,musculoskeletal infection, nervous system infection, nosocomial infection, prosthesis-associated infection, reinfection, respiratory infection, secondary infection, sepsis, sexually transmitted disease, skin infection, spleen infection, thymus gland infection, urogenital system infection, vector-borne infection, wound infection, or zoonosis.

82. The method of claim 80 or 81, wherein the disease is a bacterial infection.

83. The method of claim 82, wherein the disease is a Gram-negative bacterial infection.

84. The method of any one of claims 82-83, wherein the disease is a multidrug-resistant bacterial infection.

85. The method of any one of claims 82-84, wherein the disease is an Enterobacteriaceae infection.

86. The method of claim 85, wherein the disease is an Escherichia infection, Klebsiella infection, Kluyvera infection, Citrobacter infection, Salmonella infection, Enterobacter infection, Yersinia infection, or Serratia infection.

87. The method of claim 85, wherein the disease is an Escherichia coli infection, Klebsiella pneumoniae infection, Salmonella typhimurium infection, Yersinia pestis infection, or Serratia marcescens infection.

88. The method of claim 85, wherein the disease is a Shigella infection.

89. The method of any one of claims 69 and 71-88, wherein the subject is a human.

90. Use of a compound of any one of claims 1-65, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, or a pharmaceutical composition of claim 67 in the manufacture of a medicament for inhibiting the growth or reproduction of a microorganism or killing a microorganism in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface, treating a disease in a subject in need thereof, or preventing a disease in a subject in need thereof.

91. A compound of any one of claims 1-65, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled compound, or prodrug thereof, or a pharmaceutical composition of claim 67 for use in inhibiting the growth or reproduction of a microorganism or killing a microorganism in a subject in need thereof, cell, tissue, biological sample, or microorganism, or on a surface, treating a disease in a subject in need thereof, or preventing a disease in a subject in need thereof.